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Abstract 
Estrogen is believed to regulate fatty acid composition based on observations of 
differences between men and women, and changes associated with altered estrogen levels in 
women during pregnancy, menopause and hormone treatment. Estrogen is consistently 
associated with increased levels of 18:0, 16:1n-7 and elongase 6, an enzyme in monounsaturated 
fatty acids (MUFA) biosynthesis. In some, but not all studies, estrogen has also been associated 
with increased 22:6n-3 and FADS2 expression.  FADS2 is responsible for delta-6 desaturase 
activity, the rate-limiting step in polyunsaturated fatty acid (PUFA) biosynthesis and is necessary 
for the synthesis of 22:6n-3, which is critical for cardiovascular health and neural development. 
In this thesis, the effects of subtle changes in estrogen levels during the menstrual cycle in 
humans, and the estrous cycle in rats, on fatty acid metabolism was examined. In addition, the 
response of FADS2 to estrogen was examined using MCF7 cells. The presence of multiple 
FADS2 transcript variants in MCF7 cells was determined, and the role of two variants in PUFA 
biosynthesis was examined by transfecting them into HEK 293 cells. During the menstrual cycle 
in women and estrous cycle in rats, increased blood levels of 16:1n-7 and 22:6n-3, and decreased 
levels of 22:5n-3 were observed when blood estrogen levels were high. The increased 22:6n-3 
and decreased 22:5n-3 suggests an effect of estrogen on FADS2 expression and/or activity.  In 
the rat hepatic expression of FADS2 mRNA varied over the cycle, but protein levels did not. 
However, in estrogen sensitive MCF7 cells, FADS2 mRNA was induced by estrogen.  Changes 
in 22:6n-3 and 22:5n-3 were not observed in the MCF7 cells.  Further examination identified 
multiple transcript variants of FADS2 in MCF7 cells, and demonstrated that the expression of an 
alternatively spliced transcript variant (FADS2_v2) was considerably higher. Notably, this 
variant lacked the N-terminal cytochrome-binding domain that is critical for activity, suggesting 
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that it may not be functional. In transfected HEK 293 cells, indirect evidence of delta-6 
desaturase activity was observed for the full length wild type variant (FADS2_v0/1) but not for 
FADS2_v2. When the variants were co-transfected, FADS2_v2 interacted with and inhibited 
FADS2_v0/1. This work helps further understanding of the relationship between estrogen, lipid 
biosynthetic enzymes and fatty acid status that is important for determination of dietary 
requirements of 22:6n-3 for women throughout the lifespan. 
 
  
v 
 
Acknowledgements 
 Thank you to my supervisors, Dr. Ken Stark and Dr. Robin Duncan, for their guidance, 
mentorship and support over the course of this thesis. I am so thankful that I had two supervisors 
to learn from. Ken, thank you for always taking the time to teach me how to be a better speaker, 
writer and critical thinker. I sincerely appreciate you challenging me and helping me reach my 
potential. Robin, thank you for allowing me to pursue my independent research interests and 
ideas in such a supportive manner. I am grateful for your guidance and willingness to 
troubleshoot experiments and results, to discuss career options and life, and your always-open 
door. Thank you to my committee member Dr. Russ Tupling for his guidance during this 
process, and my internal examiner Dr. Heidi Engelhardt and my external examiner Dr. Harold 
Aukema for providing their expertise. 
 I am so thankful for mentorship, experimental and general thesis/life help from several 
lab members during my time here. There are too many to list here, but I’d like to especially thank 
Ryan Bradley for teaching me everything I needed to know about growing plasmids, bacterial 
growth and electroporating cells, and Juan Henao for performing the steroid hormone analyses 
for me, helping me troubleshoot fatty acid issues and performing many, many blood collections. 
Several undergrads helped with aspects of this thesis as well. Notably, I would like to thank 
Chloe Kurtin for obtaining the human ethics and coordinating many emails with interested 
participants, and Jason Elzinga for helping design the rat study, sacrifice the rats and perform the 
blood fatty acid analyses.  
Thank you to Jing Ouyang and Marg Burnett for performing many blood collections for 
me, as well as general lab assistance. Thank you to Dr. Eric Bombardier for ensuring everything 
on the floor runs smoothly. Thank you to Nancy Gibson and Jean Flannigan for all your help 
vi 
 
with organizing the necessary light cycle timing for the rats and all you do in taking care of the 
animals. Thank you to all of my human participants and people who helped me recruit enough 
participants. 
 I have several close girlfriends who provided such a wonderful support system for me. 
Thank you to Marta Borowska, Sophie Hogeveen, Sarah Kernaghan, Jessica Leavitt, Schuyler 
Schmidt, Diane Sepa-Kishi and Laura Williams for running with me, laughing with/at me, 
listening to me, challenging me and encouraging me. You made the past four years a whole lot 
more fun. Thank you to my teammates at Health and Performance. There are too many of you to 
name, but thank you for making me a faster runner, smarter athlete and pushing me beyond my 
limits, but more importantly becoming my second family. 
 Finally, I want to thank my family, but especially my parents, Rick and Jennifer Marks. 
Thank you for supporting my dreams with such sincere excitement and patience. I am so glad 
that you have been part of this process. Thank you for reminding me to enjoy it. You have 
provided me with a wonderful example of hard work and possess a work ethic that I seek to 
emulate. Only one more degree, I promise. 
 
  
vii 
 
Table of Contents 
Author’s Declaration          ii 
Abstract           iii 
Acknowledgements          v 
Table of Contents          vii 
List of Figures           ix 
List of Tables           x 
List of Abbreviations          xii 
Chapter 1: General Introduction        1 
Chapter 2: Biochemical Foundations        5 
Chapter 3: Rationale and Objectives        35 
 Rationale          35 
 Objectives          37 
 Hypotheses          38 
Chapter 4: Common Methods        39 
Chapter 5: The Effects of Sex, Menstrual Cycle and Oral Contraceptives on Blood  
Fatty Acids           44  
Introduction          44 
Methods and Materials        45 
Results          47 
Discussion          50 
Conclusion          54 
Chapter 6: Effect of Rat Estrous Cycle on Hepatic Expression of Fatty Acid Biosynthesis  
Enzymes           60 
Introduction          60 
Methods and Materials        61 
Results          63 
Discussion          64 
Conclusion          68 
 
Chapter 7: Effects of Estradiol Treatment on Gene Expression and Fatty Acid Composition in  
MCF7 Cells           79 
Introduction          79 
viii 
 
Methods and Materials        81 
Results          82 
Discussion          83 
Conclusion          85 
Chapter 8: Characterization of FADS2 Novel Transcript Variants    92 
Introduction          92 
Methods and Materials        92 
Results          96 
Discussion          97 
Conclusion          100 
Chapter 9: General Discussion        108 
References           115 
Appendix 1: Supplementary Forms and Data for Chapter 5     136 
Appendix 2: Supplementary Data for Chapter 6      175 
Appendix 3: Supplementary Data for Chapter 8      179 
  
ix 
 
List of Figures 
Figure 2.1 Monounsaturated fatty acid biosynthesis      31  
Figure 2.2 Polyunsaturated fatty acid biosynthesis      32 
Figure 2.3 Rat estrous cycle hormone changes      33 
Figure 2.4 Human menstrual cycle hormone changes     34 
Figure 5.1 Relative proportion of selected fatty acids in erythrocytes of men and women taking 
or not taking oral contraceptives        58 
Figure 6.1 Representative image of stained vaginal smears from rats   71 
Figure 6.2 Plasma hormone concentrations in rats over the estrous cycle   72 
Figure 6.3 Desaturase gene expression in rats over the estrous cycle   77 
Figure 6.4 Elongase gene expression in rats over the estrous cycle    74 
Figure 6.5 Desaturase protein content in rats over the estrous cycle    75 
Figure 6.6 Elongase protein content in rats over the estrous cycle    76 
Figure 6.7 Concentration of 16:1n-7, 22:5n-3 and 22:6n-3 in rats over the estrous cycle 77 
Figure 6.8 Proportion of 16:1n-7, 22:5n-3 and 22:6n-3 in rats over the estrous cycle 78 
Figure 7.1 Expression of fatty acid elongases in MCF7 cells treated with estradiol  90 
Figure 7.2 Expression of desaturases in MCF7 cells treated with estradiol   91 
Figure 8.1 Sequence alignment of D6D.1 and D6D.2     103 
Figure 8.2 Expression of Fads2 transcript variants in MCF7 cells treated with estradiol 104 
Figure 8.3 Proportion of 20:4n-6 and 22:6n-3 in HEK 293 cells expressing Fads2 variants 105 
Figure 8.4 Interaction of Fads2 transcript variants when co-expressed in HEK 293 cells 106 
Figure 8.5 Proportion of 20:4n-6 and 22:6n-3 in HEK 293 cells expressing both  
Fads2 variants          107  
x 
 
List of Tables 
Table 2.1 Summary of enzymes involved in fatty acid biosynthesis    26 
Table 2.2 Summary of sex differences in fatty acid composition    27 
Table 2.3 Summary of studies altering hormone status in rats    28 
Table 2.4 Summary of studies examining fatty acid composition in humans with altered 
hormone status          29 
Table 5.1 Plasma hormone concentrations in women over the menstrual cycle  56 
Table 5.2 Relative proportion of plasma fatty acids in men, women taking and not taking oral 
contraceptives           57 
Table 5.3 Relative proportion of plasma fatty acids in women over the menstrual cycle 59 
Table 6.1 Rat primer sequences for real-time PCR      70 
Table 7.1 Human primer sequences for real-time PCR     87 
Table 7.2 Relative proportion of fatty acids in MCF7 cells treated with estradiol or  
vehicle            88 
Table 7.3 Concentration of fatty acids in MCF7 cells treated with estradiol or vehicle 89 
Table 8.1 Human FADS2 variant summary and primer sequences for real-time PCR 102 
Table A1.1 Concentration of plasma fatty acids in men and women taking and not taking oral 
contraceptives           169 
Table A1.2 Concentration of erythrocyte fatty acids in men and women taking and not taking 
oral contraceptives          170 
Table A1.3 Relative proportion of erythrocyte fatty acids in men and women taking and not 
taking oral contraceptives         171 
Table A1.4 Concentration of plasma fatty acids in women over the menstrual cycle 172 
xi 
 
Table A1.5 Concentration of erythrocyte fatty acids in women over the menstrual cycle 173 
Table A1.6 Relative proportion of erythrocyte fatty acids in women over the  
menstrual cycle          174 
Table A2.1 Concentration of whole blood fatty acids in rats over the estrous cycle  
and males           176 
Table A2.2 Concentration of plasma fatty acids in rats over the estrous cycle and males 177 
Table A2.3 Concentration of hepatic fatty acids in rats over the estrous cycle and males 178 
Table A3.1 Relative proportion of fatty acids in HEK 293 cells electroporated with Fads2 
variants           180 
Table A3.2 Concentration of fatty acids in HEK 293 cells electroporated with Fads2  
variants           181  
Table A3.3 Relative proportion of fatty acids in HEK 293 cells electroporated with both Fads2 
variants           182 
Table A3.4 Concentration of fatty acids in HEK 293 cells electroporated with both Fads2 
variants            183  
xii 
 
List of Abbreviations 
ANOVA analysis of variance 
D5D  delta-5 desaturase 
D6D  delta-6 desaturase 
ER  estrogen receptor 
Elovl1  fatty acid elongase 1 
Elovl2  fatty acid elongase 2 
Elovl5  fatty acid elongase 5 
Elovl6  fatty acid elongase 6 
Fads1  fatty acid desaturase 1 
Fads2  fatty acid desaturase 2 
FASN  fatty acid synthase 
HUFA  highly unsaturated fatty acid 
MUFA  monounsaturated fatty acid 
ORF  open reading frame 
PUFA  polyunsaturated fatty acid 
Scd1  stearoyl-CoA desaturase 1 
SFA  saturated fatty acids 
TAG  triacylglycerol 
  
1 
 
Chapter 1 
General Introduction 
Fatty acids are involved in a wide range of cellular functions, including ATP generation 
(McCloy et al., 2004), cell signaling (Hong and Lu, 2013), neurotransmission (Garcia and Kim, 
1997), energy storage as triacylglycerols (TAG) (Raclot, 2003; Yen et al., 2008), and structural 
support (Balkova et al., 2009). Sex differences have been reported in both blood and tissue fatty 
acid composition, which may affect the proper functioning of these processes because different 
fatty acids have different physiological functions. In women, there tends to be a shift towards 
having higher levels of 18:0 and 22:6n-3 (Metherel et al., 2009; Patterson et al., 2015; Crowe et 
al., 2008) while men have higher levels of 16:0 and 22:5n-3 (Patterson et al., 2015; Marangoni et 
al., 2007).  
Differences in the fatty acid composition of body cells and tissues may contribute to sex 
differences in cardiovascular disease. Premenopausal women are at a lower risk for 
cardiovascular disease as compared with men (Barrett-Connor, 1997; Bui, Horwich, and 
Fonarow, 2011). This may be due in part to more favorable fatty acid species profiles in blood 
and plasma of women. In particular, 16:0 has previously been thought to be associated with an 
increased risk for cardiovascular disease and diabetes (Yu et al., 2002; Lionetti et al., 2007), 
although some evidence suggests that there is no relationship (Siri-Tarino et al., 2010; 
Mozaffarian, Rimm, and Herrington, 2004; Tucker et al., 2005). A diet high in 18:0 have been 
reported to lower cholesterol levels compared with a diet high in 16:0 (Storm et al., 1997). One 
particular omega-3 polyunsaturated fatty acid (PUFA), 22:6n-3, has anti-inflammatory (Flock et 
al., 2014; Dangardt et al., 2010) and anti-arrhythmic properties (GISSI-Prevenzione 
Investigators, 1999; Xiao et al., 1997). Less is known about the health effects of 22:5n-3, but it 
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appears to have some protective effects, particularly with platelet aggregation (reviewed in (Kaur 
et al., 2011)). 
These sex differences in fatty acid composition persist even when diet is controlled 
(Metherel et al., 2009; Patterson et al., 2015; Crowe et al., 2008), suggesting an underlying 
biological mechanism. Estrogen has been thought to be one such mechanism because circulating 
estradiol levels are much higher in females compared with males (Eldrup, Lindholm, and 
Winkel, 1987). Studies have examined conditions associated with changing estrogen 
concentrations, such as pregnancy, menopause, ovariectomy with or without exogenous estrogen 
provision, and oral contraceptive use, in both human and rodent models. While not all studies 
fully agree, in general increasing estrogen concentrations results in higher levels of 16:0, 18:0, 
16:1n-7 and 22:6n-3 and lower levels of 20:5n-3, 20:4n-6 and 22:5n-3 (Fehily et al., 1982; 
Kitson et al., 2013a; Marks et al., 2013a; Stark, Park, and Holub, 2003; Mason et al., 2014; 
Giltay et al., 2004; Ottosson et al., 1984; Tworek et al., 2000). 
Estrogen can regulate gene expression (Gruber et al., 2004) and appears to be involved in 
the control of enzymes involved in fatty acid elongation and desaturation. Hepatic mRNA and 
protein expression of elongase 6 has been shown to be positively regulated by estradiol in many 
models (Marks, Kitson, and Stark, 2013; Marks et al., 2013b). Stearoyl-CoA desaturase appears 
to be controlled in part by estradiol but not is not consistently responsive to estradiol (Marks, 
Kitson, and Stark, 2013; Marks et al., 2013b; Paquette et al., 2008). Hepatic Fads2 and elongase 
2 mRNA levels are increased following estrogen treatment in ovariectomized rats (Kitson et al., 
2013a), but do not increase in HepG2 cells that are treated with estradiol (Sibbons et al., 2014) or 
decrease in livers of ERα knockout mice (Kitson, 2013). These results suggest that estradiol is 
involved in mediating the expression of lipid-metabolizing enzymes to affect fatty acid 
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composition, but also suggest that the mechanism (i.e. nuclear versus non-genomic) may differ in 
different conditions and systems. Indeed, estrogen receptor α (ERα) knockout mice retain non-
genomic estrogen signaling capacity (Couse et al., 1995), HepG2 cells do not express high 
amounts of ERα (Kelly et al., 2014), ovariectomy does not always result in a decrease in 
estrogen concentrations compared with sham-operated rats (Marks et al., 2013a), while estrogen 
treatment in ovariectomized animals can result in supraphysiological concentrations of this 
hormone (Marks et al., 2013a). Thus, differences across levels of estrogen, as well as differences 
in mechanisms of estrogen-mediated signalling, are likely responsible for the incongruous nature 
of changes in lipid-metabolizing hormones, leaving this area poorly understood.  
 Many of these effects of estrogen on fatty acid composition occur with large changes in 
estrogen concentrations, such as pregnancy or menopause. However, the effects of estrogen on 
fatty acid composition have not been looked at during the human menstrual cycle. Hormones 
change cyclically over the menstrual cycle, but the change is not as dramatic as is observed 
during menopause and pregnancy. Therefore, the first objective of my thesis was to measure 
plasma and erythrocyte fatty acid composition in women at two time points of the menstrual 
cycle when estrogen concentrations should be different from each other, and expand upon 
findings from other estrogen-based models. The second objective of my thesis was to further 
explore the effects of cyclical estrogen concentrations by using a rat model. Blood and hepatic 
fatty acids were measured at all four days of the estrous cycle. Additionally, hepatic enzyme 
expression was examined at all four time points to determine how cyclical estrogen changes may 
influence hepatic gene expression and confirm findings from other models. Due to the 
importance of 22:6n-3 on human health and considerable variability in the changes in this fatty 
acid in various models examining estrogen, fatty acid desaturase and elongase enzyme mRNA 
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expression were examined in a breast cancer cell culture line (MCF7 cells) that is highly 
responsive to estrogen.  While the estrogen response and the influence on FADS2 mRNA 
expression was intact in the MCF7 cells, in these cells the gene is non-functional and does not 
produce 20:4n-6 and 22:6n-3.  FADS2 transcripts were examined in detail and a novel truncated 
Fads2 transcript variant (Fads2_v2) was identified.  This transcript variant and the intact variant 
(Fads2_v0/1) were then studied in detail by transfection into HEK 293 cells to determine their 
individual contributions on fatty acid composition as well as potential interactions between the 
variants.   
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Chapter 2.  
Biochemical Foundations 
2.1 Fatty Acids 
Fatty acids are composed of hydrocarbon chains, with a carboxylic acid (-COOH) present 
at one end, and a methyl group (-CH3) at the other end. Fatty acids are classified based on a 
variety of chemical properties. The first classification category is based on carbon chain length. 
Short-chain fatty acids have four carbons or fewer, medium-chain fatty acids have 6 to 10 
carbons, long-chain fatty acids have 12 to 18 carbons, and very long-chain fatty acids have >20 
carbons. Fatty acids are also classified based on the degree of desaturation of the carbon-carbon 
bonds. Saturated fats are completely hydrogenated, monounsaturated fatty acids have 1 double 
bond, and polyunsaturated fatty acids have 2 or more double bonds. Finally, fatty acids are also 
classified based on the location of their first double bond relative to the methyl (or omega) end. 
Omega-three fatty acids have a double bond between the third and fourth carbon, counting from 
the methyl end, and these fatty acids are designated 3, or n-3. Omega-six fatty acids have a 
double bond between carbons six and seven, and omega-nine fatty acids have a double bond 
between carbon number nine and ten. Taking all these categories together, fatty acids are 
abbreviated to give information about chain length, degree of desaturation and location of the 
first double bond. For instance, the fatty acid 22:6n-3 contains 22 carbons, and 6 double bonds. 
The first double bond is at the n-3 position (between carbons three and four relative to the methyl 
end).  The fatty acid 18:0 contains 18 carbons, and no double bonds.  
Fatty acids can be obtained through the diet or through de novo biosynthesis. Saturated 
and monounsaturated fatty acids (SFA and MUFA, respectively) are considered non-essential 
because they can be synthesized from dietary carbohydrate or amino acid precursors, while 
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18:2n-6 and 18:3n-3 polyunsaturated fatty acids (PUFA) are essential because they cannot be 
synthesized and must be obtained from the diet. Very long chain n-6 and n-3  PUFA are often 
considered “conditionally essential,” because longer chain PUFA can be synthesized from 
essential dietary precursors (Cunnane, 2000), although the extent of this conversion and whether 
it provides sufficient long chain PUFA has been extensively debated (Domenichiello, Kitson, 
and Bazinet, 2015; Goyens et al., 2005; Pawlosky et al., 2003b; Talahalli et al., 2010). Fatty acid 
biosynthesis mainly occurs in the liver and adipocytes, and involves a series of elongation and 
desaturation steps. Different enzymes are used depending on the substrate, but these desaturation 
and elongation enzymes are generally found on the endoplasmic reticulum (Nakamura and Nara, 
2004; Wang et al., 2005), while fatty acid synthase is cytosolic (Sul and Wang, 1998).  The gene 
and protein names and predominant fatty acid substrates and products are summarized in Table 
2.1. Redistribution of fatty acids from the liver to other tissues is mediated through the synthesis 
and secretion of lipoproteins. The liver is the main site of synthesis of circulating phospholipids 
(Radding and Steinberg, 1960) and TAG (Rui, 2014; Davis et al., 1979) during fasting. 
Circulating phospholipid composition is important since there is evidence that the brain derives 
22:6n-3 through the selective uptake of this fatty acid as part of a lysophosphatidylcholine 
(Nguyen et al., 2014) although there is evidence that non-esterified 22:6n-3 is the main pool for 
brain uptake (Chen et al., 2015). In conditions such as pregnancy, recirculation of fatty acids in 
blood phospholipids is a major mechanism by which the body transfers n-3 PUFA to the 
developing fetus (Burdge et al., 2006; Vlaardingerbroek and Hornstra, 2004; Postle et al., 1995). 
Metabolically active tissues such as heart and muscle hydrolyze plasma TAG using lipoprotein 
lipase (Karpe et al., 1998) to release non-esterified fatty acids, which can then be taken up into 
the tissue via several different fatty acid transporters and fatty acid binding proteins (Kiens et al., 
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1997; Turcotte, Kiens, and Richter, 1991; Kim and Dyck, 2016; Clarke et al., 2004). The 
concentration of plasma fatty acids is an important determinant of tissue fatty acid uptake, 
indicating that passive diffusion is likely an important mechanism for cellular fatty acid transport 
(Turcotte et al., 1998), likely in part related to activity of fatty acid acyl-CoA synthetases inside 
the cell influencing the concentration gradient (Coe et al., 1999; Hall, Smith, and Bernlohr, 
2003).  
2.2 Biosynthesis and Health Effects of Saturated and Monounsaturated Fatty Acids 
SFA and MUFA biosynthesis are closely related (Figure 2.1). Carbohydrate catabolism in 
excess of cellular requirements for ATP results in the elevation of cytosolic levels of acetyl-CoA, 
which is carboxylated by acetyl-CoA carboxylase to form malonyl-CoA, the major substrate for 
fatty acid synthase (FAS) (Schiller and Bensch, 1971). The final product of FAS is 16:0, which 
can be incorporated into complex lipids and stored, or used as a substrate by other synthesis 
enzymes. Elongase 6 preferentially uses 16:0 as a substrate for elongation (Green et al., 2010), 
which results in 18:0. Stearoyl-CoA desaturase (SCD) desaturates 18:0 to form 18:1n-9 
(Miyazaki, Bruggink, and Ntambi, 2006). SCD can use 16:0 as a substrate for desaturation, 
although the main SCD isoform expressed in the liver has a greater affinity for 18:0 (Miyazaki, 
Bruggink, and Ntambi, 2006). If carbohydrate intake is high, however, then SCD may use 16:0 
for desaturation instead of 18:0, resulting in an excessive amount of 16:1n-7 flooding the cell 
(Hudgins et al., 1996), which can be elongated by either elongase 5 or 6 to form 18:1n-7 (Green 
et al., 2010). Concentrations of n-7 MUFA have been reported to be as low as 10%, or up to 
50%, of the 18:1n-9 concentration in plasma from humans and rats (Puri et al., 2009; Marks, 
Kitson, and Stark, 2013). 
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Saturated fatty acids (SFA) can be stored in TAG where they can later be released and 
oxidized for energy, or they can be incorporated into phospholipids as structural components of 
membranes. SFA also make up a large proportion of the fatty acids in tissues in phospholipids. In 
rats, approximately 40% of fatty acids in plasma, erythrocytes, brain, heart, liver and muscle are 
SFA, while approximately 50% of the fatty acids in adipose tissue are SFA (Stark, Lim, and 
Salem, Jr., 2007). 
Ingestion of a diet rich in SFA, and 16:0 in particular, has been associated with an 
increase in cardiovascular disease risk, disruption of the insulin signaling cascade (Yu et al., 
2002; Griffin et al., 1999), and development of insulin resistance (Lionetti et al., 2007) and type 
II diabetes (Perdomo et al., 2015). In addition, treatment of cultured muscle and adipose cells 
with 16:0 has been found to increase the expression of several inflammatory cytokines such as 
IL-6 and TNF-α (Capel et al., 2015; Pillon et al., 2015)and act as a ligand for the 
proinflammatory toll-like receptor 4 (Huang et al., 2012). However, not all SFA have the same 
negative health effects. Another SFA, 18:0, has also been found to be positively related to 
incidence of type II diabetes in a population of older adults (Ma et al., 2015) but is also reported 
to lower serum total cholesterol concentrations compared with a diet rich in 16:0 (Storm et al., 
1997). 
As a class, MUFA are more likely to be oxidized or stored in TAG than PUFA (McCloy 
et al., 2004), possibly because SCD, the rate-limiting enzyme in MUFA biosynthesis, co-
localizes with the rate-limiting enzyme in TAG synthesis, acyl-CoA:diacylglycerol 
acyltransferase 2 (Man et al., 2006). The MUFA composition of tissues varies depending on the 
tissue. For example, 18:1n-9 is the predominant fatty acid in rat muscle, adipose and liver 
(Polozova and Salem, Jr., 2007), and the total proportion of MUFA in these tissues is 
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approximately 30-35% in rats (Stark, Lim, and Salem, Jr., 2007). However, MUFA make up 
only 11-18% of total fatty acids in plasma, heart and erythrocytes of rats (Stark, Lim, and Salem, 
Jr., 2007). 
Dietary MUFA are generally considered to be healthy and to have beneficial effects on 
the cardiovascular system, especially when replacing SFA in the diet (Baum et al., 2012; 
Perdomo et al., 2015) or when co-administered with omega-3 PUFA (Kondreddy, Anikisetty, 
and Naidu, 2016). Looking at 18:1n-9 specifically, it has been demonstrated in mice to prevent 
the hepatic inflammation and endoplasmic reticulum stress associated with a high-sucrose low-
fat diet (Liu et al., 2016). However, in humans, reports have suggested that high levels of 16:1n-
7 and 18:1n-7 in erythrocytes and plasma may be linked to an increased risk for cardiovascular 
disease (Wu et al., 2011; Djousse et al., 2012a) and MUFA in serum phospholipids has been 
associated with early increases in fasting glucose levels (Cho et al., 2014).  
The enzymes involved in SFA and MUFA biosynthesis have been implicated in obesity 
and insulin resistance (Ntambi et al., 2002; Matsuzaka et al., 2007). SCD knockout mice are 
leaner and accumulate less fat than wild type mice. This may be due to the observed increase in 
expression of lipid oxidation genes and down-regulation of lipid synthesis genes in the knockout 
mice, compared with the wild type mice (Ntambi et al., 2002). This observation may also be due 
to inefficient TAG synthesis or storage, since SCD co-localizes with the rate-limiting enzyme in 
TAG biosynthesis (Man et al., 2006). However, SCD overexpression in muscle cells prevents the 
inflammatory response associated with 16:0 (Peter et al., 2009), suggesting that part of the 
reason SCD is induced in obesity may be to help protect the cell against 16:0 toxicity. 
Elovl6 knockout animals are susceptible to diet-induced obesity to a similar degree as 
observed in wild-type animals are, since both groups of animals showed similar increases in 
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epididymal fat pad weight and total body weight percentage increases over the course of the 
study (Matsuzaka et al., 2007). However, the Elovl6 knockout animals retain insulin sensitivity, 
unlike the wild-type animals which develop insulin resistance (Matsuzaka et al., 2007). Two 
potential mechanisms for this observation have been identified. Elovl6 deletion has direct effects 
on the insulin signaling cascade. In the knockout animals, the IRS-2/Akt signaling pathway, 
which is critical for transduction of the insulin signal (Hanke and Mann, 2009), retains activity in 
the liver even with high-fat diet feeding (Matsuzaka et al., 2007). This effect on the insulin 
signaling pathway was only observed with hepatic signaling and was not evident in adipose or 
muscle, but was substantial enough to alter whole-body insulin sensitivity (Matsuzaka et al., 
2007). Changes in fatty acid composition, such as occur with Elovl6 gene ablation, change the 
substrate availability and composition of species of diacylglycerols (DAG) and ceramides, two 
signaling molecules that have been linked to insulin resistance. Increased DAG results in 
increased expression of protein kinase C, which impairs phosphorylation of IRS-1 and IRS-2 
(Samuel et al., 2007). In Elovl6 knockout animals, there are lower levels of DAG, and therefore 
lower expression of protein kinase C, resulting in greater insulin sensitivity (Matsuzaka et al., 
2007). Another potential contributing mechanism to Elovl6 knockout animals being protected 
from insulin resistance is that loss of Elovl6 result in a more favorable lipid profile. Because 16:0 
is not elongated to 18:0, SCD will use 16:0 as a substrate for desaturation, resulting in the 
synthesis of 16:1n-7. This fatty acid has been reported to be an adipose tissue-derived lipokine 
with insulin sensitizing effects on muscle (Cao et al., 2008; Dimopoulos et al., 2006). 
These conflicting health effects of SFA, MUFA and the synthesizing enzymes suggest 
that MUFA may be less toxic than SFA, but the relationship between MUFA and health is not 
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straightforward, and may be based on the concentration or specific fatty acids species present. 
This illustrates the importance of furthering our understanding of MUFA metabolism. 
2.3 Biosynthesis and Health Effects of n-6 and n-3 Polyunsaturated Fatty Acids 
Omega 6 and omega 3 PUFA compete for a common set of enzymes for biosynthesis 
(Figure 2.2). The essential precursors, 18:2n-6 for omega 6 PUFA and 18:3n-3 for omega 3 
PUFA, are first desaturated by delta-6 desaturase (D6D; gene name: Fads2) (Melin and Nilsson, 
1997). The products of this reaction are next elongated by elongase 5, and then desaturated by 
delta-5 desaturase (D5D; gene name: Fads1) to form 20:4n-6 and 20:5n-3 (Nakamura and Nara, 
2004), two physiologically important PUFA. The omega 6 pathway usually ends at 20:4n-6, but 
20:5n-3 undergoes two more rounds of elongation by elongase 2 (Pauter et al., 2014), and 
another round of D6D desaturation (Nakamura and Nara, 2004), before being oxidized in the 
peroxisome to end with 22:6n-3. There has been a report in MCF7 cells overexpressing FADS2 
that D6D can possess delta-4 desaturation ability and directly desaturate 22:5n-3 to form 22:6n-3 
(Park et al., 2015), but this has not been confirmed in vivo, and this does not occur in rodents 
(Pauter et al., 2014). Elongase 5 is the most abundant elongase in the liver (Wang et al., 2005), 
and is fairly non-specific in substrate preferences since it can use SFA, MUFA or PUFA as 
substrates (Green et al., 2010). Elongase 2 is crucial in the biosynthesis of 22:6n-3, because 
when it is knocked out, animals are unable to convert 22:5n-3 to 24:5n-3 and thereby do not 
make 22:6n-3 (Pauter et al., 2014). This confirms that elongase 2 is the only elongase that can 
perform this elongation, since it was previously thought that either elongase 2 or elongase 5 
could perform this step (Gregory et al., 2011). 
Several genetic polymorphisms have been identified in the elongases and desaturases 
involved in n-6 and n-3 PUFA biosynthesis. These polymorphisms often result in a lower 
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activity level of the enzyme, resulting in lower product levels from that enzyme. For example, in 
men, the Fads1 minor allele rs174550 is associated with lower activity of D5D, and 
correspondingly results in lower levels of 20:4n-6 and 20:5n-3 in plasma (Takkunen et al., 2016). 
Some minor alleles in Fads1 and Fads2 (rs174546 and rs968567, respectively) are associated 
with higher levels of 18:3n-3 and lower levels of the longer chain n-3 PUFA products, and some 
minor alleles in Elovl2 (rs2236212 and rs12662634) are associated with higher levels of 20:5n-3 
and 22:5n-3, but lower levels of 22:6n-3 (Lemaitre et al., 2011). In men, minor allele carriers in 
both Fads1 and Fads2 (rs174537 and rs174576, respectively) show lower levels of 20:5n-3 at 
baseline, but greater increases in 20:5n-3 content in erythrocytes following fish oil 
supplementation (Roke and Mutch, 2014), indicating that the response to dietary omega-3 PUFA 
can be gene dependent.  
N-6 and n-3 PUFA are generally found in cell membrane phospholipids. Replacing SFA 
with either n-3 or n-6 PUFA in cell membranes can negate the effects of 16:0 on inflammatory 
markers and insulin resistance in muscle cells (Capel et al., 2015) and improve plasma LDL 
cholesterol levels (Summers et al., 2002).  N-6 and n-3 PUFA from membrane phospholipids can 
be used as substrates for signalling molecules (Fitzpatrick and Soberman, 2001; Bazan, 
Calandria, and Gordon, 2013). Signalling molecules derived from n-6 PUFA tend to have a pro-
inflammatory effect (Khan et al., 2014; Bagga et al., 2003), while n-3 PUFA-derived signaling 
molecules are anti-inflammatory (Flock et al., 2014; Dangardt et al., 2010; Hong and Lu, 2013; 
Bagga et al., 2003; Allam-Ndoul et al., 2016). A balance between these classes of PUFA is thus 
important for maintaining health, with the optimal ratio of intake of n-6/n-3 being between 3:1 
and 5:1. Most western diets provide a ratio of approximately 15:1 (Simopoulos, 2002; 
Simopoulos, 2008; Lands, 2014).  
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N-3 PUFA have a role in reducing the risk for sudden cardiac death (GISSI-Prevenzione 
Investigators, 1999; Musa-Veloso et al., 2011), and have antiarrhythmic (Xiao et al., 1997)  and 
TAG lowering effects (Zulyniak et al., 2015). A large amount of n-3 PUFA are not required to 
see these effects. Intake of as little as 250-500 mg/day of 20:5n-3 plus 22:6n-3, compared with 
little to no intake, can result in a reduction of coronary heart disease risk by 25% (Mozaffarian 
and Rimm, 2006). Maximal effects on the anti-arrhythmic properties of 20:5n-3 and 22:6n-3 are 
seen at intakes of 750 mg/day, but the relative strength of the effect of these fatty acids on 
lowering blood pressure, heart rate and blood TAG levels continues to increase past this dose 
(Mozaffarian and Rimm, 2006), indicating that small changes in blood and tissue omega 3 
content have large physiological effects. 
Omega-3 PUFA are highly concentrated in the brain (Svennerholm, 1968; Breckenridge, 
Gombos, and Morgan, 1972; Salem, Jr. et al., 1980) and retina (Anderson and Sperling, 1971; 
Anderson, 1970; van Kuijk and Buck, 1992). In particular, 22:6n-3 comprises 25-40% of total 
fatty acids in these tissues, likely due to the importance of this specific fatty acid in brain 
development (Lauritzen et al., 2016), cell signaling (Speizer, Watson, and Brunton, 1991), 
neurotransmission (Garcia and Kim, 1997) and ocular function (Rotstein et al., 2003; Uauy et al., 
2001). The heart also has a relatively high proportion of n-3 PUFA, with ~10% of heart fatty 
acids being n-3 PUFA. Omega-3 PUFA make up approximately 5% of total fatty acids in tissues 
such as muscle, liver, plasma and erythrocytes, whereas n-3 PUFA levels are extremely low in 
adipose tissue, being less than 1.5% of total fatty acids (Stark, Lim, and Salem, Jr., 2007) 
Omega-6 PUFA are required for proper growth and development. Omega-6 deficiency is 
associated with dermatitis (Fujii et al., 2013) and hair loss, and a 15% decrease in body weight 
(Cunnane and Anderson, 1997). Health effects of n-6 PUFA supplementation are less clear. 
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Some studies have shown benefits of dietary 18:2n-6 on reducing blood cholesterol levels 
(Mensink et al., 2003) and n-6 PUFA in reducing the risk for coronary heart disease (Jakobsen et 
al., 2009; Wu et al., 2014), but not all studies agree (Chowdhury et al., 2014; Ramsden et al., 
2013). This is possibly due to the competition between n-6 and n-3 PUFA for synthesis enzymes 
(Simopoulos, 2008) and the pro-inflammatory properties of n-6 PUFA. In rats, tissue n-6 PUFA 
composition varies greatly between different tissues. There are low levels of n-6 PUFA in brain 
and adipose tissue (approximately 10-12% of total fatty acids), intermediate levels in liver and 
muscle (16-19% of total fatty acids) and greater concentrations in plasma, heart and erythrocytes 
(29-35% of total fatty acids) (Stark, Lim, and Salem, Jr., 2007). 
2.4 Factors that Influence Fatty Acid Composition 
 Besides synthesis and tissue specificity, several factors influence body fatty acid 
composition. Diet has a strong effect on tissue and blood fatty acid composition. Increasing the 
amount of omega-3 PUFA in the diet, such as through eating oily fish or taking a fish oil 
supplement, results in an increased proportion of omega-3, specifically the biologically 
important 20:5n-3 and 22:6n-3, in the blood of humans (Dewailly et al., 2001; Patterson et al., 
2015; Metherel et al., 2009) and rats (Kim, Jin, and Park, 2015; Tu et al., 2010). In addition to fat 
composition of the diet, excessive carbohydrate intake can also influence fatty acid composition, 
by increasing de novo fatty acid biosynthesis (Hudgins et al., 1996). Excess carbohydrate intake 
results in greater amounts of acetyl-CoA, the precursor for de novo synthesis of 16:0, thereby 
increasing levels of this fatty acid and its metabolites in the body.  
Vegetarians and vegans of both sexes generally have lower plasma and erythrocyte levels 
of 20:5n-3 and 22:6n-3, and higher levels of 18:3n-3, compared with omnivores (Kornsteiner, 
Singer, and Elmadfa, 2008; Rosell et al., 2005; Agren et al., 1995; Sanders, Ellis, and Dickerson, 
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1978; Melchert et al., 1987), since protein intake is more associated with omega-3 status than fat 
intake due to n-3 PUFA being present in phospholipids rather than TAG (Stark and Patterson, 
2012; Miles et al., 2011). Furthermore, levels of n-3 PUFA are even lower in vegans compared 
with vegetarians (Kornsteiner, Singer, and Elmadfa, 2008). In vegans and vegetarians, omega-6 
levels tend to be higher than in omnivores, while 16:0, 16:1n-7 and 18:1n-9 are lower (Agren et 
al., 1995; Sanders, Ellis, and Dickerson, 1978); however, these MUFA differences are not 
always observed (Kornsteiner, Singer, and Elmadfa, 2008), likely due in part to whether there are 
differences in the proportion of MUFA in the diet between vegans/vegetarians and omnivores or 
not (Kornsteiner, Singer, and Elmadfa, 2008; Rosell et al., 2005).  
Another dietary consideration that affects fatty acid composition is general nourishment. 
Malnourished children have lower levels of essential fatty acids compared with healthy controls 
(Holman et al., 1981; Smit et al., 1997; Leichsenring et al., 1995; Koletzko et al., 1986; Wolff et 
al., 1984), which is likely due to a combination of low overall energy intake and the scarce food 
source sources that are available are a poor source of essential fatty acids, malabsorption, and 
oxidation of body lipid stores and what fatty acids are present in the diet (Smit et al., 1997; 
Koletzko et al., 1986). However, this relationship is complex. Different types of malnutrition 
show different effects on fatty acid composition. For example, children with marasmus have 
lower levels of 20:4n-6 compared with children with kwashiorkor (Vajreswari, Narayanareddy, 
and Rao, 1990; Wolff et al., 1984).  
Two unmodifiable factors are also associated with fatty acid composition: age and sex. 
Age is positively associated with plasma and erythrocyte omega-3s and negatively associated 
with omega-6s in Japanese and James Bay Cree populations (Ogura et al., 2010; Dewailly et al., 
2002). Both omega-3 and omega-6 PUFA are positively associated with age in adipose tissue 
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(Bolton-Smith, Woodward, and Tavendale, 1997).   With sex, the proportion of 22:6n-3 is higher 
in women compared with men, after controlling for diet in several different populations, 
(Dewailly et al., 2001; Childs et al., 2014; Giltay et al., 2004; Bakewell, Burdge, and Calder, 
2006; Crowe et al., 2008; Marangoni et al., 2007; Metherel et al., 2009; Patterson et al., 2015). 
The proportion of 16:0, 16:1n-7 and 18:1n-7 is lower, while the proportion of 18:1n-9 and 22:5n-
3 is higher, in men compared with women (Giltay et al., 2004; Marangoni et al., 2007; Metherel 
et al., 2009; Patterson et al., 2015). These observations have been corroborated in animal models.  
Female rats tend to have higher levels of 18:0, 18:3n-6 and 22:6n-3 (Extier et al., 2010; Kitson et 
al., 2012; Burdge et al., 2008) and lower levels of 16:0, 18:1n-7, 18:1n-9 and 22:5n-3 compared 
with males (Burdge et al., 2008; Kitson et al., 2012; Marks, Kitson, and Stark, 2013), when fed 
the same diet during the experimental period. A summary of sex differences in human and rat 
fatty acid composition is found in Table 2.2. These results indicate that sex plays an independent 
role in determining fatty acid composition, since both humans (with diet controlled), and rodents 
on a standard chow diet, show sex differences in fatty acid composition. 
 Modifiable factors such as smoking and alcohol consumption are also associated with 
fatty acid composition. The relative percent mass of 20:5n-3 and 22:6n-3 are lower in smokers 
compared with non-smokers (Dewailly et al., 2001; Dewailly et al., 2002; Scaglia et al., 2016). 
Generally, the proportion of 22:6n-3 decreases in plasma of humans as the number of alcoholic 
drinks per week increases (Dewailly et al., 2002). The same effect of 22:6n-3 depletion is 
observed in liver, plasma, heart and brain of several different animal models who are chronically 
fed ethanol, including decreases in activity of synthesis enzymes such as D5D and D6D 
(Littleton, John, and Grieve, 1979; Nakamura et al., 1994; Pawlosky and Salem, Jr., 1995; 
Pawlosky and Salem, Jr., 1999), with compensatory increases in 22:5n-6 (Pawlosky and Salem, 
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Jr., 1995) and 20:3n-9 (Pawlosky and Salem, Jr., 1995), suggesting disrupted essential fatty acid 
metabolism.  
 Endurance training is another modifiable factor that also influences tissue fatty acid 
composition. Levels of 18:2n-6, 18:3n-6 and 18:3n-3 increase in hepatic phospholipids in 
endurance trained rats compared with untrained animals, while hepatic TAG are not changed in 
trained animals (Petridou et al., 2005). As expected, the concentration of most fatty acids in 
TAG, as well as total TAG, decrease in muscle during exercise, but the relative proportion shows 
a decrease in levels of 16:1n-7 and increases in levels of 18:0, 18:3n-6 and 20:5n-3. Few changes 
are observed in phospholipids in muscle (Petridou et al., 2005). Concentrations of MUFA 
increase in adipose TAG, although TAG are enriched with n-6 PUFA rather than MUFA during 
exercise (Petridou et al., 2005). Conversely, during obesity, total TAG accumulate in muscle, 
adipose and liver (Donnelly et al., 2005; Puri et al., 2009; Belfiore et al., 1987; Bonen et al., 
2004), and these TAG generally contain SFA and MUFA and low levels of PUFA (Borkman et 
al., 1993). Obese individuals also have higher levels of SFA, MUFA and some n-6 PUFA in 
plasma phospholipids and cholesteryl esters, and lower levels of 22:6n-3, compared with normal 
weight individuals (Warensjo, Ohrvall, and Vessby, 2006; Klein-Platat et al., 2005). 
2.5 Cell Culture Models and Fatty Acid Composition 
Cell culture conditions, such as nutrient composition, hormones, silencing or 
overexpressing of genes, and more, can be easily manipulated and tightly controlled.  As such 
the specific effects of individual experimental parameters on gene expression or fatty acid 
composition to be examined, making them a useful complement to human or animal studies. 
However, there are some considerations when choosing which cell line to use, since there are 
benefits and limitations to each.  
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One of the greatest limitations to studying fatty acid metabolism using cell culture is that 
fatty acid composition of most cell lines is unknown. One  study reported the relative proportion 
of nine fatty acids in several common cancer and normal cell lines (Fermor et al., 1992). To our 
knowledge, no other reports of fatty acid composition in cell culture models have been reported. 
HEK 293 cells are commonly used for experiments studying genes involved in fatty acid 
biosynthesis (Wu, Li, and Gou, 2010; Sinner et al., 2012; Li et al., 2016; Chen et al., 2011), 
because these cells can be easily transfected to express a gene of interest, but the fatty acid 
composition of these cells has not been reported.  In addition, the media used can drastically alter 
cellular fatty acid composition (Stoll and Spector, 1984). Levels of 22:6n-3 in fetal bovine 
serum, which is commonly used to supplement cell culture media, are quite high (van den Elsen 
et al., 2013), and can inhibit endogenous 22:6n-3 synthesis and mask any subtle effects that 
might be occurring due to treatment. Cells need the nutrients and hormones in the FBS to grow 
properly, but these fatty acids may interfere with fatty acid synthesis experiments. Charcoal 
treating the serum removes hormones and fatty acids, and can be used prior to experiments 
where those may interfere (Aakvaag et al., 1990). Finally, immortalized hepatic cell lines are 
useful for studying fatty acid metabolism because they have a long lifespan, they can be 
genetically stable (Castell et al., 2006), and the liver is one of the major sites of fatty acid 
metabolism in animals and humans. However, these cell lines also have some disadvantages. 
Immortalized cell lines are often genetically manipulated which may alter their phenotype, 
response to experimental treatment and overall normal function (Kaur and Dufour, 2012).  
Primary liver cell cultures may allow for a more physiological representation of fatty acid 
metabolism, including hormone studies, but have limitations as they often stop growing after 
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reaching confluence, they cannot be subdivided easily, and their mRNA expression is disrupted 
by the collagenase treatment required to prepare the tissue for culturing (Castell et al., 2006). 
2.6 Rat Estrous Cycle and Human Menstrual Cycle 
Female rats have a four-day estrous cycle. Each stage of the cycle lasts for approximately 
twenty-four hours. During the cycle, estrogen concentrations fluctuate from 30 pg/ml during the 
estrus stage, to 40-50 pg/ml during the metestrus and diestrus stages, to highs of 150 pg/ml 
during proestrus (Flores et al., 2011). Progesterone levels are lowest during estrus, at 5 ng/ml. 
Levels rise during metestrus and diestrus to approximately 20 ng/ml and peak at 40 ng/ml during 
proestrus (Smith, Freeman, and Neill, 1975). Typical hormone changes over the rat estrous cycle 
are shown in Figure 2.3. 
During a regular, 28-day human menstrual cycle, hormones change in a predictable 
pattern, but do not reach the dramatically high or low concentrations observed during pregnancy 
or menopause, respectively. The first phase of the menstrual cycle is the follicular phase, which 
occurs from day 1 until ovulation on day 14. At the beginning of the follicular phase, the 
circulating estrogen concentration is low (approximately 0.1 nmol/L). Then it begins to increase 
around day 10, and peaks at 0.7 nmol/L prior to ovulation. Following ovulation, the luteal phase 
occurs. Estrogen concentrations decrease slightly but remain elevated compared with the 
follicular phase, at 0.5 nmol/L through the duration of the luteal phase (ovulation to day 28) 
(Sramkova et al., 2015). Progesterone is generally low from menses until ovulation, where it 
rises sharply and remains elevated throughout the luteal phase (Sramkova et al., 2015). The 
changes in estrogen, progesterone and leuteinizing hormone over a regular menstrual cycle are 
shown in Figure 2.4. In general, total triacylglycerols (TAG) and cholesterol in the blood are 
lower during the luteal phase of the menstrual cycle compared with the follicular phase, in 
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women with regular menstrual cycles (Pahwa, Seth, and Seth, 1998; Barnett et al., 2004; Kim 
and Kalkhoff, 1979; Schisterman, Mumford, and Sjaarda, 2014). Plasma non-esterified fatty 
acids concentrations in blood do not appear to differ based on menstrual cycle phase (Heiling 
and Jensen, 1992). 
Women taking hormonal-based oral contraceptives, which work by either providing a 
constant dose of hormones over the menstrual cycle (monophasic birth control) or differing 
doses of hormones depending on the week (bi- and triphasic birth control). Many oral 
contraceptives have a twenty-one day active period where women take the hormones followed 
by seven days where no hormones are consumed. Withdrawal bleeding usually occurs 
approximately four to five days after women stop taking the hormones (Sulak et al., 2000). Some 
oral contraceptives have different lengths of the active hormone and the off period, but twenty-
one days on and seven days off is the most common (Nappi, Kaunitz, and Bitzer, 2016). 
Hormone dose varies widely in different brands and types of oral contraceptives. 
2.7 Estrogen Signaling 
 Estrogen is a name referring to a group of sex hormones that is synthesized mainly in the 
ovaries and the testes from cholesterol by the enzyme aromatase (Graham-Lorence et al., 1991). 
There are 3 main biological forms of estrogen: estradiol, estrone and estriol. Of these, estradiol 
displays the greatest potency in both breast cancer proliferation and estrogen receptor binding 
assays (Gutendorf and Westendorf, 2001). Some synthetic forms of estrogen, such as 
ethinylestradiol and diethylstilbestrol, are actually more potent and bind more strongly to 
estrogen receptors than estradiol (Gutendorf and Westendorf, 2001). These synthetic forms of 
estrogen are often used in hormone-based oral contraceptives and hormone therapy. 
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 There are two major isoforms of the estrogen receptor: estrogen receptor alpha (ERα) and 
estrogen receptor beta (ERβ). ERα is expressed in uterus, ovaries, pituitary gland, kidney, liver, 
adrenal gland, heart, testis, prostate gland and the epididymis (Kuiper et al., 1997), and is the 
primary form involved in mediating female reproduction.  ERα is also the major estrogen 
receptor involved in estrogen signalling in the liver, and therefore is most likely to be the ER 
form involved in mediating effects of estrogen on hepatic fatty acid biosynthesis. ERβ is more 
involved in “non-classical” target tissues and in signaling in the male reproductive system, and is 
expressed in testis, prostate gland, epididymis, pituitary gland, ovaries, bladder, lung, spinal cord 
and several regions of the brain (Kuiper et al., 1997). 
 In classic genomic signaling, estrogen crosses the cell membrane and binds to a receptor 
(ERα or ERβ), which is inactive and surrounded by chaperone proteins. Upon ligand binding, the 
chaperones dissociate and the receptor dimerizes with another ER, forming a homo- or hetero-
dimer (ERα/ERα, ERβ/ERβ or ERα/ERβ) (Cowley et al., 1997), and translocates to the nucleus. 
This complex can bind to a specific sequence in the promoter region of a gene called the 
estrogen response element (ERE). The consensus sequence for the ERE is GGTCAnnnTGACC 
(where n is any base pair) (Gruber et al., 2004). After this binding occurs, transcription of the 
gene is either increased or decreased. Several co-activators and co-repressors can also interact 
with the estrogen receptor dimer to regulate its effect on gene expression (Safe and Kim, 2004; 
Safe and Kim, 2008).  
In addition to this classical, genomic signalling pathway, membrane-localized ER have 
also been reported, which can activate alternate signalling cascades. Three major pathways have 
been shown to be influenced by membrane ER signalling: Ras-Raf-MEK-MAPK, Src-PI3K-Akt-
eNOS, and PLC-PKC-cAMP-PKA (Zhang and Trudeau, 2006). While influencing gene 
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expression can take hours, membrane ER signaling is very rapid, and occurs within seconds to 
minutes. In addition, however, these processes can also influence genomic signalling of ER, 
since these cascades may phosphorylate one of the co-activators or co-repressors of ER action, or 
phosphorylate ER itself (Zhang and Trudeau, 2006). In this way, the rapid, non-classical 
membrane-ER pathway can influence the classical, genomic regulatory action of ER by 
influencing ability of the nuclear form to bind to an ERE. 
2.8 Estrogen Effects on Fatty Acid Composition 
The higher blood levels of 16:0 and 22:6n-3, and lower levels of 18:1n-9, in women 
compared with men (Metherel et al., 2009; Marangoni et al., 2007; Crowe et al., 2008) have been 
hypothesized to be due to effects of estrogen, since estrogen concentrations are much higher in 
women compared with men (Eldrup, Lindholm, and Winkel, 1987). Several studies in 
ovariectomized rodents and/or treating rodents with estrogen pellets have been completed (see 
Table 2.3 for summary of rodent hormonal manipulation studies). In general, ovariectomized 
animals treated with estrogen have higher blood and hepatic levels of 18:0, 16:1n-7, 18:1n-7, and 
22:6n-3, compared with untreated ovariectomized animals (Kitson et al., 2013a; Marks et al., 
2013a; Mason et al., 2014).  In rodent models, MUFA composition and elongase 6 expression 
appear to consistently respond to estrogen. Levels of 18:0 are higher and 16:1n-7 and 18:1n-7 are 
lower in; females compared with males (Marks, Kitson, and Stark, 2013), ovariectomized rats 
given hormone treatment as compared with untreated ovariectomized rats (Oh, Jin, and Park, 
2015; Marks et al., 2013a), and ERα knockout mice compared with wild type mice (Kitson, 
2013). The opposite trend is seen in ERα-positive breast cancer cells treated with estrogen. 
MCF7 and MCF-10F cells have lower levels of 18:0 and higher levels of 16:1n-7 and 18:1n-7 
when treated with estrogen (Belkaid et al., 2015), suggesting there may be disrupted MUFA 
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metabolism in cancer cells that is different from an animal model. This is possibly due to an 
induction in SCD expression in MCF7 cells (Belkaid et al., 2015), which is usually repressed by 
estrogen in animals (Paquette et al., 2008). Aromatase knockout mice lack the capacity to 
synthesize estrogens. Aromatase knockout mice are obese and have hepatic steatosis (Jones et 
al., 2000), which appears to be due to an increase in fatty acid uptake rather than decreased 
lipolysis or increased de novo biosynthesis (Misso et al., 2003). Aromatase knockout animals are 
also hyperinsulinemic, hyperleptinemic and hypertriglyceridemic (Jones et al., 2000). These 
effects are not unique to the aromatase knockout model. Ovariectomized animals are also 
hyperphagic and accumulate TAG in the liver (Kitson et al., 2015). In both of these models, 17β-
estradiol reverses these effects (Chow et al., 2011; Hewitt et al., 2004; Kitson et al., 2013b; 
Marks et al., 2013b), suggesting that estrogen is an important regulator of lipid metabolism. 
However, no work has examined fatty acid composition in aromatase knockout mice. 
Women tend have higher blood levels of very long chain omega 3 fatty acids as 
compared with men after controlling for diet (Metherel et al., 2009; Patterson et al., 2015; 
Marangoni et al., 2007; Crowe et al., 2008). It has been hypothesized that this sexual dimorphism 
exists to support the fetal demand for 22:6n-3 during pregnancy and is associated with estrogen 
concentrations (Burdge and Calder, 2005).   The omega-3 fatty acid changes after manipulation 
of estrogen status in rodents by either ovariectomy or knocking out ERα gene expression are not 
always consistent with this estrogen-based hypothesis from human studies. Female rats have a 
greater capacity to synthesize 22:6n-3 from dietary precursors compared with males (Burdge and 
Calder, 2005; Alessandri et al., 2012). Estrogen treatment of ovariectomized rats increases very 
long chain omega 3 PUFA levels and D6D protein levels (Kitson et al., 2013a; Mason et al., 
2014), but ERα knockout mice do not show reduced 22:6n-3 or D6D gene levels (Kitson, 2013). 
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However, ERα knockout mice have membrane-bound ERα, as it is only the DNA binding 
domain of the ERα gene that is disrupted (Couse et al., 1995).  Therefore it is possible membrane 
based ERα signalling could be supporting omega-3 PUFA metabolism, which has been proposed 
previously (Kitson, Stroud, and Stark, 2010).  Additionally, in the ERα knockout model estrogen 
concentrations are ten times higher compared with wild type animals as a compensatory reaction, 
therefore any membrane based ERα signalling is likely enhanced (Couse et al., 1995). 
The effect of sex hormones on fatty acid metabolism in humans can also be examined in 
models where sex hormones change endogenously such as pregnancy, menopause and over the 
menstrual cycle or through exogenous use such as oral contraceptives and hormone therapy with 
menopause (see summary Table 2.4 for summary of studies examining fatty acid composition 
during hormone changes).  In pregnant women estrogen increases more than seven-fold from 
approximately 3.2 nmol/L during the first trimester to 22.6 nmol/L during the third trimester 
(Soldin et al., 2005; Meyer et al., 2013). Over the same time course, the plasma proportions of 
16:0, 16:1n-7, 22:5n-3 and 22:6n-3 rise, and then decrease back to baseline levels following 
delivery (Al et al., 1995; Stark et al., 2005; Kuipers et al., 2011; Ghebremeskel et al., 2000), 
while the proportion of 18:0 and 20:5n-3 remains lower in pregnant women compared with non-
pregnant women (Stark et al., 2005). During menopause estradiol falls from an average 
concentration of 0.43 nmol/L in premenopausal women to approximately 0.08 nmol/L in post-
menopausal women (Walsh et al., 1991; Bojar et al., 2015; Fuhrman et al., 2014) and 
premenopausal women have higher 16:0, 18:1n-9, 18:2n-6 and 22:6n-3 in erythrocytes as 
compared with postmenopausal women (Tworek et al., 2000). Postmenopausal women taking 
hormonal therapy have higher levels of 16:0, 16:1n-7, 20:3n-6, and 20:5n-3, and a lower 
18:0/16:0 ratio and lower levels of 22:5n-3 than those not taking hormonal therapy (Stark, Park, 
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and Holub, 2003; Sumino et al., 2003; Ottosson et al., 1984; Stark et al., 2000). Effects of 
hormone therapy on concentrations of 22:6n-3 in the blood have been mixed (Sumino et al., 
2003; Stark, Park, and Holub, 2003). However, the pattern of fatty acid changes with increased 
estrogen tend to mimic response of increased estrogen during pregnancy.  Increased estrogen 
appears to mediate a response resulting in higher 16:0, 16:1n-7, and 22:6n-3. During the 
follicular phase of the menstrual cycle, estrogen concentrations are approximately 0.1 nmol/L. 
These levels peak at 0.7 nmol/L during ovulation and remain at approximately 0.5 nmol/L 
through the luteal phase (Sramkova et al., 2015).  To our knowledge, only one study has 
examined lipid changes over the menstrual cycle and was completed when determining long 
chain PUFA such as 22:6n-3 by gas chromatography was more difficult and often not reported. 
The relative proportion of 16:0, 18:0 and 18:1n-9 in plasma cholesteryl esters is higher during 
the luteal phase compared with the follicular phase (Mattsson, Silfverstolpe, and Samsioe, 1985) 
and levels of 18:0 and 18:1n-9 in plasma phospholipids are lower during the luteal phase 
(Mattsson, Silfverstolpe, and Samsioe, 1985). Full fatty acid composition or quantitative data 
have not been reported during the menstrual cycle. Studies examining oral contraceptive use 
have reported higher levels of 16:0, 16:1n-7 and 22:6n-3 in plasma cholesteryl esters (Giltay et 
al., 2004) and lower concentrations of 20:4n-6, 20:5n-3 and 22:5n-3 in plasma and erythrocytes 
(Fehily et al., 1982) in women taking oral contraceptives compared with women not taking oral 
contraceptives. 
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Table 2.1. Summary of enzymes involved in de novo fatty acid biosynthesis. 
Common name Gene name Protein name Usual substrates Usual products 
Fatty acid 
synthase 
Fasn FASN Malonyl-CoA 16:0 
Stearoyl-CoA 
desaturase 
Scd1 SCD1 18:0, 16:0 18:1n-9, 16:1n-7 
Elongase 6 Elovl6 ELOVL6 16:0 18:0 
Delta-5 
desaturase 
Fads1 D5D 20:4n-3, 20:3n-6 20:5n-3, 20:4n-6 
Delta-6 
desaturase 
Fads2 D6D 18:3n-3, 24:5n-3, 18:2n-6, 
24:4n-6 
18:4n-3, 24:6n-3, 18:3n-6, 
24:5n-6 
Elongase 2 Elovl2 ELOVL2 20:5n-3, 22:5n-3, 20:4n-6, 
22:4n-6 
22:5n-3, 24:5n-3, 22:4n-6, 
24:4n-6 
Elongase 5 Elovl5 ELOVL5 18:4n-3, 20:5n-3, 18:3n-6, 
20:4n-6, 16:1n-7 
20:4n-3, 22:5n-3, 20:3n-6, 
22:4n-6, 18:1n-7 
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Table 2.2. Summary of studies reporting sex differences in fatty acid composition in rats and humans. 
Study Subjects Diet Results 
Rat studies 
Marks et al. 2013 Male and female Sprague-Dawley 
rats, aged 14 weeks of age 
Ad libitum access to AIN-93G diet Females had lower concentrations of 16:0, 18:1n-7 and 18:1n-
9, and higher 18:0, in hepatic phospholipids and plasma total 
lipids compared with males 
Extier et al. 2010. Male and female Wistar rats, aged 8 
weeks of age. 
Ad libitum access to a diet containing sub-
optimal amounts of 18:3n-3 
Females had higher 22:6n-3 in plasma and liver phospholipids 
compared with males 
Kitson et al. 2012 Male and female Sprague-Dawley 
rats, aged 14 weeks of age 
Ad libitum access to AIN-93G diet Females had lower concentrations of 18:2n-6 and 22:5n-3, and 
higher 18:3n-6 and 22:6n-3 in hepatic phospholipids and 
plasma total lipids, compared with males 
Burdge et al. 2008 Male and female Wistar rats, aged 
15 weeks of age 
Mothers were fed four different diets; 
during lactation and after weaning, rats all 
received the same diet 
The proportion of 16:0, 18:1n-9, 18:2n-6 and 20:5n-3 were 
lower, while the proportion of 18:0, 20:4n-6 and 22:6n-3 were 
higher in hepatic phospholipids of females compared with 
males 
Human Studies 
Dewailly et al. 
2001 
Adult men and women from the 
Inuit population of Nunavik 
Habitual intake, measured by 24 hour food 
recall, and FFQ in women 
Women have a higher proportion of 20:5n-3 and 22:6n-3 in 
plasma compared with men 
Childs et al. 2014 British adult men and women Subjects received either 1.5g/day or 
9.5g/day of 18:3n-3 for 6 months 
Women who received 9.5 g/day of 18:3n-3 had higher 20:5n-3 
in plasma phospholipids compared with men 
Giltay et al. 2004 Men, women who take oral 
contraceptives and women who do 
not take oral contraceptives from 
The Netherlands 
Strictly controlled laboratory diet for 3 
weeks 
Women have higher proportions of 16:0, 16:1, 18:1n-7 and 
22:6n-3, and lower proportions of 18:0 and 18:1n-9 in plasma 
cholesteryl esters compared with men 
Bakewell, Burdge 
and Calder. 2006 
Adult British men and women; of 
the women, half took an oral 
contraceptive, half did not; blood 
was taken on day 10 of menstrual 
cycle 
Habitual intake, measured with FFQ Women have higher 22:6n-3 in plasma compared with men 
Crowe et al. 2008 New Zealanders who were at least 
15 years of age 
Habitual intake, measured with 24 hour 
recall 
Women have lower 20:5n-3 and 22:5n-3, and higher 22:6n-3 
in plasma phospholipids compared with men 
Marangoni et al. 
2007 
Italian adults Habitual intake, measured with 3 day food 
record 
Women have lower 18:1n-9 and 22:5n-3 in whole blood 
compared with men 
Metherel et al. 
2009 
Canadian men and women Habitual intake, measured with 3 day diet 
record 
Women have a higher proportion of 16:0 and 22:6n-3, and a 
lower proportion of 22:5n-3 in blood, compared with men 
Patterson et al. 
2015 
Canadian men and women Habitual intake, measured with FFQ Women have a lower proportion of 22:5n-3 and a higher 
proportion of 22:6n-3 in blood than men 
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Table 2.3. Summary of studies reporting fatty acid composition and enzyme expression changes during situations of altered hormone status in 
rodents. 
Hormonal manipulation (rodents) 
Alessandri et al. 
2011. 
Female Wistar rats Rats were ovariectomized and received either zero, one or 
two estradiol constant-release pellets, or sham-operated 
Levels of 22:6n-3 were higher in hepatic phospholipids of the 
animals who received estradiol pellets, compared with sham 
operated and ovariectomized animals 
Marks et al. 
2013. 
Female Sprague-
Dawley rats 
Rats were ovariectomized or sham-operated. 
Ovariectomized rats received either no pellet, or a pellet 
containing estradiol, progesterone, or both, for two weeks 
Elongase 6 and stearoyl-CoA desaturase expression and hepatic 
and plasma phospholipid concentrations of 16:0 and 18:1n-7 
were highest in ovariectomized animals receiving estradiol, 
while 18:0 was lowest in these groups, compared with sham 
operated, ovariectomized, and animals receiving progesterone. 
Jones et al. 
2000. 
Aromatase 
knockout mice 
No intervention Aromatase knockout mice are obese and have hepatic steatosis. 
They are also hyperinsulinemic, hyperleptinemic and 
hypertriglyceridemic. 17β-estradiol reverses these effects. 
Mason et al. 
2014. 
Athymic female 
mice (BALB/c 
nu/nu) 
Ovariectomized mice had an estradiol pellet implanted for 
two weeks, after which time half of the animals had it 
removed.  
18:0 and 22:6n-3 were significantly higher in the animals 
receiving estradiol, while 18:1n-7 and 18:1n-9 were lower in 
these animals. 
Kitson et al. 
2013. 
Female Sprague-
Dawley rats 
Rats were ovariectomized or sham-operated. 
Ovariectomized rats received either no pellet, or a pellet 
containing estradiol, progesterone, or both, for two weeks 
Delta-6 desaturase expression and hepatic and plasma 
phospholipid concentrations of 20:5n-3, 22:5n-3, 22:6n-3 and 
22:5n-6 were the highest in ovariectomized rats receiving 
estrogen, compared with the other groups.  
Bryzgalova et 
al. 2006. 
ERα knockout 
mice, wild type 
controls 
No intervention Hepatic expression of stearoyl-CoA desaturase 1 was twice as 
high in ERα knockout mice compared with controls 
Paquette et al. 
2008. 
Female Sprague-
Dawley rats 
Rats were ovariectomized or sham operated. 
Ovariectomized rats received either no pellet, or a pellet 
containing estradiol 
Stearoyl-CoA desaturase 1 expression was higher in 
ovariectomized animals compared with sham operated animals, 
and this effect was not observed in ovariectomized rats who 
received estrogen pellets. 
Kitson et al. 
2015. 
Female Sprague-
Dawley rats 
Rats were ovariectomized or sham operated. 
Ovariectomized rats were either allowed ad libitum access 
to food, or were pair-fed with the sham operated rats. 
Ovariectomized rats had higher stearoyl-CoA desaturase 1 
expression compared with sham operated rats. This effect was 
not observed in pair-fed ovariectomized rats. 
Pregnancy (Rats) 
Chen, Yang and 
Cunnane. 1992. 
Pregnant Sprague-
Dawley rats 
Fatty acids were analyzed in non pregnant rats, and at 
days 13, 15 and 21 of gestation 
The proportion of 16:0 and 22:6n-3 increased over gestation, 
while 18:0 and 20:4n-6 decreased, in serum and hepatic 
phospholipids. 
Burdge, Hunt 
and Postle. 
1994. 
Late pregnancy in 
Wistar rats  
Non-pregnant or pregnant rats at 16 and 21 days of 
gestation were injected with labelled choline or 
methionine 
Phospholipids containing 16:0/22:6n-3 increased during the first 
16 days of pregnancy, and continued until term. 
29 
 
 
Table 2.4. Summary of studies reporting fatty acid composition changes during situations of altered hormone status in humans. 
Study Subjects Study Design Results 
Pregnancy (Human) 
Stark et al. 
2005. 
African-American 
women at 24 weeks 
gestation, delivery and 
3 months postpartum 
Comparison of plasma fatty acid composition at 24 weeks 
gestation, delivery and 3 months postpartum. 
In plasma, the proportion 16:0 increased over the course of 
gestation, while 16:1 and 20:5n-3 decreased. Postpartum, 
16:0, 16:1 and 22:6n-3 decreased, while 20:5n-3 increased. 
Al et al. 1995. Pregnant, healthy 
women 
Blood samples were taken at 10, 14, 18, 22, 26, 30, 32, 35, 
36 and 40 weeks gestation 
22:6n-3 concentrations increased significantly through 
gestation, although the relative proportion remained stable. 
Concentration of 22:6n-3 leveled off towards the end of 
pregnancy in plasma phospholipids. 6 months after 
delivery, the proportion was lower than during pregnancy. 
Kuipers et al. 
2011. 
Women from 3 
different populations, 
consuming either a 
low, medium or high 
fish diet 
Comparison of maternal erythrocyte profiles at delivery and 
3 months postpartum. 
22:6n-3 erythrocyte concentrations were higher at delivery 
as compared with postpartum erythrocyte concentrations, 
in all 3 populations. 
Otto et al. 2001. Postpartum fatty acid 
composition of 
lactating and non-
lactating women  
Plasma and erythrocyte fatty acid composition was 
compared between these 2 groups and over time, beginning 
at 36 weeks gestation and ending at 64 weeks postpartum. 
22:6n-3 percentages declined steadily in both groups 
postpartum, with a significant difference between groups. 
Ghebremeskel 
et al. 2000. 
Non-pregnant Korean 
women and Korean 
women in their third 
trimester 
Fatty acid composition of plasma and were compared 
between these 2 groups. 
Pregnant women have a higher proportion of 16:0, 16:1, 
18:1n-9 and 22:6n-3, and lower 18:0 and 22:5n-3, 
compared with non-pregnant women in plasma 
phospholipids. 
Burdge et al. 
2006. 
Non-pregnant women 
and pregnant women 
Plasma phospholipid composition was measured and 
compared between non-pregnant women and pregnant 
women in early (20-22 weeks) and late (30-34) gestation, 
and postpartum 
The concentration of 22:6n-3 in plasma phospholipids 
increased throughout pregnancy, and was approximately 
230% higher in pregnant and post partum women, 
compared with non pregnant women.  
Menopause    
Stark and 
Holub. 2000. 
Postmenopausal 
women 
Algal 22:6n-3 supplementation in postmenopausal women 
taking and not taking hormone therapy. 
Retroconversion of 22:6n-3 to 20:5n-3 was lower in 
postmenopausal women taking hormone therapy. 
Stark et al. 
2003. 
Premenopausal women 
and postmenopausal 
women  
Postmenopausal women were receiving or not receiving 
hormone therapy. 
The postmenopausal women receiving hormone therapy 
had higher concentrations 16:0, 16:1, 20:3n-6 and 22:5n-3 
than the women in the other two groups. 
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Tworek et al. 
2000. 
Premenopausal and 
postmenopausal 
women 
No intervention. Postmenopausal women had lower amounts of 16:0, 18:1n-
9, 18:2n-6 and 22:6n-3 in erythrocytes compared with 
premenopausal women. 
Sumino et al. 
2003. 
Postmenopausal 
women 
Half of the women received hormone therapy and half did 
not, for one year 
Concentration of 20:5n-3 and 22:6n-3 increased at the one 
year mark compared with baseline, in women who received 
hormone therapy. 
Ottosson et al. 
1984. 
Postmenopausal 
women 
Women received either ethinyl estradiol or estradiol valerate Treatment with ethinyl estradiol reduced 16:0 and 
increased 18:0 levels 
Menstrual cycle/oral contraceptives 
Pahwa, Seth and 
Seth. 1998. 
Indian women with 
regular menstrual 
cycles 
Venous blood was collected at day 10-12 of the menstrual 
cycle (follicular phase) and day 22-24 (luteal phase) 
Serum triacylglycerols were higher during the follicular 
phase of the menstrual cycle 
Barnett et al. 
2004. 
Caucasian women with 
regular menstrual 
cycles 
Women consumed a standard laboratory diet. Venous blood 
was collected at day 3-9 of the menstrual cycle (follicular 
phase) and approximately 10 days after ovulation (luteal 
phase) 
Total LDL-cholesterol was higher during the follicular 
phase compared with the luteal phase of the menstrual 
cycle 
Kim and 
Kalkhoff. 1979. 
Women with menstrual 
cycles 21-35 days in 
length 
Venous blood was collected every 3-5 days for 3 menstrual 
cycles 
Total plasma triacylglycerols were highest at ovulation and 
fell during the luteal phase, and cholesterol concentrations 
were the lowest during the luteal phase 
Heiling and 
Jensen. 1992. 
Women with regular 
menstrual cycles, 28-35 
days in length 
Venous blood was collected at day 4-10 of the menstrual 
cycle (follicular phase) and day 18-24 (luteal phase) 
Plasma non-esterified fatty acid concentrations were not 
different between the different menstrual cycle phases. 
Fehily et al. 
1982. 
British adult women Women who use estrogen and progesterone combination 
oral contraceptives and age-matched controls who do not 
use oral contraceptives 
16:0 was higher, and 18:0, 20:4n-6, 20:5n-3 and 22:5n-3 
were lower in plasma phospholipids, in women who use 
oral contraceptives compared with those who do not 
Giltay et al. 
2004. 
Women from the 
Netherlands who take 
or do not take oral 
contraceptives 
Women consumed the same standard laboratory diet for 3 
weeks. Blood was collected during the follicular phase of 
the menstrual cycle 
Women taking oral contraceptives had a higher proportion 
of 16:0, 16:1 and 18:1n-9, and lower 18:0, compared with 
women not taking oral contraceptives 
Mattsson et al. 
1985. 
Swedish adult women 
with regular menstrual 
cycles 
Venous blood was collected at day 6-8, 13-15, 20-22 and 
27-29 of the menstrual cycle 
16:0,18:0 and 18:1n-9 increased in plasma cholesteryl 
esters during the luteal phase. 18:0 and 18:1n-9 were lower 
during the luteal phase compared with the follicular phase 
in plasma phospholipids.  
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Figure 2.1. Diagram of the de novo biosynthesis pathway of saturated and monounsaturated fatty 
acids. Solid lines represent the usual pathway, while dashed lines represent an alternate pathway 
that is activated when levels of 16:0 are elevated. Acc: acetyl-CoA carboxylase; Elovl5: 
elongation of fatty acids family member 5; Elovl6: elongation of fatty acids family member 6; 
Fasn: fatty acid synthase; Scd1: stearoyl-CoA desaturase 1. 
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Figure 2.2. Diagram of de novo biosynthesis pathway of n-6 and n-3 polyunsaturated fatty acids. 
Elovl2: elongation of fatty acids family member 2; Elovl5: elongation of fatty acids family 
member 5; Fads1: fatty acid desaturase 1; Fads2: fatty acid desaturase 2. 
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Figure 2.3 Typical hormone pattern of estrogen, progesterone and leuteinizing hormone over the 
rat estrous cycle. Taken from (Smith, Freeman, and Neill, 1975). 
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Figure 2.4 Typical hormone pattern of A. estradiol B. progesterone and C. leuteinizing hormone 
over a regular human menstrual cycle.  
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Chapter 3.  
Rationale and Objectives 
3.1 Rationale 
 Fatty acids are involved in a wide range of cellular functions, including oxidation for 
energy (McCloy et al., 2004), structural support (Farkas et al., 2000), neurotransmission (Bazan, 
Musto, and Knott, 2011; Zimmer et al., 2000), cell signaling (Bazan, Musto, and Knott, 2011; 
Huang et al., 2012) and more. Maintaining adequate n-3 PUFA metabolism is critical during 
pregnancy because the fetus requires substantial amounts of 22:6n-3 for proper brain 
development (Burdge et al., 2003; Ghebremeskel et al., 2000; Lauritzen et al., 2016; Roy et al., 
2012), which continues during lactation (Koletzko, Cetin, and Brenna, 2007; Otto et al., 2001; 
Rodriguez-Cruz et al., 2011). N-3 PUFA are also important during later life stages and have been 
linked to cognition (Carlson, 2001; Luchtman and Song, 2013; McNamara and Carlson, 2006) 
and a reduction in the risk for cardiovascular disease (GISSI-Prevenzione Investigators, 1999). 
Blood levels of other fatty acids such as SFA and MUFA have been associated with an increased 
risk of cardiovascular disease and diabetes (Cho et al., 2014; Dimopoulos et al., 2006; Djousse et 
al., 2012b; Jakobsen et al., 2009), although this relationship is not entirely clear. Therefore, it is 
necessary to understand the factors influencing blood and tissue fatty acid composition. Previous 
work indicates that estrogen is one such factor, because female sex (Crowe et al., 2008; 
Marangoni et al., 2007), pregnancy (Bascunan et al., 2014; Burdge et al., 2006; Kuipers et al., 
2011; Ramos et al., 2003; Vlaardingerbroek and Hornstra, 2004), menopause (Stark and Holub, 
2004; Stark et al., 2000; Tworek et al., 2000) and estrogen treatment (Kitson et al., 2013b; Marks 
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et al., 2013b; Magnusardottir et al., 2009; Giltay et al., 2004) all result in changes in fatty acid 
composition. However, the mechanism underlying these changes is unknown. 
 Estrogen may influence fatty acid composition by regulating fatty acid elongase and 
desaturase mRNA expression, since many reports of estrogen-based changes in fatty acids are 
accompanied by changes in mRNA levels (Kitson et al., 2013b; Marks et al., 2013b; Childs et 
al., 2012; Sibbons et al., 2014). Many of these effects occur with large changes in estrogen 
levels, such as pregnancy or menopause, but it is not known if smaller changes in estrogen levels 
would have the same effect. Additionally, there are many limitations to hormonal and gene 
manipulation studies in animals, so it is difficult to make conclusions regarding the role of 
estrogen in regulating fatty acid elongase and desaturase expression and fatty acid composition 
because estrogen is not the only factor that is changing. 
The effects of small physiological changes in estrogen levels in blood fatty acid 
composition over the human menstrual cycle and rat estrous cycle were examined. Additionally, 
hepatic enzyme expression was measured in rats during the estrous cycle. Since the direct effect 
of estrogen on regulating gene expression and fatty acid composition has not been measured, an 
estrogen responsive cell line was used to examine the effects of estrogen on gene expression. 
Lastly, a novel Fads2 transcript variant was found to be expressed in MCF7 cells, and its activity 
towards synthesis of 20:4n-6 and 22:6n-3 was examined. These findings will expand our 
knowledge of the role of sex and estrogen on regulating fatty acid composition and enzyme 
expression in general, but will also aid in developing guidelines for dietary fat intake over the 
life cycle.  
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3.2 Objectives 
The first objective of this thesis was to examine if the subtle changes in circulating estrogen 
concentrations that occur over the menstrual cycle in women would be associated with changes 
in blood fatty acid composition and if those changes are similar to what is observed during other 
models of hormone changes. The fatty acid changes suggested that expression and/or activity of 
Fads2 may be induced by estrogen. Therefore, the second objective was to expand the findings 
from the first objective by using rats. Blood and hepatic fatty acid levels were measured during 
the estrous cycle, the rat equivalent of the human menstrual cycle. By using rats, I was also able 
to examine hepatic enzyme expression and determine if small changes in estrogen mediate 
changes in fatty acid desaturase and elongase mRNA expression and protein levels.  Hepatic 
fatty acid elongase and desaturase expression did change during the estrous cycle, but not always 
in accordance with estrogen changes. Thus, the third objective of my thesis was to examine a 
direct role for estrogen in the regulation of fatty acid biosynthesis by using highly controlled cell 
culture conditions and examining fatty acid desaturase and elongase expression in MCF7 cells, 
an estrogen-responsive cell line, when treated with estrogen. Although FADS2 expression is 
induced by estrogen in MCF7 cells, levels of 20:4n-6 and 22:6n-3 are not increased. Therefore, 
the final purpose of my thesis was to examine perturbations in MCF7 fatty acid metabolism. The 
presence and induction of multiple transcript variants of FADS2 in MCF7 cells in response to 
estrogen was determined. The functionality of each transcript variant in the ability to synthesize 
20:4n-6 and 22:6n-3 was characterized, in addition to protein interactions between the two 
variants that may lead to decreased synthesis.  
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3.3 Hypotheses 
1. Blood levels of 18:0, 16:1n-7 and 22:6n-3 will be higher during the luteal phase of the 
menstrual cycle compared with the follicular phase. 
 
2. Blood levels of 18:0, 16:1n-7 and 22:6n-3 will be higher in women who take oral 
contraceptives, compared with women who do not take oral contraceptives and men. 
 
3. Hepatic expression of Elovl6, Elovl2 and Fads2 as mRNA and protein will be highest during 
proestrus in rats, when circulating estrogen concentrations are highest. 
 
4. Estradiol treatment of MCF-7 cells will increase mRNA expression of FASN, ELOVL6, 
ELOVL2, and FADS2 to elevate concentrations of 16:0, 18:0, 16:1n-7, and 22:6n-3 in MCF-7 
cells. 
 
5.  FADS2_v2, which lacks the cytochrome binding domain that is critical for activity, will not 
synthesize 20:4n-6 or 22:6n-3 when overexpressed in HEK293 cells, while overexpressing 
FADS_v0/1 will increase the levels of these two fatty acids. 
 
6. FADS2_v2 will bind to FADS2_v0/1when both are expressed in HEK293 cells to inhibit 
synthesis of 20:4n-6 and 22:6n-3 by FADS2_v0/1. 
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Chapter 4. 
Common Methods 
4.1 Fatty Acid Analyses 
 Liver, serum, plasma, adipose and cellular total lipids were extracted in 2:1 
chloroform:methanol (v:v) according to the method of Folch (Folch, Lees, and Sloane Stanley, 
1957) . Red blood cell lipids were extracted using 2:2:1.8 chloroform:methanol:water (v:v:v) 
with cold methanol and overnight freezing at -80ºC (Bligh and Dyer, 1959; Metherel et al., 2009; 
Reed et al., 1960). All fatty acid extractions were done in the presence of butylated 
hydroxytoluene as an antioxidant, and an internal standard: 22:3n-3 ethyl ester (Nu-Chek Prep 
Inc, Elysian, MN) for total lipids, triheptadecanoate (T-155 Nu-Chek Prep) for triacylglycerols 
(TAG) and 1,2-diheptadecanoyl-sn-glycerol-3-phosphocholine (850360P, Avanti Polar Lipids 
Inc, Alabaster, AL) for phospholipids, as necessary. 
TAG and phospholipids were isolated by thin layer chromatography using 20 x 20 cm 
plates with a 60Ǻ silica gel layer (Whatman International LTD, Maidstone, England) and a 
mobile phase of 60:40:2 heptane:diethyl ether: acetic acid (v:v:v) (Christie, 1989).  Bands were 
identified by visualization under UV light with 2,7-dichlorofluorescein (Sigma-Aldrich, 
Oakville, ON) and comparison to a reference standard. Phospholipids and TAG were collected 
by scraping the band from the plate and extracting lipids from the silica in 2:1 
chloroform:methanol (v:v). 
Fatty acids in total lipid extracts, in TAG, and in phospholipids were transesterified to 
fatty acid methyl esters with 14% BF3 in methanol at 85°C for 1 hour (Morrison and Smith, 
1964), which were then separated by fast gas chromatography (Stark and Salem, Jr., 2005; 
Metherel, Aristizabal Henao, and Stark, 2013) using a Varian 3900 gas chromatograph (Varian 
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Inc, Mississauga, ON) with settings as described previously (Metherel, Aristizabal Henao, and 
Stark, 2013). The column used was a DB-FFAP capillary column with a 15m x 0.10mm inner 
diameter x 0.10mm film thickness. Hydrogen was used as the carrier gas which had a flow rate 
of 30 ml/minute. The injector temperature was 250ºC. The flame ionization detector was set at 
300ºC. Peaks were identified by comparison to a reference mixture of fatty acids (GLC-569, Nu-
Chek Prep Inc) and quantified relative to the internal standard. Fatty acid results are expressed 
quantitatively per milligram of liver, per 100 microliters of plasma or whole blood and per 200 
milligrams of erythrocyte packed cells. Data are expressed qualitatively as relative weight % of 
total fatty acids. 
4.2 Steroid Hormone Analyses 
Two millilitres of anhydrous diethyl ether were added to 500µL plasma. Samples were 
vortexed thoroughly for 1 minute and centrifuged at 1734  g for 5 min. The supernatant was 
collected, samples were dried under a stream of N2 gas and reconstituted into 75uL of 100mM 
NaHCO3 (pH = 9.0) plus 75uL of 3 mg/mL 1-methylimidazole-2-sulfonylchloride in acetone (Li 
and Franke, 2015). Samples were heated at 65ºC for 15 minutes. After cooling, samples were 
transferred to glass vials, spiked with 500 pmol 1,2-diheptadecanoyl-sn-glycero-3-
phosphatidylcholine to account for sample-to-sample variability, dried fully under N2 and 
reconstituted in 100uL acetonitrile:isopropanol:water +0.1% formic acid. Samples were stored in 
the dark at 4ºC until analysis by ultra-high performance liquid chromatography coupled to 
tandem mass spectrometry (UHPLC-MS/MS). Progesterone, estrone, estriol and 17β-estradiol 
standards were purchased (Sigma-Aldrich, St. Louis, MO, USA) and dilution curves were 
prepared to quantitate steroids in plasma. UHPLC-MS/MS analyses were performed using a 
Dionex UltiMate 3000 UHPLC System (Dionex Corporation, Bannockburn, IL, USA) coupled to 
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a Thermo Q-Exactive Quadrupole-Orbitrap Mass Spectrometer (Thermo-Fisher Scientific, 
Waltham, MA, USA). The column used was a C 18 Ascentis Express, 15 cm x 2.1 mm x 2.0 um 
(Sigma-Aldrich, St. Louis, MO, USA). The mobile phase consisted of solutions A (60:40 
water:methanol) and B (90:10 isopropanol:acetonitrile +10mM ammonium formate +0.1% 
formic acid). The gradient protocol used was as follows: from 0 – 2.0 minutes it was 1% solution 
B, from 2.0 – 6.0 min 20% solution B, 6.0 – 8.0 min 30% solution B, 8.0 – 14.0 min 100% 
solution B with a hold until 19.5 min. From 19.5 – 20 min solution B was decreased to 1%, and 
allowed to equilibrate until the 24 minute mark. The flow was set to 260 uL/min, column 
temperature at 45ºC and tray temperature at 4ºC. The mass spectrometer was operated in positive 
electrospray ionization mode, spray voltage +3.0kV, 35000 resolution and scan range m/z 200-
2000. 
4.3 RNA Extraction and Reverse-Transcriptase Real-Time PCR 
RNA was extracted from animal livers by homogenization in Trizol® reagent (Invitrogen 
Co, Frederick, MD), or from cells by direct addition of Trizol® to the plate (Marks, Kitson, and 
Stark, 2013). Phases were separated by the addition of chloroform. Purity of the extracted RNA 
was determined by using the 260/280 ratio on a Nanodrop c2000 (Thermo Scientific, 
Wilmington, DE). Samples with a 260/280 ratio of 1.90 or greater were used for cDNA 
synthesis, using a high capacity cDNA reverse transcription kit (Applied Biosystems, 
Streetsville, ON) with an MJ mini personal thermal cycler (Biorad Laboratories, Mississauga, 
ON) with program cycle of 25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 seconds, and 
4°C until storage at -80°C. 
 The Primer-BLAST program on the NCBI website was used to design primers. Specific 
primers and sequences are listed in subsequent chapters. Primers were ordered from Sigma-
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Aldrich. Reverse transcriptase real-time PCR was performed using SsoFast EvaGreen Supermix 
(BioRad) on a CFX Connect Real-Time System (BioRad). The program had an initial incubation 
of 95°C for 1 minute, followed by 40 cycles of 95°C for 15 seconds and 65°C for 45 seconds. 
Analysis of data was performed by normalizing the threshold cycle number (Ct) of the gene of 
interest in a control sample to the Ct for the housekeeping gene, 18S ribosomal RNA, to produce 
a ΔCt, which was then normalized to the ΔCt of test sample using the 2-ΔΔCt method. Changes are 
expressed as relative values. 
4.4 Immunodetection 
Livers and cells were homogenized in a buffer containing 25 mM Tris, 130 mM NaCl, 
2.7 mM KCl, 5 mM EDTA and 1% Triton X-100. Protein content was determined using a 
bicinchoinic acid procedure (Smith et al., 1985), and an equal amount of protein was separated 
on a 12% polyacrylamide gel or a 12% TGX Stain-Free fast-cast gel (Bio-Rad), and transferred 
to a polyvinylidene difluoride membrane. The membranes were blocked with 5% skim milk 
powder or 5% BSA in tris-buffered saline (TBS) with 0.5% (v:v) Tween-20 (TBST) at room 
temperature for 1 hour, followed by incubation either for 1 hour at room temperature or at 4ºC 
overnight with primary antibodies in TBST with 1% skim milk powder or 1% BSA. Membranes 
were washed in TBST for fifteen minutes followed by two five-minute TBST washed, incubated 
with appropriate secondary antibodies in the same conditions (5% BSA or 5% skim milk in 
TBST) as the primary antibody for 1 hour at room temperature, washed again with TBST, and 
detected by chemiluminescence using a BioRad ChemiDoc system. Protein content was 
normalized to total protein loaded on the gel, as determined either by gel activation and 
visualization prior to transfer using the ChemiDoc system, or using a Ponceau S stain (Dam et 
al., 2012). 
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4.5 Cell Culture Maintenance 
 MCF7 cells were maintained in 50% Dulbecco’s Modified Eagle’s Medium (DMEM) 
with 50% Ham’s F12 (DMEM/F12), and HEK 293 cells were grown in DMEM. Medium for 
both cell lines was supplemented with 10% fetal bovine serum (FBS) and 100 U/mL penicillin 
and 100 mg/mL streptomycin were added. Cells were grown in an incubator at 37°C with 5% 
CO2 (Roh et al., 2012). Reagents were from Thermo Scientific (Wilmington, DE) unless 
otherwise specified. Cells were grown to 80% confluence and then subdivided at an approximate 
1:6 ratio following trypsin digest. Specific study protocols using MCF7 or HEK 293 cells are 
described in individual chapters.  
4.6 Statistical Analyses 
Statistical analyses were performed using either SPSS for Windows, or GraphPad Prism v4.0. 
Significance was inferred when p < 0.05. Specific statistical tests are described in individual 
chapters. 
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Chapter 5. 
The Effects of Sex, Menstrual Cycle and Oral Contraceptives on Blood Fatty Acids 
5.1 Introduction 
Changes in estrogen concentrations are associated with changes in fatty acid composition 
in humans. This has mainly been observed in comparisons where there are dramatic differences 
in circulating estrogens and includes pregnancy (Al et al., 1995; Stark et al., 2005; Kuipers et al., 
2011; Ghebremeskel et al., 2000), menopause and hormone therapy during menopause (Stark et 
al., 2005) and hormone therapy in transsexuals (Giltay et al., 2004).  It is believed these effects 
are being mediated by estrogenic effects on the expression of elongase and desaturase enzymes.  
These effects typically result in shifts in blood fatty acid compositions with increased estrogen 
being associated with shifts towards increased proportions of 16:0, 16:1n-7 and 22 carbon highly 
unsaturated fatty acids (HUFA) such as 22:6n-3, and decreased proportions of 18:0, 20:5n-3 but 
also 22:5n-3.  The lack of consistency of an estrogen effect, particularly on n-3 HUFA warrants 
further investigation.  This may be due to differences in the size of the concentration shifts as 
estrogen increases more than six-fold during pregnancy compared with non-pregnant women 
(Soldin et al., 2005; Meyer et al., 2013), and decreases approximately five-fold during 
menopause compared with pre-menopausal women (Walsh et al., 1991; Bojar et al., 2015; 
Fuhrman et al., 2014).   
During regular menstrual cycles, hormones change cyclically but do not reach the 
dramatically high or low levels as observed during pregnancy and menopause. Studies 
examining lipid changes over the menstrual cycle are much more limited than pregnancy studies, 
and to our knowledge, no studies have reported blood fatty acid composition during the 
menstrual cycle. There have been examinations of women using hormonal-based oral 
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contraceptives. Oral estrogen was associated with increased 16:0, 16:1n-7 and 22:6n-3 in plasma 
cholesteryl esters (Giltay et al., 2004) and lower concentrations of 20:4n-6, 20:5n-3 and 22:5n-3 
in plasma and erythrocytes (Fehily et al., 1982).  Unfortunately, hormone brand and information 
on monophasic (constant dose of hormones over the menstrual cycle) or triphasic (varying 
hormone concentrations depending on the week) use was not reported.   
Therefore, we wanted to determine if the subtle, physiological changes in sex hormones 
the resulted in changes in fatty acid composition.  Women not taking oral contraceptives and 
women taking the same brand of a monophasic oral contraceptive were examined at two time 
points coinciding with high and low blood levels of estrogen.  A group of age controlled men 
were also included as an additional comparison point to confirm previous observations of sex 
differences in fatty acid composition 
5.2 Materials and Methods 
Male and female participants between the ages of 17 and 29 were recruited from the 
University of Waterloo community through posters, email advertisements, oral announcements 
during lectures, and word-of-mouth (advertisements are shown in Appendix 1). Women were 
included if they took Alesse brand oral contraceptives (which contains ethinyl estradiol and 
levonorgestrel at a constant dose over the active period, with a 21 days on, 7 days off protocol), 
or no form of hormonal based contraceptives within 6 months of the study participation, and had 
regular menstrual cycles between 28-35 days in length. Individuals with existing cardiovascular 
disease, diabetes mellitus, lipid disorders or any disorders that affect circulating estrogen were 
excluded, as were individuals on a vegetarian or vegan diet, or individuals who regularly 
consumed fatty fish, fish oil or any form of hormonal birth control other than Alesse. 
Respondents were screened, and filled out prior to their study participation; a food frequency 
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questionnaire validated for EPA + DHA intake (Patterson et al., 2012) (FFQ found in Appendix 
1), a health screening form and a menstrual health questionnaire. All participants signed an 
informed written consent form (all forms are found in Appendix 1) and all procedures were 
approved by an Ethics Committee at the University of Waterloo. 
Women who were eligible participants attended two blood collections over the menstrual 
cycle: the first was at day 6-8 of the menstrual cycle, representing the follicular phase of the 
menstrual cycle, and the second blood collection was completed during day 21-23 of the 
menstrual cycle, representing the luteal phase. Men attended one blood collection at the 
beginning of the study. All blood collections were done by a certified phlebotomist in the 
Laboratory of Nutritional and Nutraceutical Research at the University of Waterloo, after an 
overnight fast of minimum eight hours. Whole blood was collected by venipuncture into 
Vacutainers, and EDTA was added as an anticoagulant. Whole blood was centrifuged at 3000 
rpm for 15 minutes at 4ºC to separate plasma, buffy coat and erythrocytes. Erythrocytes were 
washed twice with 0.9% saline prior to storage (Patterson et al., 2015). Aliquots of whole blood, 
plasma and erythrocytes were stored in a -80ºC freezer prior to fatty acid analyses.  Plasma and 
erythrocyte lipids were extracted and fatty acids analyzed as described in Chapter 4. Plasma 
hormone concentrations were determined for a randomly selected subset of each group of 
women (n=6 per group) by UHPLC-MS/MS, as described in Chapter 4. 
 Statistical analyses were done using SPSS (IBM, Armonok, NY, version 23). 
Significance was inferred when p < 0.05. Data are presented as mean ± standard deviation. In 
order to examine sex differences in fatty acid composition, each group of women had the fatty 
acid values averaged over the two time points, to represent an average representative value that 
incorporates different menstrual cycle stages, resulting in three groups: men, women taking oral 
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contraceptives, and women not taking oral contraceptives. A one-way ANOVA was used to 
examine differences between these three groups. Following a significant F-value, Tukey’s post 
hoc test was used to determine differences between groups.  The secondary objective was to 
determine how fatty acids change over the menstrual cycle, in women who took oral 
contraceptives and women who did not take oral contraceptives, by examining fatty acid 
composition in these two groups at two different time points of the menstrual cycle. The linear 
mixed models procedure for repeated measures was used to examine the effect of hormone status 
(Alesse or no oral contraceptives), time (day 6-8 or 21-23 of the menstrual cycle) and their 
interaction as fixed factors on blood fatty acid measurements. 
5.3 Results 
5.3.1 Participant characteristics 
 Recruitment began in February 2015 and concluded September 2015. A total of 55 
individuals were screened after expressing interest in participation (17 men, 38 women). All 17 
men were enrolled and completed the study and included in the analyses. Of the 38 women who 
expressed interest, 32 were enrolled into the study (n=12 for the ethinyl estradiol and 
levonorgestrel group, herein referred to as oral contraceptive users, and n=20 for the women who 
were not receiving any oral contraceptives). Two women were not enrolled because they 
consumed fish oil, and four women were not enrolled because they had irregular menstrual 
cycles. Of the 12 participants taking oral contraceptives, one participant was excluded from 
analyses due to hyperlipidemic plasma lipid levels determined during fatty acid analysis, 
resulting in a final group total of 11. Of the 20 women not taking any oral contraceptives, 2 were 
excluded for not being able to provide a venous blood sample, and 3 were excluded for not 
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following the study protocol in regards to maintaining low fish intake throughout the study time 
period, resulting in a final group total of 15.  
 The men were 23.7 ± 2.2 years old, the women taking oral contraceptives were 22.5 ± 2.7 
years old, and the women not taking any oral contraceptives were 21.9 ± 3.0 years old.   The 
menstrual cycle length was 27.8 ± 0.6 days in length in women taking oral contraceptives and 
28.6 ± 1.5 days in length those not taking oral contraceptives. As expected, the women who did 
not take oral contraceptives had lower estradiol, estrone and progesterone concentrations at day 
6-8 (follicular phase), which increased at day 21-23 (luteal phase). This cyclical change in 
endogenous hormones was not observed in women taking oral contraceptives (Table 5.1). The 
oral contraceptive provides 100 µg levonorgestrel and 20 µg of ethinyl estradiol per pill. 
Levonorgestrel was detected in women who took oral contraceptives, but was not found in the 
women who had not taken oral contraceptives, confirming they did not use oral contraceptives 
during the experimental time period. Ethinyl estradiol, the other component of the oral 
contraceptive, was not detectable in the blood samples available using the current analytical 
procedures. 
5.3.2 Sex Differences in Fatty Acid Composition 
 There were numerous fatty acid differences between men and women taking and not 
taking oral contraceptives in plasma (proportions in Table 5.2, concentrations in in Appendix 1 - 
Table A1.1) and erythrocytes (select fatty acids in Figure 5.1, full fatty acid profiles in Appendix 
1 - Table A1.2 and Table A1.3).     However, there were are distinct identifiable patterns. In 
general, women taking oral contraceptives had a higher proportion of 16:0 and 16:1n-7, and a 
lower proportion of 18:0 and 22:5n-3, in both plasma and erythrocytes, compared with men and 
women not taking oral contraceptives. There were more differences in the plasma as compared 
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with erythrocytes. Women taking oral contraceptives had a higher proportion of 20:3n-6 in 
plasma compared with the other groups, and a higher amount of 22:6n-3 compared with men 
only. Accordingly, the DHA:DPAn-3 ratio was higher in oral contraceptive users compared with 
men and women not taking oral contraceptives. The DHA:EPA ratio was not different between 
the groups. 
5.3.3 Menstrual Cycle Fatty Acid Composition 
A significant oral contraceptive use status x time interaction was observed for the 
proportions of 20:1n-9, 20:2n-6, 20:3n-6 and the DHA:EPA ratio in plasma fatty acids  (Table 
5.3, concentration data in Appendix 1, Table A1.4). These fatty acids and the DHA:EPA ratio 
were higher in the women taking oral contraceptives during high exogenous hormone levels (day 
21-23), and did not differ statistically between the other three groups.  An effect of hormone 
status (oral contraceptive use) was observed in the proportion of several fatty acids in plasma 
(Table 5.3). Women taking oral contraceptives had a higher proportion of 16:0, 16:1n-7 and 
20:3n-3, and a lower proportion of 18:0 and 22:5n-3 in plasma than women who did not take oral 
contraceptives. A higher DHA:DPAn-3 ratio was observed in plasma of women taking oral 
contraceptives, which appears to be driven by the lower levels of 22:5n-3. Finally, effects of time 
on plasma fatty acid composition were also observed. In general, at day 6-8 (the follicular 
phase), women had lower proportions of several SFA, 20:1n-9, 22:1n-9, 24:1n-9, 20:2n-6, 22:5n-
6 and 22:6n-3, compared with day 21-23 (the luteal phase). Accordingly, the DHA:DPAn-3 ratio 
was increased during the luteal phase. During the follicular phase, the proportions of 16:0, 16:1n-
7 and 18:3n-6 were higher than during the luteal phase. Fewer changes were observed in 
erythrocyte fatty acids over the menstrual cycle, and they were mainly observed in the weight 
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percentage of fatty acids and not concentrations and they tended to reflect fatty acid differences 
observed in plasma (Appendix 1, Table A1.5 and A1.6).  
5.4 Discussion 
Previous studies have reported sex differences in fatty acid composition (Crowe et al., 
2008; Metherel et al., 2009; Patterson et al., 2015; Marangoni et al., 2007). Sex differences in 
fatty acid composition have been hypothesized to be partially due to the effects of estrogen 
(Kitson, Stroud, and Stark, 2010; Giltay et al., 2004; Burdge and Calder, 2005). However, these 
studies have not controlled for or separated women based on oral contraceptive use or menstrual 
cycle stage. In the present study we observed that in women taking oral contraceptives 
containing ethinyl estradiol and levonorgestrel in a constant dose, proportions of 16:0, 16:1n-7, 
20:1n-9, 22:1n-9, 24:1n-9, 20:3n-6 and 22:6n-3 were higher and proportions of 18:0 and 22:5n-3 
in plasma total lipids were lower, agreeing with previous reports. Interestingly, many of these 
differences were between women who take oral contraceptives and men.  Women with natural 
cycles had either intermediary values or were similar to men, except for 22:5n-3, which was 
consistently lower in both groups of women.  
There are several reasons why oral contraceptives may have a potent effect on fatty acid 
metabolism.  Ethinyl estradiol has been shown to bind to the estrogen receptors more strongly 
than estradiol (Kuiper et al., 1997), and have a longer half-life than naturally occurring estrogens 
(Kapp, 2009).  Oral contraceptive use is also associated with a higher hepatic load due to first 
pass metabolism.  The lack of differences between men and women with natural cycleswas 
somewhat surprising based on previous observations (Metherel et al., 2009).  While it is possible 
that sex differences were largely attributed to women participants taking oral contraceptives 
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within the women grouping, it is possible that the female participants in the present study had 
slightly higher levels of fish and omega-3 intake.  
Sex differences in blood and tissue content of long chain n-3 PUFA appear to be 
dependent on low intakes of 20:5n-3 and 22:6n-3 (Pawlosky et al., 2003b), with dietary intake 
being the strongest factor in determining blood and tissue omega-3 composition (Block, Harris, 
and Pottala, 2008). Previous studies have reported a higher DHA:EPA and DHA:DPAn-3 ratio in 
women compared with men that decrease with fish oil supplementation (Metherel et al., 2009; 
Patterson et al., 2015). Specifically, DHA:EPA in the plasma was reported as 4.82 ± 1.47 for 
women at baseline (Metherel et al., 2009), while presently plasma DHA:EPA was only 3.30 ± 
0.85 in women taking and 2.67 ± 0.85 in women not taking oral contraceptives.  The sum of the 
percentage of EPA+DHA in erythrocytes, an established biomarker of omega-3 PUFA intake 
(Harris and Von, 2004) was approximately 4.5% for all women in the present study, whereas in 
the previous studies it was approximately 3.9% for the women (Metherel et al., 2009; Patterson 
et al., 2015). While all of these studies were done in our laboratory, the previous studies 
specifically recruited participants with low baseline omega-3 levels and did baseline blood 
testing prior to admitting participants into the study. Although our exclusion criteria presently 
included participants with high fish or omega-3 supplementation intake, participants did not have 
any blood screening done prior to study admittance. Future studies should examine fatty acid 
composition in men and women taking and not taking oral contraceptives in populations with 
very low intake. An examination of the effect of omega-3 supplementation may also show 
different responses when comparing women taking and not taking oral contraceptives, and 
should be done in future studies. 
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This differences between  the women taking and not taking oral contraceptives is in 
agreement with a previous report of higher proportions of 16:0, 16:1n-7 and 22:6n-3 in women 
who take oral contraceptives compared with women who do not (Giltay et al., 2004), and a lower 
proportion of 22:5n-3 in contraceptive users compared with women who do not use 
contraceptives (Fehily et al., 1982). Interestingly, the fatty acid changes in women who take oral 
contraceptives observed presently are similar to observations in postmenopausal women taking 
hormone therapy (Stark, Park, and Holub, 2003; Ranganath et al., 1996). Both hormone therapy 
in menopause and monophasic birth control use examined in these studies provided oral ethinyl 
estradiol at constant doses. Examinations using different dosing paradigms (triphasic birth 
control), different types of estrogens and different modes of delivery (oral vs. transdermal) may 
give further insights into the mechanism of estrogens effect on fatty acids. 
The higher proportions of 16:0 and 16:1n-7, and lower 18:0 and 22:5n-3 in women taking 
oral contraceptives was also observed in erythrocyte fatty acids.  Erythrocyte fatty acid 
compositions tend to reflect long-term fatty acid status (Katan et al., 1997; Patterson et al., 
2014), thereby suggesting that these changes in fatty acids are chronic and not transient in 
women taking oral contraceptives. Stronger effects were observed in plasma fatty acids 
compared with erythrocyte fatty acids. This is likely due to the impact of estrogen on plasma 
lipoproteins, since estrogen therapy decreases plasma LDL cholesterol levels and increases TAG 
and TAG-rich VLDL (Walsh et al., 1991; Granfone et al., 1992; Schaefer et al., 1983). Many of 
the fatty acids that were higher in women, including many SFA and MUFA, are generally found 
in TAG, which may be one reason that plasma fatty acid composition has more differences 
between groups than erythrocytes. However, the effects of estrogen on lowering 22:5n-3 levels 
and increasing 22:6n-3 levels would not be driven by changes in plasma TAG, because these n-3 
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PUFA are more often found in phospholipids (Marszalek et al., 2005; Ogura et al., 2010). This 
indicates that estrogen may be influencing plasma n-3 PUFA composition through a different 
mechanism than for SFA and MUFA. One such mechanism may be through inducing hepatic 
elongase and desaturase expression, thereby increasing the synthesis of 22:6n-3.  
Plasma lipoproteins also change over the menstrual cycle (Pahwa, Seth, and Seth, 1998; 
Schisterman, Mumford, and Sjaarda, 2014; Barnett et al., 2004; Kim and Kalkhoff, 1979). Total 
plasma TAG and LDL-cholesterol concentrations are higher during the follicular phase 
compared with the luteal phase. Our findings indicate that fatty acid composition also changes 
during the menstrual cycle. In both groups of women, plasma proportions of 16:0, 18:0, 16:1n-7, 
18:3n-6 and 22:5n-3 all decrease while 18:1n-7 and 22:6n-3 increase during the luteal phase. The 
changes in 22:6n-3 and 22:5n-3 were great enough to result in a higher DHA:DPAn-3 ratio 
during the luteal phase compared with the follicular phase. Overall, these changes corresponded 
to higher plasma estradiol and progesterone in the luteal phase than in the follicular phase in the 
present study in the women not taking oral contraceptives.  Since SFA and MUFA are often 
found in TAG, it is possible that the decreased overall plasma TAG levels during the luteal phase 
may partly explain why these fatty acids decreased. However, changes in plasma lipoproteins 
would not explain the changes in 22:5n-3 and 22:6n-3, since these fatty acids are not found in 
high amounts in TAG. Studies using compartmentalized models showing that the main sex 
difference in 22:6n-3 biosynthesis appears to be the conversion from 22:5n-3 to 22:6n-3 (Burdge 
and Wootton, 2002; Burdge and Calder, 2005). It appears that small increases in estrogen from 
the follicular phase to the luteal phase may be associated with a shift towards fatty acids that are 
produced as a result of increased elongation and desaturation expression and/or activity, 
specifically increasing at the steps between 22:5n-3 and 22:6n-3. Although progesterone levels 
54 
 
are higher during the luteal phase as well, progesterone has minimal effects on fatty acid 
composition and elongase and desaturase enzyme expression in rats while estrogen or estrogen 
plus progesterone have large effects (Kitson et al., 2013b; Marks et al., 2013b; Alessandri et al., 
2011; Alessandri et al., 2012), suggesting that estrogen rather than progesterone is likely a 
greater determinant of fatty acid composition in the present study. 
Many of the changes in fatty acid content observed between collection times were 
observed in both groups of women. Although oral contraceptive users do not have fluctuations in 
hormone levels during the active time of the contraceptive use because each pill provides the 
same dose of ethinyl estradiol and levonorgestrel, the day 6-8 blood collection would mainly be 
at the end of the no hormone time period, while the day 21-23 blood collection was well into the 
active oral contraceptive use (Sulak et al., 2000). This was confirmed by the five-fold increase in 
levonorgestrel at day 21-23 compared with day 6-8. Similar changes in fatty acid composition in 
women taking and not taking oral contraceptives as hormone levels increase further supports the 
hypothesis that estrogen is one contributing factor in fatty acid composition. However, there are 
possibly other factors contributing to blood fatty acid composition during the menstrual cycle, 
since there was a significant hormone x time interaction in plasma levels of several fatty acids. 
5.5 Conclusions 
This is the first study to report a comprehensive examination of sex differences in fatty 
acid composition, by separating women based on contraceptive use, and using fatty acid data 
from two different time points, in addition to examining fatty acid changes over the menstrual 
cycle. Some changes in SFA and MUFA levels over the menstrual cycle in both groups of 
women may be due to the effects of estrogen on plasma lipoprotein levels. Plasma TAG levels 
decrease during the luteal phase of the menstrual cycle, and so do 16:0, 18:0, 16:1n-7 and 18:3n-
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6. The decreased levels of 22:5n-3 and increased levels of 22:6n-3, and corresponding increase in 
DHA:DPAn-3 ratio, are not likely a result of increased plasma TAG because these fatty acids are 
generally found in low concentrations in TAG. It appears that estrogen is increasing desaturase 
and/or elongase activity to result in greater conversion from 22:5n-3 to 22:6n-3. This conversion 
has been shown to be higher in women compared with men previously (Burdge and Wootton, 
2002; Burdge and Calder, 2005). The fatty acid data from the present study indicates that this 
conversion may be further induced during the luteal phase, when estrogen levels are higher. This 
further supports a role for estrogen in mediating elongase and desaturase expression. Future 
research should also examine the mechanism of estrogen therapy on fatty acid composition, 
because women who take oral contraceptives in this study have similar fatty acid profiles to 
those previously reported in postmenopausal women who take estrogen therapy (Stark, Park, and 
Holub, 2003; Tworek et al., 2000). Overall, this work shows that there are fatty acid composition 
differences between women with pharmacological and physiological sources of estrogen, and 
differences over the menstrual cycle. These factors should be considered in future work 
examining fatty acid composition and blood lipid levels in women. 
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Table 5.1: Plasma hormone concentrations in women who take ethinyl estradiol and 
levonorgestrel and women who do not take oral contraceptives during the follicular phase and 
luteal phase of the menstrual cycle 
Plasma Hormones 
pg hormone/ml plasma 
 Women taking oral contraceptives Women with natural cycles 
 Day 6-8 Day 21-23 Day 6-8 Day 21-23 
Estrone 23 ± 23ab 7 ± 6a 8 ± 3a 33 ± 15b 
Estradiol 51 ± 62ab 3 ± 3a 17 ± 19ab 62 ± 24b 
Progesterone 120 ± 133a 123 ± 82a 83 ± 27a 8466 ± 3793b 
Levonorgestrel 1865 ± 1173 9399 ± 15502* n.d. n.d. 
Values are mean ± sd. Means with different letters are significantly different by Tukey’s post-hoc test, 
following a significant F-value for birth control status x time by the linear mixed models procedure. * 
p<0.05 by student’s t-test. n.d. not detected.  
57 
 
Table 5.2: Relative proportion of plasma fatty acids in men, women who take oral contraceptives 
and women who do not take any oral contraceptives. 
Plasma Fatty Acids 
% weight total fatty acids 
Name Men 
Women taking oral 
contraceptives 
Women with natural 
cycles 
C 12:0 0.12 ± 0.05 0.11 ± 0.03 0.14 ± 0.06 
C 14:0 0.94 ± 0.22 1.02 ± 0.28 0.88 ± 0.19 
C 16:0 22.92 ± 1.22a 25.29 ± 2.74b 23.09 ± 2.14a 
C 18:0 7.10 ± 0.70a 6.43 ± 0.73b 7.17 ± 0.61a 
C 20:0 0.18 ± 0.03 0.19 ± 0.03 0.20 ± 0.03 
C 22:0 0.40 ± 0.09 0.42 ± 0.08 0.44 ± 0.05 
C 24:0 0.37 ± 0.08 0.37 ± 0.07 0.36 ± 0.05 
SFAs 32.28 ± 1.62 34.03 ± 2.51 32.44 ± 1.64 
C 14:1 0.04 ± 0.02a 0.06 ± 0.03b 0.06 ± 0.03b 
C 16:1n-7 1.37 ± 0.43a 2.05 ± 0.79b 1.42 ± 0.31a 
C 18:1n-7 1.71 ± 0.21 1.81 ± 0.26 1.66 ± 0.13 
C 18:1n-9 18.82 ± 2.29 18.19 ± 1.40 19.32 ± 1.87 
C 20:1n-9 0.14 ± 0.03a 0.17 ± 0.04b 0.14 ± 0.03ab 
C 22:1n-9 0.07 ± 0.03a 0.12 ± 0.03b 0.12 ± 0.03b 
C 24:1n-9 0.55 ± 0.14a 0.67 ± 0.13b 0.61 ± 0.08ab 
MUFAs 22.71 ± 2.55 23.07 ± 2.06 23.34 ± 1.95 
C 18:2n-6 29.42 ± 2.62 28.03 ± 2.89 29.69 ± 1.97 
C 18:3n-6 0.34 ± 0.11 0.29 ± 0.06 0.36 ± 0.13 
C 20:2n-6 0.16 ± 0.04ab 0.21 ± 0.07a 0.15 ± 0.05b 
C 20:3n-6 1.23 ± 0.30a 1.59 ± 0.29b 1.29 ± 0.44ab 
C 20:4n-6 6.99 ± 1.01 6.70 ± 1.32 6.58 ± 1.14 
C 22:2n-6 0.02 ± 0.02 0.03 ± 0.01 0.02 ± 0.01 
C 22:4n-6 0.17 ± 0.03 0.18 ± 0.05 0.16 ± 0.05 
C 22:5n-6 0.12 ± 0.04 0.10 ± 0.08 0.15 ± 0.05 
N-6 38.42 ± 2.55 37.13 ± 3.20 38.34 ± 2.05 
C 18:3n-3 0.62 ± 0.18 0.67 ± 0.18 0.65 ± 0.14 
C 20:3n-3 0.04 ± 0.01ab 0.04 ± 0.01a 0.03 ± 0.01b 
C 20:5n-3 0.49 ± 0.14 0.50 ± 0.10 0.51 ± 0.14 
C 22:5n-3 0.43 ± 0.07a 0.32 ± 0.05b 0.40 ± 0.09a 
C 22:6n-3 1.19 ± 0.24a 1.57 ± 0.37b 1.33 ± 0.24ab 
N-3 2.77 ± 0.31a 3.10 ± 0.47b 2.92 ± 0.28ab 
EPA+DHA 1.68 ± 0.29a 2.07 ± 0.42b 1.85 ± 0.26ab 
DHA:EPA 2.61 ± 0.91 3.30 ± 0.85 2.67 ± 0.85 
DHA:DPAn-3 2.89 ± 0.84a 5.13 ± 1.43b 3.43 ± 1.11a 
Total 316.58 ± 52.96 352.03 ± 76.52 325.13 ± 46.81 
Values are means ± SD. Means with different letters are significantly different by Tukey’s post-hoc test, 
following a significant F-value for one way ANOVA. DHA: 22:6n-3; EPA: 20:5n-3; DPAn-3: 22:5n-3.  
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Figure 5.1: Relative proportion of selected fatty acids in erythrocyte in men, women taking oral 
contraceptives and women not taking oral contraceptives. Values are means ± SD. Means with 
different letters are significantly different by Tukey’s post-hoc test, following a significant F-value for 
one way ANOVA.  
59 
 
Table 5.3: Plasma fatty acid proportion in women taking and not taking oral contraceptives during the 
follicular and luteal phase of the menstrual cycle 
Plasma Fatty Acids 
% weight total fatty acids 
 Women taking oral contraceptives Women with natural cycles 
Name 
Day 6-8  
(no hormone phase) 
Day 21-23 
(active hormone phase) 
Day 6-8  
(follicular phase) 
Day 21-23 
(luteal phase) 
C 16:01,2 26.01 ± 2.76 24.57 ± 2.99 23.52 ± 2.25 22.65 ± 2.45 
C 18:02 6.55 ± 0.68 6.32 ± 0.91 7.18 ± 0.59 7.15 ± 0.67 
C 20:01 0.18 ± 0.04 0.19 ± 0.03 0.19 ± 0.03 0.20 ± 0.03 
C 22:01 0.41 ± 0.10 0.43 ± 0.08 0.42 ± 0.05 0.46 ± 0.08 
C 24:01 0.35 ± 0.07 0.39 ± 0.08 0.35 ± 0.06 0.38 ± 0.08 
SFAs1 34.93 ± 2.90 33.13 ± 2.59 32.93 ± 1.84 31.94 ± 1.89 
C 16:1n-71,2 2.21 ± 0.74 1.88 ± 0.90 1.56 ± 0.37 1.28 ± 0.33 
C 18:1n-71 1.74 ± 0.29 1.89 ± 0.28 1.65 ± 0.12 1.67 ± 0.18 
C 18:1n-9 18.13 ± 1.48 18.25 ± 1.67 19.29 ± 2.08 19.35 ± 1.79 
C 20:1n-9 0.14 ± 0.03a 0.20 ± 0.04b 0.13 ± 0.03a 0.15 ± 0.03a 
C 22:1n-91 0.10 ± 0.03 0.14 ± 0.04 0.11 ± 0.03 0.12 ± 0.03 
C 24:1n-91 0.63 ± 0.13 0.70 ± 0.16 0.60 ± 0.10 0.63 ± 0.08 
MUFAs 23.02 ± 2.11 23.12 ± 2.35 23.41 ± 2.18 23.27 ± 1.89 
C 18:2n-6 27.66 ± 3.09 28.40 ± 3.10 29.40 ± 2.13 29.97 ± 2.02 
C 18:3n-61 0.34 ± 0.08 0.25 ± 0.07 0.39 ± 0.17 0.32 ± 0.12 
C 20:2n-6 0.17 ± 0.05ab 0.24 ± 0.10a 0.15 ± 0.05b 0.16 ± 0.05b 
C 20:3n-6 1.50 ± 0.25ab 1.68 ± 0.36a 1.31 ± 0.43b 1.26 ± 0.49b 
C 20:4n-6 6.64 ± 1.45 6.75 ± 1.34 6.42 ± 1.12 6.74 ± 1.21 
C 22:2n-6 0.03 ± 0.02 0.02 ± 0.01 0.03 ± 0.02 0.02 ± 0.01 
C 22:4n-6 0.17 ± 0.04 0.20 ± 0.06 0.16 ± 0.05 0.16 ± 0.07 
C 22:5n-61 0.12 ± 0.03 0.16 ± 0.07 0.15 ± 0.04 0.16 ± 0.05 
N-61 36.60 ± 3.57 37.67 ± 3.25 37.95 ± 2.15 38.72 ± 2.20 
C 18:3n-3 0.64 ± 0.21 0.71 ± 0.19 0.63 ± 0.15 0.67 ± 0.17 
C 20:3n-32 0.04 ± 0.02 0.05 ± 0.01 0.03 ± 0.02 0.03 ± 0.01 
C 20:5n-3 0.55 ± 0.16 0.46 ± 0.11 0.49 ± 0.14 0.54 ± 0.19 
C 22:5n-32 0.32 ± 0.05 0.31 ± 0.06 0.41 ± 0.11 0.39 ± 0.09 
C 22:6n-31 1.47 ± 0.36 1.66 ± 0.44 1.30 ± 0.25 1.37 ± 0.29 
N-3 3.02 ± 0.45 3.17 ± 0.55 2.86 ± 0.26 2.99 ± 0.47 
EPA+DHA 2.02 ± 0.45 2.11 ± 0.50 1.79 ± 0.22 1.91 ± 0.37 
DHA:EPA 2.83 ± 0.85ab 3.78 ± 1.13a 3.00 ± 1.20ab 2.81 ± 0.74b 
DHA:DPAn-3 4.71 ± 1.40 5.55 ± 1.56 3.47 ± 1.26 3.74 ± 1.05 
Total1 (µg 
fatty acid/100 
µl plasma) 362.81 ± 83.68 341.24 ± 75.64 334.87 ± 48.69 315.39 ± 57.37 
Values are mean ± sd. Means with different letters are significantly different by Tukey’s post-hoc test, following a 
significant F-value for birth control status x time by the linear mixed models procedure. DHA: 22:6n-3; EPA: 20:5n-
3; DPAn-3: 22:5n-3. 
1 significant main effect of time 2 significant main effect of birth control status 
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Chapter 6. 
Effect of Rat Estrous Cycle on Hepatic Expression of Fatty Acid Biosynthesis Enzymes 
6.1 Introduction 
 Sex differences in blood and tissue fatty acid composition in humans are observed even 
after controlling for diet (Metherel et al., 2009; Patterson et al., 2015; Crowe et al., 2008; 
Marangoni et al., 2007).  Circulating sex hormones has been proposed as a potential mechanism 
(Kitson, Stroud, and Stark, 2010) and studies in humans during pregnancy, hormone therapy 
with menopause and in transsexuals support an estrogenic effect on fatty acid metabolism.  In the 
previous chapter, we confirmed that fatty acid differences are also observable in humans during 
the menstrual cycle, with changes in levels and ratios of the n-3 HUFA being particularly 
intriguing.  
Rat fatty acid metabolism has been demonstrated to be representative of human fatty acid 
metabolism, making rats a useful model for studying hepatic gene expression changes which are 
difficult to obtain in humans. Women often have higher levels of 16:0 compared with males, 
likely due to higher carbohydrate intake (Garriguet, 2007), while female rats tend to have higher 
levels of 18:0 compared with male rats, because rats are fed the same diet and females have 
higher levels of elongase 6 (Marks, Kitson, and Stark, 2013). The rat lipoprotein profile is quite 
different than humans (Yin et al., 2012), and there has been some hypothesis that D6D in 
humans can possess delta-4 desaturation ability (Park et al., 2015), which is not present in rats 
(Pauter et al., 2014), but in general hepatic fatty acid metabolism in rats is similar to that of 
humans. Rat models have been observed to have sex differences in tissue content of fatty acids, 
but also in hepatic enzyme expression. Females express higher levels of Elovl6 (Marks, Kitson, 
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and Stark, 2013), Elovl2, Fads1 and Fads2 (Kitson et al., 2012; Extier et al., 2010; Burdge et al., 
2008), compared with males. Estrogen may be an important mediator of these differences.   The 
expression of Elovl6 and Fads2 is decreased in ovariectomized rats compared with sham 
operated rats, while estradiol treatment of ovariectomized rats increases the expression of these 
gene products (Kitson et al., 2013a; Marks et al., 2013a; Alessandri et al., 2011). However, in 
these rodent studies, changes in estrogen concentrations tend to be dramatic withdrawals or 
treatment that results in supraphysiological levels (Marks et al., 2013a; Strom et al., 2012; Cao 
and Gregoire, 2016). To the best of our knowledge, the effects of the rat estrous cycle on fatty 
acid composition has not been examined. During the estrous cycle of the rat, estrogen 
concentrations fluctuate from 30 pg/ml during the estrus stage, to 40-50 pg/ml during the 
metestrus and diestrus stages, to highs of 150 pg/ml during proestrus (Flores et al., 2011). Unless 
rats are pregnant or pseudopregnant, they do not have a real luteal phase (Wilson, Adler, and Le, 
1965), thereby limiting how representative the rat estrous cycle may be of the human menstrual 
cycle. However, using a rodent model allows for the determination of hepatic fatty acid 
composition and measurements of the hepatic expression of genes involved in fatty acid 
metabolism.  Because of the previously demonstrated effects of estrogen on Elovl6, Fads2 and 
Elovl2 (Alessandri et al., 2011; Kitson et al., 2013a; Marks et al., 2013a), we hypothesized the 
expression of these genes would fluctuate during the estrous cycle in association with estradiol 
levels. Therefore, female rats were sacrificed daily for four days to collect rats at each stage of 
the estrous cycle to examine hepatic enzyme expression and fatty acid composition.  The stages 
of the estrous cycle were confirmed using vaginal smears (Hubscher, Brooks, and Johnson, 
2005) along with measures of sex hormones in rat plasma. A group of male rats was also 
included as an additional comparison.  
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6.2 Materials and Methods 
All animal experiments were carried out according to guidelines of the University of 
Waterloo Animal Care Committee and Canadian Council on Animal Care. Eight-week old male 
and female Sprague-Dawley rats (Harlan Laboratories, Mississauga, ON) were housed at a 
temperature of 21 ± 1 °C with ad libitum access to AIN-93G standard chow and water, in the 
Central Animal Housing Facility at the University of Waterloo. Female rats were group housed, 
in an attempt to synchronize their estrous cycles (McClintock, 1978).  All rats were maintained 
on a cycle of lights on at 6 am and off at 6 pm in order to achieve estrous cycle timing as 
previously described (Hubscher, Brooks, and Johnson, 2005). At 10 weeks of age, rats were 
fasted overnight and sacrificed via cardiocentesis after sedation by intraperitoneal sodium 
pentobarbital injection. Eight or nine female rats were sacrificed each day for four days, to 
ensure there were enough female rats at each estrous cycle stage. Four male rats were sacrificed 
on the first day of sacrifice, and four male rats were sacrificed on the last day. 
Blood was collected by cardiocentesis into an EDTA-containing syringe. Blood was 
separated by centrifugation at 3000g to isolate plasma and red blood cells, which were stored at -
80°C prior to fatty acid analyses. Livers were quickly excised, washed in saline (0.9% NaCl, 
w/v) and frozen in liquid nitrogen prior to storage at -80°C. Plasma hormone analysis was 
performed as described in Chapter 4. Whole blood, plasma and erythrocyte fatty acids were 
extracted and analyzed as described in Chapter 4. 
Hepatic expression of Elovl6, Scd1, Elovl2, Elovl5, Fads1 and Fads2 was determined in 
males and females at the four different estrous cycle stages by qPCR, as described in Chapter 4.  
Primer sequences for these genes are in Table 6.1. Antibodies used for hepatic protein content 
determination included ELOVL6 (ab69857, Abcam, 1:1000 in milk), SCD1 (ab19862, Abcam, 
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1:1000 in milk), ELOVL2 (ab176327, Abcam, 1:1000 in milk), ELOVL5 (ARP49667, Aviva 
Systems Biology, 1:1000 in milk), D5D (Fads1, ab126706, Abcam, 1:1000 in milk) and D6D 
(Fads2, ab72189, Abcam, 1:1000 in milk). 
Estrous cycle stage was determined by obtaining vaginal smears at the time of sacrifice, 
staining using a modified Papanicolaou stain as described previously (Hubscher, Brooks, and 
Johnson, 2005) and comparing the stained images to expected cell morphology at each estrous 
cycle stage.  Animals were sorted into groups based on the images obtained from staining for 
estrous cycle. Data are presented as mean ± s.e for genes and proteins, and mean ± s.d. for fatty 
acids.  Differences in mRNA, protein and fatty acids between the five groups was determined 
using a one-way ANOVA with Tukey’s post hoc test. 
6.3 Results 
6.3.1 Estrous Cycle Stage Determination 
 Representative images of stained vaginal smears from each stage of the estrous cycle are 
presented in Figure 6.1. During proestrus, cells are predominantly large and nucleated while 
during estrus, some nucleated cells remain, but there are a large proportion of sloughed off, non-
nucleated cells. During metestrus, the proportion of leukocytes increases, and during diestrus the 
leukocytes and nucleated cells are found in similar proportions. As such, the female rats were 
grouped into 4 groups after staining: diestrus (n= 8), metestrus (n=7), proestrus (n=9) and estrus 
(n=10) A group of males was included (n=8).  Estradiol and progesterone levels of the females 
tended to reflect expectations for each estrous cycle stage (highest levels at proestrus and lowest 
levels at estrus and metestrus), but there was large variability in the measurements that resulted 
in no significant differences (data shown in Figure 6.2). 
6.3.2 Sex and Estrous Stage Differences in Hepatic Gene Expression 
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 Hepatic expression of Fads2 and Elovl6 mRNA were generally higher during estrus 
compared with the other stages of and with males (Figure 6.3 and 6.4), while males had highest 
expression of Elovl5 (Figure 6.4). Fads1 mRNA was highest during diestrus and in males. No 
sex or estrous cycle differences were observed in Scd1 or Elovl2 mRNA (Figure 6.3 and 6.4).  
Protein content of genes involved in fatty acid biosynthesis also reflected differences in sex and 
estrous cycle stage (Figures 6.5 and 6.6). Content of D5D was higher in males compared with 
females during metestrus. ELOVL5 protein was lowest in males and females during proestrus, 
and SCD1 was lowest in males and females during metestrus. ELOVL2 was higher in metestrus 
than males and females in diestrus. The protein content of FADS2 and ELOVL6 did not differ 
across any group. 
6.3.3 Sex and Estrous Stage Differences in Blood and Liver Fatty Acid Composition 
 The main fatty acids that demonstrated sex and estrous cycle differences consistently in 
blood and liver were 16:1n-7, 22:5n-3 and 22:6n-3 (Figure 6.7 and 6.8; full fatty acid 
composition is shown in Appendix 2, Tables A2.1-2.3). Females during diestrus had lower 
amounts of 16:1n-7 compared with females during metestrus, in both the relative proportion and 
absolute amounts in whole blood, and lower amounts compared with females during estrus in 
liver total lipids. Absolute amounts of 22:5n-3 in whole blood were highest in males compared 
with females during diestrus and estrus. This pattern was not identical in plasma and liver, but 
males tended to have higher amounts than females. Concentrations of 22:6n-3 in whole blood 
were highest in females during proestrus compared with females during diestrus and estrus, and 
males, but were not different in plasma or liver. 
6.4 Discussion 
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 This study demonstrates that hepatic gene expression of fatty acid desaturases and 
elongases changes depending on estrous cycle stage.  This suggests that the small changes in 
hormones during the estrous cycle, can have an effect on gene expression and fatty acid 
composition.  In general, the gene and protein data presently are showing agreement with each 
other, although no mRNA changes were observed in Elovl2 or Scd1, but there were protein 
differences, while mRNA changed in Fads2 and Elovl6 but not protein. This is not entirely 
unusual, as it has been reported that mRNA does not always predict protein levels (Maier, Guell, 
and Serrano, 2009), and it is possible that there are still sex or estrous cycle differences in 
enzyme activity. It is also possible that there is a time lag between transcription of a gene and 
when the mRNA is translated into protein, and increases in protein levels may not be observed 
until the following stage of the estrous cycle, since the cycle stages are so short. 
 Changes in hepatic elongase and desaturase gene expression over the four stages of the 
estrous cycle suggests that estrogen is one contributor to controlling expression of these genes. 
Presently, the mRNA expression of Fads1 was highest in males and females during diestrus, 
rather than females being higher than males (Kitson et al., 2012; Extier et al., 2010) or no sex 
differences in Fads1 expression (Childs et al., 2010), as previously reported.  Interestingly, 
pooling all of the females in the present study also resulted in no sex differences in Fads1 
expression (data not shown).   Fads2 expression was highest in estrus and diestrus as compared 
with males, confirming findings of higher Fads2 in females (Extier et al., 2010) and regulation 
by estradiol (Childs et al., 2012; Kitson et al., 2013a) although some reports show no effect of 
estradiol on Fads2 expression (Sibbons et al., 2014). We expected Fads2 expression to be the 
highest during proestrus as this is when both estrogen and progesterone concentrations are 
highest in rats, and increasing levels of estrogen or both estrogen and progesterone have been 
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previously shown to increase levels of D6D in animals (Kitson et al., 2013b). It is possible other 
mechanisms are regulating Fads2 expression. High 22:6n-3 intake in females is associated with 
reduced conversion of 22:5n-3 to 22:6n-3 using stable isotope tracers and compartmental 
modelling (Pawlosky et al., 2003b). Blood levels and hepatic levels of 22:6n-3 tended to peak at 
proestrus, so it is possible that feedback inhibition could have occurred although differences in 
22:6n-3 were subtle and not always significantly different from other stages. 
Estrogen appears to have different effects on elongase mRNA expression that is specific 
to each individual elongase, rather than affecting all elongases in the same way. Elovl2 mRNA 
expression did not show any differences, but was higher in females overall when females were 
pooled as one group (data not shown), agreeing with previous reports (Kitson et al., 2012). It is 
possible that only low concentrations of estrogen are required to induce Elovl2 expression and 
maximize the effect on mRNA expression, which is why no further increases were seen when 
estrogen increases. Elovl6 expression is higher during estrus compared with metestrus. Estrogen 
levels are similar at these two estrous cycle stages, so it is not known why expression would be 
higher during estrus compared with metestrus. Elovl5 expression was highest in males as has 
been previously reported (Kitson et al., 2012), and estrus had higher expression compared with 
proestrus, suggesting that estrogen may negatively regulate Elovl5 expression, since it is higher 
in males and estrous cycle stages when estrogen is lower. The rats in this study were sacrificed at 
10 weeks of age, while other studies have used rats that were 14 weeks old (Kitson et al., 2012). 
No sex differences have been reported in gene expression at either 3 or 5 weeks of age (Extier et 
al., 2010), so while 10 and 14 weeks of age are both sexually mature, it would be prudent to 
characterize the effect of age on expression of enzymes involved in fatty acid biosynthesis 
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Fewer studies report protein than those that report genes, but females have been reported 
to have higher protein levels of D5D, D6D and ELOVL6 (Kitson et al., 2012; Marks, Kitson, and 
Stark, 2013; Extier et al., 2010), suggesting estrogen mediates an increase in protein levels of 
these specific enzymes. The results from this thesis do not entirely match this hypothesis. There 
are differences between males and females during metestrus in D5D, but no estrous cycle 
differences, and no sex or estrous stage differences in D6D. ELOVL2 is higher during metestrus 
than diestrus and proestrus, but not different from males, confirming previous results of no sex 
differences (Kitson et al., 2012). The role of estrogen in mediating ELOVL2 protein content 
requires further examination. ELOVL5 protein is lowest in females during proestrus and males. 
This is unlikely to be due to estrogen signaling, because these two groups have very different 
estrogen levels.  Overall, it is possible that estrogen is influencing the activity of these enzymes 
to modulate fatty acid composition rather than absolute protein content, especially since there are 
differences in hepatic 22:5n-3 and whole blood 22:6n-3 content over the estrous cycle and 
between sexes. While this observation may be partly due to estrogen-regulated differences in 
synthesis, since females have been shown to have a greater capacity to convert 22:5n-3 to 22:6n-
3 compared with males (Pawlosky et al., 2003b), this does not appear to be the sole factor 
controlling hepatic and blood fatty acid composition. For example, in the present study, 22:5n-3 
is not higher in whole blood and plasma in males compared with all of the female groups. 
Metestrus appears to be more similar to males in both fatty acid composition and hepatic 
expression of desaturases and elongases. There may be an estrous cycle effect on hepatic 
lipoprotein packaging or export of fatty acids, or on mobilization from other tissue stores, that 
results in higher 22:5n-3 in metestrus compared with the other stages in females. This may be 
supported by findings from 22:6n-3, since there were no differences observed in liver amounts 
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when comparing estrous cycle stage or sex, but levels of 22:6n-3 in plasma were highest during 
proestrus and metestrus, suggesting there may be some sort of regulation of hepatic fatty acids 
into the blood. 
SCD1 is highest during diestrus and proestrus, although content of these proteins have 
not been previously shown to change based on sex (Kitson et al., 2012; Marks, Kitson, and Stark, 
2013), while ELOVL6 surprisingly shows no sex or estrous cycle differences, despite evidence 
of its regulation by estrogen (Marks, Kitson, and Stark, 2013; Marks et al., 2013b). Amounts of 
16:1n-7 were consistently lowest in females during diestrus. The gene data cannot fully explain 
this finding, since SCD1 protein was highest during diestrus, and there were no changes in 
ELOVL6. Specific increases in 16:1n-7 occur when hormone levels are highest, such as during 
pregnancy and in menopausal women taking hormone therapy (Stark, Park, and Holub, 2003; 
Stark et al., 2005). Hormone levels are lower during diestrus compared with the other estrous 
cycle stages, which may be one reason that 16:1n-7 is also lower. Future studies should examine 
the nature of the relationship between 16:1n-7 and estradiol, since the effect seems to be 
independent of synthesis.  
6.5 Conclusions 
 This is the first study to examine hepatic enzyme expression over the estrous cycle, as 
well as examine specific fatty acid changes during the estrous cycle, rather than looking at lipid 
classes as a whole. As such, we have identified that sex differences in hepatic enzyme expression 
are not uniform across all estrous cycle stages, and are not directly related to estrogen levels. 
Increasing estrogen levels appear to increase FADS2 mRNA levels, but not protein. Despite no 
differences in D6D protein content over the estrous cycle, we did observe differences in 22:6n-3 
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content. Given the importance of 22:6n-3 in human health, a more specific examination of the 
regulation of 22:6n-3 biosynthesis by estrogen is warranted.  
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Table 6.1 Rat primer sequences for reverse transcriptase real-time PCR 
Gene Name Accession Code Sequence (5’-3’) 
18S M11188 Forward: CGGACACGGACSGGATTGACAGAT 
Reverse: ATCGCTCCACCAACTAAGAACGGC 
Elovl2 AB071986.1 Forward: TGCTTGCCCGTGAGAGCCAC 
Reverse: TGCCACAGGAAGGCGACGAC 
Elovl5 NM_134382.1 Forward: CTCTCGGGTGGCTGTACTTC 
Reverse: AGAGGCCCCTTTCTTGTTGT 
Elovl6 NM_134383.2 Forward: CACAGCCTCGGGCTTGTTCGT 
Reverse: CTATGGGCCGCCTTCTCGGGA 
Fads1 NM_053445 Forward: CCTCTTGTAAAGCACGAGCC 
Reverse: CAAGGGGTCACACTGTTCCT 
Fads2 NM_031344 Forward: TCAAAACCAACCACCTGTTCTTC 
Reverse: ACCAGGCGATGCTTTCCA 
Scd1 NM_139192.2 Forward: TGTTCCAGAGGAGGTACTACAAGCC 
Reverse: GCAGGAAAGTTTCGCCCCAGC 
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Figure 6.1. Representative figure of stained vaginal smears from 10-week old female rats at the 
time of sacrifice. Smears were stained using a modified Papanicolaou stain as described 
previously (Hubscher, Brooks, and Johnson, 2005) and compared to expected cell morphology at 
each estrous cycle stage. 
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Figure 6.2. Plasma concentrations of A. estrogen and B. progesterone in female rats over the 
estrous cycle. Data are mean ± s.d. 
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Figure 6.3. mRNA expression of fatty acid desaturases in 10-week old female rats over the 
estrous cycle and 10-week old male rats. Data are mean ± s.e. Within a gene, means with a 
different letter are significantly different by Tukey’s post hoc test following a significant one-
way ANOVA F-value. Fads1: fatty acid desaturase 1; Fads2: fatty acid desaturase 2; Scd1: 
stearoyl-CoA desaturase 1. 
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Figure 6.4. mRNA expression of fatty acid elongases in 10-week old female rats over the estrous 
cycle and 10-week old male rats. Data are mean ± s.e. Within a gene, means with a different 
letter are significantly different by Tukey’s post hoc test following a significant one-way 
ANOVA F-value. Elovl2: fatty acid elongase 2; Elovl5: fatty acid elongase 5; Elovl6: fatty acid 
elongase 6. 
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Figure 6.5. Protein content of fatty acid desaturases in 10-week old female rats over the estrous 
cycle and 10-week old male rats. Data are mean ± s.e. Within a gene, means with a different 
letter are significantly different by Tukey’s post hoc test following a significant one-way 
ANOVA F-value. D5D: dela-5 desaturase; D6D: delta-6 deasturase; SCD1: stearoyl-CoA 
desaturase 1. 
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Figure 6.6. Protein content of fatty acid elongases in 10-week old female rats over the estrous 
cycle and 10-week old male rats. Data are mean ± s.e. Within a gene, means with a different 
letter are significantly different by Tukey’s post hoc test following a significant one-way 
ANOVA F-value. ELOVL2: fatty acid elongase 2; ELOVL5: fatty acid elongase 5; ELOVL6: 
fatty acid elongase 6. 
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Figure 6.7. Concentration of A. 16:1n-7 B. 22:5n-3 and C. 22:6n-3 in 10-week old female rats 
over the estrous cycle and 10-week old male rats. Data are presented as µg fatty acid/100 µl 
whole blood or plasma, or µg fatty acid/mg liver. Data are mean ± s.d. Within a gene, means 
with a different letter are significantly different by Tukey’s post hoc test following a significant 
one-way ANOVA F-value. 
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Figure 6.8 Relative percentage of A. 16:1n-7 B. 22:5n-3 and C. 22:6n-3 in 10-week old female 
rats over the estrous cycle and 10-week old male rats. Data are presented as µg fatty acid/100 µl 
whole blood or plasma, or µg fatty acid/mg liver. Data are mean ± s.d. Within a gene, means 
with a different letter are significantly different by Tukey’s post hoc test following a significant 
one-way ANOVA F-value.  
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Chapter 7. 
Effects of Estradiol Treatment on Expression of Fatty Acid Biosynthesis Genes and Fatty 
Acid Composition in MCF7 Cells 
7.1 Introduction 
Estrogen has been hypothesized to contribute to previously reported sex differences in 
both human whole blood (Crowe et al., 2008; Metherel et al., 2009; Giltay et al., 2004; 
Marangoni et al., 2007) and rodent tissue and blood (Kitson et al., 2012; Marks, Kitson, and 
Stark, 2013; Burdge et al., 2008) fatty acid composition. Although there are sex differences in 
progesterone levels as well, few changes are observed in ovariectomized animals treated with 
progesterone (Kitson et al., 2013b; Marks et al., 2013a), so most research has focused on the 
effects of estrogen on fatty acid metabolism. Females have higher concentrations of 18:0 and 
lower concentrations of 16:0 and 16:1n-7 (Marangoni et al., 2007), which may be driven by 
higher hepatic expression of Elovl6 (Marks, Kitson, and Stark, 2013) compared with males. 
Females also have higher concentrations of 22:6n-3 and lower levels of 20:5n-3 and 22:5n-3 
compared with men (Metherel et al., 2009; Patterson et al., 2015), possibly as a result of higher 
hepatic expression of Fads2 and Elovl2 (Kitson et al., 2012).  Support for this hypothesis comes 
from the observation of parallel changes in both fatty acid composition and related hepatic gene 
expression in animal models such as the estrogen receptor α (ERα) knockout mouse model 
(Bryzgalova et al., 2006), and the rat ovariectomy model with or without estrogen treatment 
(Kitson et al., 2015; Alessandri et al., 2011; Paquette et al., 2008; Marks et al., 2013a; Kitson et 
al., 2013a; Mason et al., 2014). However, these animal models have several limitations that 
confound their use in identifying isolated effects of estrogen on the regulation of fatty acid 
biosynthesis. For example, the knockout of ERα in mice has been accomplished by disrupting 
80 
 
the DNA binding domain, while leaving the rest of the gene intact. As a result, these animals 
retain non-genomic ERα-signaling abilities, limiting the conclusions that can be made regarding 
the regulation of biological processes by estrogen in these animals (Couse et al., 1995). 
Additionally, ovariectomized animals are generally hyperphagic (Kitson et al., 2015), and 
estrogen levels are not always decreased relative to the sham-operated animals (Marks et al., 
2013a), possibly due to increased synthesis of estrogen in adipose tissue (Simpson, 2003). It is 
therefore also difficult to make conclusions on the biological role of estrogen based on findings 
from this model.  
Results from Chapters 5 and 6 suggest that changes in estrogen is accompanied by 
changes in blood fatty acids and hepatic enzyme expression. Cell culture may be a useful model 
for the study of isolated cellular effects of estrogen, because conditions can be tightly controlled. 
At least one study has examined effects of 17α-ethinyl estradiol on the regulation of genes 
involved in fatty acid biosynthesis and demonstrated no effect on mRNA levels of FADS1, 
FADS2, ELOVL2, ELOVL5 or on the conversion of 18:3n-3 to 22:6n-3 (Sibbons et al., 2014). In 
that work, however, HepG2 cells were used. Since this cell line is male and has limited ERα 
expression (Kelly et al., 2014), it is possible that estrogen signalling is either deficient, or too low 
to significantly affect gene expression of fatty acid biosynthesis. MCF7 cells, a human breast 
cancer cell line, are commonly used for studies of the biological effect of estrogen, because these 
cells are ERα-positive and are responsive to estrogen treatment (Kim et al., 2015; Horwitz, 
Costlow, and McGuire, 1975). Expression of Fas has been demonstrated to be regulated in a 
similar manner by sterol regulatory element binding protein-1c in MCF7 cells compared with 
healthy hepatocytes and adipocytes (Yang et al., 2003), suggesting that these cells may be a 
representative model of fatty acid biosynthesis. Expression and regulation of other genes 
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involved in fatty acid biosynthesis have not been examined in MCF7 cells, although Fas, Fads1, 
Fads2, Elovl5, and Elovl6 are expressed in healthy mammary tissue during pregnancy and 
lactation in rats. Composition of 22:6n-3 is higher in mammary tissue of lactating rats compared 
with non-pregnant rats, suggesting that mammary tissue can synthesis and accumulate PUFA 
(Rodriguez-Cruz et al., 2011), likely in conjunction with hepatic synthesis and adipose tissue 
mobilization. However, no studies have yet examined fatty acid composition or gene expression 
in MCF-7 cells in response to estrogen treatment. 
Therefore, the purpose of this study is to expand upon the findings that estrogen appears 
to be an important regulator of fatty acid composition and enzyme expression in the human study 
in Chapter 5 and the rat study in Chapter 6 by examining the effect of isolated estradiol treatment 
on fatty acid composition and enzyme expression in MCF7 cells, an ERα-positive cell line. 
7.2 Methods and Materials 
MCF7 cells were grown as described in Chapter 4. Twenty-four hours prior to any 
experiment with estradiol, the media was changed to media that was free of phenol red, since this 
compound has weak ER-binding capabilities (Berthois, Katzenellenbogen, and 
Katzenellenbogen, 1986). The FBS used in the media was also changed to charcoal-stripped 
FBS, since this process removes all lipids and hormones present from the donor animal, limiting 
the confounding effects of exogenous fatty acid provision and exogenous hormonal influence 
(Dang and Lowik, 2005; Aakvaag et al., 1990). At time point 0, 17-estradiol (Santa Cruz 
Biotechnology, Santa Cruz, CA) was dissolved in ethanol and added to 100% charcoal-stripped 
FBS at 10 the maximum concentration (i.e. 1000 nM), where it was allowed to complex with 
naturally occurring albumin prior to dilution at a 1:10 ratio with phenol red-free DMEM/F12. 
The final ethanol concentration in the medium was 0.001% (v/v). 
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Cells were treated with vehicle control (ethanol), or 0.1, 1, 10 or 100 nM estradiol for 
eight hours, after which time RNA was collected by addition of Trizol directly to the plate, and 
cDNA was synthesized, as described in Chapter 4. Gene expression of ELOVL1, ELOVL2, 
ELOVL5, ELOVL6, FASN, SCD1, FADS1 and FADS2 at these different estradiol concentrations 
was determined by qPCR. Primer sequences for these genes can be found in Table 7.1. 
Additional plates of cells were treated with vehicle control or 10 nM estradiol, which had the 
greatest effect on expression of fatty acid biosynthesis genes, for twenty-four hours, and then 
cells were collected for fatty acid analysis. Total lipid extracts from these cells were analyzed as 
described in Chapter 4.  
One-way ANOVA was used to determine differences in gene expression. Following a 
significant one-way ANOVA result, Tukey’s post hoc test was used to determine differences in 
gene expression between different estrogen concentrations. Student’s t-test was used to 
determine differences in fatty acid composition between vehicle treated cells, and cells treated 
with estradiol.  
7.3 Results 
7.3.1 Effects of Estradiol on Gene Expression in MCF7 Cells 
ELOVL2, ELOVL6 and FADS2 were all significantly induced in response to estrogen in 
MCF7 cells (Figures 7.1 and 7.2). A dose-dependent effect of estrogen treatment was evident for 
FADS2 and ELOVL2, whereas ELOVL6 was only induced by 10 nM estrogen. ELOVL1, 
ELOVL5, SCD1, FADS1 and FASN were not significantly induced by treatment with estradiol at 
any of the concentrations examined (Figures 7.1 and 7.2). 
7.3.2 Fatty Acid Composition of Total Lipid Extracts from MCF7 Cells Treated with Estradiol 
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The relative fatty acid composition of MCF7 cells treated with either vehicle control or 
10 nM estradiol for 24 hours is presented in Table 7.2. Changes in the relative proportion of fatty 
acids were few. The relative percent weight of 10:0 decreased significantly, from 0.65  0.46 to 
0.29  0.20. The relative percent weight of 16:1n-7 increased significantly from 9.27  1.34 to 
10.22 1.26, and the relative percent of 20:5n-3 decreased from 0.33  0.24 to 0.15  0.06 in 
estradiol treated cells.  Importantly, there were no significant changes in any of the very long 
chain highly unsaturated fatty acids that would be expected to increase with induction of Fads2 
and Elovl2, such as 20:4n6 or 22:6n3. When total lipid extracts were examined quantitatively, 
there was no significant difference in the concentration of total fatty acids between cells treated 
with vehicle only or with estradiol (31.72  5.62 g/mg cellular protein versus 32.55  5.52 
g/mg protein, respectively) (Table 7.3). The only fatty acid that remained statistically 
significantly different when concentrations rather than relative proportions were considered was 
10:0. Total cellular levels of 10:0 decreased from 0.33  0.14 to 0.17  0.05 g/mg protein in 
cells treated with 10 nM estradiol. 
7.4 Discussion 
This is the first study to report both changes in the expression of genes involved in fatty 
acid biosynthesis, and changes in fatty acid composition in MCF7 cells in response to estrogen 
treatment. Although prior studies have examined these outcomes in HepG2 cells that are male 
(Aden et al., 1979; Kalthoff et al., 2013), this work is of particular importance since MCF7 cells 
are an estrogen-responsive, ERα-positive cell line (Kim et al., 2015; Horwitz, Costlow, and 
McGuire, 1975). A strength of this study is that these changes were measured in a highly 
controlled manner. Treatment media used in experiments was phenol red-free, which eliminated 
the weak pseudo-estrogenic binding of phenol red to ERα (Berthois, Katzenellenbogen, and 
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Katzenellenbogen, 1986; de Faria et al., 2015). FBS used during experiments was treated with 
charcoal, eliminating confounding exogenous sources of estrogen and other fatty acids and lipids 
that may be present in variable quantities (de Faria et al., 2015; Simoncini et al., 2005). Thus, the 
cells were exposed only to the controlled amounts of 17β-estradiol added to the media and its 
estrogen signaling, so that the effects of estrogen could therefore be examined specifically. 
 Sex differences and hormonal effects on n-3 polyunsaturated fatty acids (PUFA) have 
been studied extensively. Specifically, 22:6n-3 is higher in females compared with males 
(Marangoni et al., 2007; Metherel et al., 2009; Crowe et al., 2008; Kitson et al., 2012; Patterson 
et al., 2015), in postmenopausal women who take hormone therapy compared with 
postmenopausal women who do not (Stark, Park, and Holub, 2003), and in male-to-female 
transsexuals who take oral estrogen therapy (Giltay et al., 2004). Women seem to have a greater 
capacity to synthesize 22:6n-3 than males (Pawlosky et al., 2003a; Burdge and Wootton, 2002; 
Burdge, Jones, and Wootton, 2002). The results from the present support this hypothesis. 
Estradiol treatment increases expression of ELOVL2 and FADS2 in the present study, which are 
involved in the elongation and desaturation of the precursors to 20:4n-6 and 22:6n-3 (Pauter et 
al., 2014; Melin and Nilsson, 1997). However, although ELOVL2 and FADS2 were induced 
following estradiol treatment of MCF7 cells in the present study, no differences were observed in 
20:4n-6 or 22:6n-3 content in MCF7 cells treated with estradiol. It has been proposed that 
FADS2 is non-functional in MCF7 cells (Park et al., 2011), although it is not known if this lack 
of function is due to a mutation or deletion in the Fads2 gene, a post-translational modification 
or other mechanism. This would explain the lack of a change in 20:4n-6 and 22:6n-3 in our 
study, but not the presence of 20:4n-6 or 22:6n-3.  It is possible that the these fatty acids were 
taken up from the media during the normal growth phase and retained in the cells, before 
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charcoal stripped media was used just prior to estradiol treatment.  It is also possible that some 
delta-6 desaturase activity remains in MCF7 cells.  
Treatment of MCF7 cells with 10 nM estradiol in the present study significantly 
increased the relative proportion of 16:1n-7 in total cellular lipids. This fatty acid is higher in 
livers and plasma of male rats compared with females (Marks, Kitson, and Stark, 2013), but is 
also increased in ovariectomized rats treated with both estrogen and progesterone compared to 
ovariectomized rats (Marks et al., 2013a),. The finding of an increase in 16:1n-7 in MCF7 cells 
treated with estrogen is somewhat surprising, for two reasons. First, ELOVL6 expression is 
increased at this estradiol dose. ELOVL6 functions to elongate 16:0 to 18:0, which should reduce 
levels of 16:0 substrate needed for formation of 16:1n-7. Second, SCD1, the enzyme that acts to 
desaturate 16:0 to 16:1n-7, does not appear to be estrogen responsive. It thus seems unlikely that 
increased synthesis is the main factor responsible for the observed increase in 16:1n-7. 
Additional studies will clearly be required to fully understand this phenomenon. Blood and tissue 
levels of monounsaturated fatty acids like 16:1n-7, and hepatic expression of the genes that 
synthesize them, have shown to respond similarly in previous studies of hormonal manipulation, 
including ERα knockout, ovariectomy and estrogen therapy in menopausal women (Paquette et 
al., 2008; Stark, Park, and Holub, 2003; Marks et al., 2013a; Marks, Kitson, and Stark, 2013; 
Marangoni et al., 2007). The present results, taken together with previous findings, suggest that 
estrogen is an important mediator of monounsaturated fatty acid composition, although the 
mechanism as-of-yet remains unclear. 
7.5 Conclusion 
 In the present work, treatment of MCF7 cells with 17β-estradiol resulted in an increase in 
expression of the ELOVL2, ELOVL6 and FADS2 genes. Minimal changes in the relative 
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proportion of fatty acids in total cellular lipids were observed, with the exception of 16:1n-7, 
which was higher in cells treated with estradiol, and 10:0 and 20:5n-3, which were both lower in 
cells treated with estradiol. Multiple studies have demonstrated that MUFA are consistently 
responsive to estradiol treatment and/or hormonal manipulation involving estrogen, suggesting 
an important role for this hormone in regulating MUFA composition. While MCF7 cells provide 
a useful model for studying the effects of estradiol on gene expression, since these cells are ERα-
positive, there are limitations to using these cells for fatty acid experiments, since FADS2 has 
been reported to be non-functional in this cell line (Park et al., 2011).  Future studies using an 
estrogen responsive, non-cancerous cell line, or primary hepatocytes from a female animal, may 
alleviate some of the limitations of MCF7 cells.  However, a better understanding of the 
perturbations in fatty acid metabolism MCF7 cells is also needed.  
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Table 7.1 Human primer sequences for reverse transcriptase real-time PCR 
Gene Name Accession Number Primer Sequence (5’-3’) 
18S M11188 Forward: CGGACACGGACSGGATTGACAGAT 
Reverse: ATCGCTCCACCAACTAAGAACGGC 
FASN NM_004104.4 Forward: TTCTGGGACAACCTCATCGGCG 
Reverse: CCTAGACAGGTCCTTCAGCTTGCC 
SCD1 NM_005063.4 Forward: ACCGGACACGGTCACCCGTT 
Reverse: AGCTGGTTGTCGGCGCTAGC 
ELOVL1 NM_022821.3 F: ACGGAGTCCTTAGCCAGGAT 
R: GGTCATTAGCAAGGGGGACC 
ELOVL2 NM_017770.3 Forward: CTCCGCGTACATGCTGGCAGA 
Reverse: CGGATGTCAGCTTCCCCTGCG 
ELOVL5 NM_021814.4 Forward: TCCCGGGCCGCATGACATCA 
Reverse: GAACGTGGGCTGACCGTGAC 
ELOVL6 NM_024090.2 Forward: CGGTGGTCGGCACCTAATGAAT 
Reverse: GCACCAGTTCGAAGAGCACCGAA 
FADS1 NM_013402.4 F: GGCTCGGCCAATGGGAA 
R: GGGCTCCAGGAGTGGATTTG 
FADS2 NM_004265.3 F: ACTTTGGCAATGGCTGGATTCCTACCCTC 
R: ACATCGGGATCCTTGTGGAAGATGTTAGG 
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Table 7.2 Relative proportion of fatty acids in total lipids of MCF7 cells treated with vehicle 
only or 10 nM estradiol for twenty-four hours. 
MCF7 Cellular Fatty Acids 
% weight total fatty acids 
Name Control 10 nM Estradiol 
C 10:0 0.65 ± 0.46 0.29 ± 0.20* 
C 12:0 0.50 ± 0.18 0.42 ± 0.17 
C 14:0 1.96 ± 0.58 2.27 ± 0.51 
C 16:0 19.94 ± 3.79 19.70 ± 3.07 
C 18:0 13.95 ± 1.58 14.29 ± 1.90 
C 20:0 0.30 ± 0.10 0.36 ± 0.11 
C 22:0 0.38 ± 0.16 0.33 ± 0.10 
C 24:0 0.55 ± 0.12 0.48 ± 0.13 
SFAs 40.09 ± 4.38 40.18 ± 2.34 
C 12:1 0.10 ± 0.10 0.09 ± 0.05 
C 14:1 0.30 ± 0.20 0.29 ± 0.11 
C 16:1n-7 9.27 ± 1.34 10.22 ± 1.26* 
C 18:1n-7 8.01 ± 1.18 8.48 ± 0.95 
C 18:1n-9 29.88 ± 3.40 29.53 ± 1.80 
C 20:1n-9 0.89 ± 0.22 0.86 ± 0.09 
C 22:1n-9 0.80 ± 0.19 0.79 ± 0.24 
C 24:1n-9 0.96 ± 0.22 1.03 ± 0.13 
MUFAs 50.15 ± 5.02 51.28 ± 2.95 
C 18:2n-6 1.86 ± 0.32 1.73 ± 0.27 
C 18:3n-6 0.12 ± 0.06 0.16 ± 0.08 
C 20:2n-6 0.23 ± 0.33 0.19 ± 0.09 
C 20:3n-6 0.45 ± 0.09 0.43 ± 0.12 
C 20:4n-6 3.00 ± 0.48 2.83 ± 0.34 
C 22:2n-6 0.46 ± 0.36 0.38 ± 0.28 
C 22:4n-6 0.28 ± 0.14 0.25 ± 0.08 
C 22:5n-6 0.30 ± 0.21 0.43 ± 0.25 
N-6 6.70 ± 1.42 6.37 ± 0.89 
C 18:3n-3 0.36 ± 0.21 0.36 ± 0.14 
C 20:3n-3 0.12 ± 0.09 0.10 ± 0.05 
C 20:5n-3 0.33 ± 0.24 0.15 ± 0.06* 
C 22:5n-3 0.47 ± 0.11 0.39 ± 0.14 
C 22:6n-3 1.01 ± 0.21 1.01 ± 0.21 
N-3 2.26 ± 0.60 2.01 ± 0.29 
Results are mean ± sd. Values with a * are significantly different by student’s t test. 
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Table 7.3 Concentration of fatty acids in total lipids of MCF7 cells treated with vehicle only or 
10 nM estradiol for twenty-four hours. 
MCF7 Cellular Fatty Acids 
µg fatty acid/mg cellular protein 
Name Control 10 nM Estradiol 
C 10:0 0.33 ± 0.14 0.17 ± 0.05* 
C 12:0 0.19 ± 0.06 0.13 ± 0.03 
C 14:0 0.40 ± 0.10 0.56 ± 0.16 
C 16:0 5.14 ± 1.19 5.28 ± 0.83 
C 18:0 4.70 ± 0.94 4.64 ± 0.79 
C 20:0 0.09 ± 0.04 0.11 ± 0.04 
C 22:0 0.12 ± 0.07 0.12 ± 0.06 
C 23:0 0.06 ± 0.04 0.05 ± 0.03 
C 24:0 0.17 ± 0.06 0.17 ± 0.05 
SFAs 12.64 ± 2.53 13.09 ± 2.93 
C 12:1 0.05 ± 0.02 0.04 ± 0.02 
C 14:1 0.09 ± 0.04 0.11 ± 0.02 
C 16:1n-7 2.85 ± 0.39 3.39 ± 0.86 
C 18:1n-7 2.59 ± 0.75 2.62 ± 0.49 
C 18:1n-9 10.31 ± 2.48 10.06 ± 1.23 
C 20:1n-9 0.33 ± 0.10 0.30 ± 0.06 
C 22:1n-9 0.20 ± 0.03 0.24 ± 0.10 
C 24:1n-9 0.34 ± 0.11 0.37 ± 0.07 
MUFAs 16.72 ± 3.67 17.12 ± 2.66 
C 18:2n-6 0.55 ± 0.16 0.53 ± 0.12 
C 18:3n-6 0.05 ± 0.03 0.07 ± 0.02 
C 20:2n-6 0.04 ± 0.02 0.03 ± 0.02 
C 20:3n-6 0.13 ± 0.03 0.11 ± 0.03 
C 20:4n-6 0.83 ± 0.18 0.89 ± 0.15 
C 22:2n-6 0.07 ± 0.12 0.04 ± 0.02 
C 22:4n-6 0.07 ± 0.03 0.06 ± 0.02 
C 22:5n-6 0.07 ± 0.06 0.06 ± 0.04 
N-6 1.82 ± 0.43 1.79 ± 0.27 
C 18:3n-3 0.06 ± 0.01 0.08 ± 0.04 
C 20:3n-3 0.03 ± 0.02 0.02 ± 0.01 
C 20:5n-3 0.08 ± 0.06 0.05 ± 0.02 
C 22:5n-3 0.15 ± 0.03 0.15 ± 0.04 
C 22:6n-3 0.26 ± 0.07 0.25 ± 0.04 
N-3 0.54 ± 0.10 0.55 ± 0.08 
Total 31.72 ± 5.62 32.55 ± 5.52 
Results are mean ± sd. Values with a * are significantly different by student’s t test. 
  
90 
 
 
Figure 7.1 Gene expression of fatty acid elongases in response to 0, 0.1, 1, 10 and 100 nM 
estradiol for 8 hours. Data are mean ± s.e. Within a gene, means with a different letter are 
significantly different by Tukey’s post hoc test following a significant one-way ANOVA F-
value. Elovl1: fatty acid elongase 1; Elovl2: fatty acid elongase 2; Elovl5: fatty acid elongase 5; 
Elovl6: fatty acid elongase 6. 
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Figure 7.2 Gene expression of fatty acid desaturases in response to 0, 0.1, 1, 10 and 100 nM 
estradiol for 8 hours. Data are mean ± s.e. Within a gene, means with a different letter are 
significantly different by Tukey’s post hoc test following a significant one-way ANOVA F-
value. Fads1: fatty acid desaturase 1; Fads2: fatty acid desaturase 2; Scd1: stearoyl-CoA 
desaturase 1; Fasn: fatty acid synthase. 
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Chapter 8.  
Characterization of FADS2 Novel Transcript Variants 
8.1 Introduction 
It has been proposed that FADS2, one of the enzymes responsible for synthesizing n-3 
and n-6 polyunsaturated fatty acids (PUFA) does not make 20:4n-6 or 22:6n-3 in MCF7 cells 
(Park et al., 2011) or metabolize shorter-chain omega-6 and omega-3 fatty acids into longer-
chain PUFA (Grammatikos et al., 1994). The reason for this observation is not known: we did 
detect FADS2 mRNA in MCF7 cells in Chapter 7, but it is unknown if the gene sequence 
contains a deletion or is mutated and therefore non-functional, or if activity of the protein is 
repressed because of some other factor. It has also been proposed that FADS2 is non-functional 
in HeLa cells (Jaudszus et al., 2014).  Both MCF7 (present findings) and HeLa cells (Jaudszus et 
al., 2014) contain measurable amounts of 20:4n-6 or 22:6n-3.  Interestingly, no mutations were 
identified in the coding sequence of FADS2 in HeLa cells to explain the proposed lack of 
function (Jaudszus et al., 2014).  Alternate mechanism or mechanisms other than loss of 
structure-based enzymatic activity, per se, must result in inactivity of this enzyme.  Activity of 
proteins, including PCYT2 and GHRH receptor, can be repressed when a non-active isoform of 
the enzyme produced from alternative splicing binds to an active form of the same enzyme 
(Pavlovic, Singh, and Bakovic, 2014; McElvaine and Mayo, 2006; Motomura et al., 1998). This 
suggests an alternative hypothesis for why D6D, the product of the FADS2 gene, may be absent 
in MCF7 cells, even if the FADS2 gene is not mutated. Therefore, the purpose of the present 
study was to investigate whether MCF7 cells lack D6D activity because of the presence of, and 
inhibitory interaction with, a dominant-negative alternate D6D isoform.  
8.2 Methods and Materials 
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8.2.1 Identifying FADS2 Variants 
The “Gene” search function on the NCBI website was used to identify two transcripts 
that coded for identical full-length “wildtype” isoforms of D6D (AF084559.1/NM_004265.3 
encoding AAG23121.1/NP_004256.1; transcript variants 0/1; FADS2_v0/1). This search 
function was also used to identify a transcript variant produced from alternative splicing, which 
results in a different coding sequence in the 5’ region. As a result, this alternative transcript 
(NM_001281501.1 encoding NP_0012684301.1; transcript variant 2; FADS2_v2) results in 
production of a protein with a different N-terminal sequence than the wildtype protein. 
Characterization of protein isoforms arising from alternative splicing is a relatively new field, 
and naming conventions have not yet been fully developed. According to current best practices, 
we are therefore naming the wildtype isoform of the D6D protein that is produced from either the 
FADS2_v0 or FADS2_v1 transcripts D6D.1. The isoform produced from the FADS2_v2 
transcript should be called D6D.2.  
Based on the protein sequences of D6D.1 and D6D.2, we used UniProt to identify 
catalytically important domains. Information on these domains, as well as a sequence alignment 
of these two transcripts, is found in Figure 8.1. Sequence alignment was performed using 
EMBOSS Needle http://www.ebi.ac.uk/Tools/psa/emboss_needle/ with the default settings 
(Rice, Longden, and Bleasby, 2000). Primers that could distinguish FADS2_v0/1 from 
FADS2_v2 (sequences in Table 8.1) were designed to determine expression of transcripts 
encoding for D6D.1 and D6D.2 in MCF7 cells treated with vehicle, 0.1, 1, 10 or 100 nM 
estradiol for eight hours as described in Chapter 7. 
8.2.2 Transfecting FADS2 Variants into HEK 293 Cells 
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Plasmids encoding the open reading frame (ORF) for the full-length FADS2_v0/1 
transcript (AF084559.1/NM_004265.3), and the alternate FADS2_v2 transcript, were ordered 
from GenScript (Piscataway, NJ, USA). The FADS2_v0/1 ORF was cloned into the 
pcDNA3.1+C-His vector in-frame with the DNA sequence for a “His-tag”, consisting of 6 
repeated CAC codons that results in attachment of six histidine residues at the C-terminal end of 
the protein upon translation. The FADS2_v2 ORF was cloned into the pcDNA3.1+C-HA vector 
in-frame with a sequence encoding a hemagglutinin tag, which produces the peptide sequence 
“YPYDVPDYA” fused to the C-terminal end of the translated protein. Upon arrival, competent 
E. Coli cells were transformed to serve as an ongoing source of the plasmids.  The cells were 
grown on agar plates containing ampicillin as a selection agent for colonies containing the 
plasmid. Colonies were picked and grown in LB medium containing 100µg/ml ampicillin at 
37ºC. Plasmid DNA was mini-prepped from the E. Coli cells according to the manufacturer’s 
instructions using a commercially available EZ-10 Spin Column kit (BioBasic, Markham, ON). 
DNA was stored at -20 ºC prior to use. 
HEK 293 cells were collected by trypsinization and transferring to approximately eight 
ml of DMEM and spinning at 1000 x g for 5 minutes. The DMEM/trypsin supernatant was 
removed and cells were resuspended in 400 µl of DMEM. Cells were mixed with approximately 
10 µg of plasmid DNA containing plasmids encoding for either D6D.1 or D6D.2, isoforms or for 
pCMV-3-Tag-3a as an empty vector control, and electroporated in 4 mm-gap electroporation 
cuvettes using an ECM 830 Square Wave Electroporation System (BTX, Holliston, MA) with 
the following settings, according to the manufacturer’s protocol: 5  four-ms pulses at 230 V). 
An additional control group of HEK cells was electroporated under identical conditions, except 
that no vector was used. Cells were immediately transferred to new plates containing fresh media 
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(DMEM + 10% FBS and antibiotics, as described in Chapter 4), and allowed to grow and adhere 
to the plate for at least 4 hours. After this time, the media was changed to DMEM with 10% 
charcoal stripped FBS, which had been depleted of fatty acids. This is an important consideration 
in studies on PUFA biosynthesis, since there is a particularly high percentage of 22:6n-3 in 
regular FBS (van den Elsen et al., 2013), and provision of exogenous 22:6n-3 has been shown to 
inhibit endogenous synthesis of this fatty acid (Domenichiello et al., 2014; Gibson et al., 2013). 
HEK cells were then cultured for an additional four days after electroporation before harvest. 
On day four, cells were collected by centrifuging at 1000  g for 5 minutes at room 
temperature. Pellets were lysed by vortexing vigorously in immunoprecipitation (IP) buffer (20 
mM Tris-HCl, 137 mM NaCl, 2 mM EDTA and 1% Triton X-100), and were placed on ice for 
15 minutes. Finally, this mixture was centrifuged at 5000  g for 10 minutes. The cell debris was 
discarded and the supernatant was stored at -80ºC . An aliquot of the supernatant was used for 
fatty acid extraction and isolation of phospholipids by thin layer chromatography as described in 
Chapter 4. 
To examine D6D isoform interactions, 5 µg of plasmid encoding the ORF from each of 
the FADS2 variants were electroporated together into HEK cells, which were collected four days 
later. Aliquots of the cells were incubated with either a primary antibody against HA or against 
His, the unique tags at the end of the gene sequence in the plasmids, or with a secondary 
antibody, as a negative control. Immunoprecipitations were carried out overnight at 4 ºC with 
rotation. Antibody/protein complexes were collected by incubation with Protein A/G beads for 2 
hours at 4 ºC with rotation. Beads were centrifuged and washed five times using IP buffer. 
Finally, protein-loading dye was added to the beads, and the entire mixture was boiled to remove 
the proteins from the beads. This mixture was then ready for analysis by Western blotting, as 
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described in Chapter 4. Antibodies used for immunodetection were anti-His (2365P, Cell 
Signaling, 1:1000 in BSA) or anti-HA (2367S, Cell Signaling, 1:1000 in milk). 
To determine if the interaction of D6D.1 with D6D.2 resulted in a loss of activity and 
inhibited 20:4n-6 or 22:6n-3 biosynthesis, cells were electroporated with a constant amount of 
the FADS2_v0/1-expressing plasmid (5 µg), and increasing amounts of FADS2_v2-expressing 
plasmid (0, 2.5, or 5 µg). After electroporation, cells were collected, and phospholipids were 
isolated and analyzed for fatty acid composition, as described earlier in this chapter. 
Student’s t-test was used to determine whether expression of alternate FADS2 transcript 
variants (encoding for D6D.1 and D6D.2) differed significantly when MCF7 cells were exposed 
to estradiol compared with controls. One-way ANOVA was used to determine differences in 
fatty acid composition in HEK 293 cells electroporated with transcript variants. Following a 
significant one-way ANOVA result, Newman-Keul’s post hoc test was used to determine 
differences in fatty acid levels between groups 
8.3 Results 
8.3.1 FADS2_v0/1 and FADS2_v2 are Induced by Estradiol in MCF7 Cells 
 Primers were designed to determine expression of transcripts encoding D6D.1 (i.e. 
FADS2_v0/1) and D6D.2 (i.e. FADS2_v2). Both gene variants are detected in MCF7 cells when 
treated with vehicle only (Figure 8.2). At this baseline, FADS2_v2 mRNA levels are 
approximately 6-fold higher than FADS2_0/1 mRNA levels (p<0.05). Expression of 
FADS2_v0/1 increases 6-fold when MCF7 cell are treated with 10 nM estradiol, but no other 
concentration of estradiol results in increased FADS2_v0/1 expression compared with controls. 
Expression of FADS2_v2 significantly increases with 0.1, 1 and 10 nM estradiol (Figure. 8.2), 
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compared with vehicle treated controls. Expression of FADS2_v2 remains significantly higher 
than that of FADS2_v0/1 at all estradiol concentrations tested. 
8.3.2 Fatty Acid Composition of HEK 293 Cells Expressing Control Vector, FADS2_v0/1 or 
FADS2_v2 
 Cells electroporated to express FADS2_v0/1, encoding for the D6D.1 isoform, have 
higher relative amounts of one of the major D6D products, 20:4n-6, compared with control cells 
electroporated with pCMV-3Tag-3a (Figure 8.3; full fatty acid composition is in Appendix 3, 
Table A3.1 and A3.2). Cells electroporated to express FADS2_v2, encoding for the D6D.2 
isoform, did not show any differences in the products of D6D activity (i.e. 22:6n-3 or 20:4n-6) 
compared with controls. As a result, the relative levels of 20:4n-6 were lower in cells transfected 
with FADS2_v2 compared with FADS2_v0/1 (Figure 8.3). 
8.3.3 D6D.2 Interacts withD6D.1 and Inhibits Activity  
 D6D.1 and D6D.2 were found to co-immunoprecipitate when cells were electroporated 
with plasmids encoding both isoforms (Figure 8.4). Evidence suggested that this interaction 
allows D6D.2 to negatively regulate the activity of D6D.1.  Addition of D6D.1 alone 
significantly increased cellular levels of 20:4n-6. Electroporation of FADS2_v2 along with 
FADS2_v0/1 in a 1:1 ratio, however, resulted in a significant reduction in the cellular content of 
20:4n-6, essentially back to control levels. Notably, transfection of cells with an equimolar ratio 
of FADS2_v0/1:FADS2_v2 expression plasmid was required to produce this effect. Co-
transfection of cells with FADS2_v0/1:FADS2_v2 in a 1:0.5 ratio was insufficient to alter 20:4n-
6 levels (Figure 8.5; full fatty acid composition in Appendix 3, Table A3.3 and A3.4).  
8.4 Discussion 
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 MCF7 cells express different alternatively spliced transcript variants of the FADS2 gene. 
Two reported transcripts (Accession numbers: AF084559.1 (FADS2_v0) and NM_004265.3 
(FADS2_v1)) encode for the same full-length D6D protein, which we refer to as D6D.1 in the 
current work. These transcripts have highly similar exonal organization, and identical coding 
regions, differing only by the presence of an additional 207 base pair sequence at the start of the 
5’ UTR in transcript variant 1 (FADS2_v1) that is not present in the originally reported reference 
sequence for FADS2 (FADS2_v0). An alternate transcript, FADS2_v2 (Accession number 
NM_001281501.1), encodes for an isoform of the D6D protein (referred to as D6D.2 in the 
current work) that is 22 amino acids shorter than the full-length isoform. This truncated isoform 
also has a unique N-terminal sequence that differs from the sequence present at the start of the 
D6D.1 isoform. D6D.2 is missing the first 68 amino acids that D6D.1 has, and instead has 40 
different amino acids (Figure 6.1). The D6D.1 and D6D.2 isoforms are, however, identical 
throughout the C-terminal 374 bp. The alternate transcript is present at six-fold higher levels than 
the wild-type transcript. Expression of both transcript variants is induced by estrogen treatment, 
but levels of FADS2_v2 remained higher than FADS2_v0/1 at all levels of estrogen tested. 
 The full-length D6D.1 isoform has been shown previously to catalyze the desaturation of 
very long chain fatty acids, and over-expression of this isoform in cells has been found to 
increase the synthesis of 20:4n-6 and 22:6n-3 in cells (Le et al., 2014). The function of the 
D6D.2 isoform has not yet been reported. In the wild-type isoform, D6D.1, amino acids 18-95 
contain a cytochrome b5-heme binding domain and specifically a 53-His-Pro-Gly-Gly-56 
sequence that allows the histidine at amino acid position 53 to bind heme with greater affinity 
(Cho, Nakamura, and Clarke, 1999). These motifs are essential for catalysis (Cho, Nakamura, 
and Clarke, 1999), since mutagenesis of His53 to alanine in both the rat D6D and the plant 
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homologue of D6D abrogates synthesis of the usual D6D products (Sayanova, Shewry, and 
Napier, 1999; Guillou et al., 2004). Since the D6D.2 isoform lacks these N-terminal sequences 
(Figure 8.1), we predicted that this alternate form of the enzyme would lack functional 
desaturase activity. Furthermore, we hypothesized that impaired synthesis of 20:4n-6 and 22:6n-
3 in MCF7 cells may occur as a result of a dominant-negative effect of the FADS2_v2-encoded 
D6D.2 isoform. To test this, we transfected HEK 293 cells with plasmids expressing either the 
wildtype coding region of FADS2_v0/1 (encoding D6D.1) or the alternate FADS2_v2 coding 
region (encoding D6D.2). 
As expected, the wild-type D6D.1 was found to have increased activity. Overexpression 
of plasmid encoding this variant in HEK 293 cells resulted in phospholipids enriched with 15% 
more 20:4n-6 compared with control cells electroporated with pCMV only. Conversely, levels of 
20:4n-6 in cells expressing FADS2_v2 in the present study were not different from control cells, 
and were lower than in cells expressing FADS2_v0/1. This work demonstrates that the D6D.2 
isoform is not catalytically active, and further suggests the necessity of the cytochrome b5- heme 
binding domain for catalytic activity of human D6D.  
PCYT2 (Pavlovic, Singh, and Bakovic, 2014) and GHRH receptor (McElvaine and 
Mayo, 2006; Motomura et al., 1998) have been demonstrated to have multiple splice variants 
that interact with each other, with the variant isoforms having a dominant negative effect on the 
activity of the wild type variant. We hypothesized that a similar effect might occur in MCF7 
cells, because FADS2_v2 is expressed at a higher level than FADS2_v0/1 in this cell line, and 
because the D6D.2 isoform appears to be non-functional in HEK 293 cells. Therefore, we 
directly tested whether D6D.2 could interact with D6D.1 through co-immunoprecipitation, and 
found that both isoforms associated with each other when expressed in the same cells (Figure 
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6.4). We hypothesized that this interaction, or at least the presence of both transcript variants, 
would result in inhibition of 20:4n-6 biosynthesis, since D6D.2 is inactive on its own. Indeed, 
when HEK cells were electroporated with a constant amount of FADS2_v0/1 and increasing 
amounts of FADS2_v2, levels of 20:4n-6 were no longer elevated compared with controls, unlike 
in cells electroporated with FADS2_v0/1 only. This suggests that D6D.2 is having a dominant 
negative effect on the ability of D6D.1 to form 20:4n-6. The mechanism behind this effect, and 
whether it is dependent on the interaction between the two proteins remains unknown, but these 
results indicate that when D6D.1 and D6D.2 are present in equal amounts, D6D.1 is unable to 
synthesize 20:4n-6. 
Of interest, the proportion of 22:6n-3 was not changed by overexpression of either of the 
D6D isoforms. Cellular levels of free 18:2n-6, the precursor of 20:4n-6, are typically 5-10 fold 
higher than cellular levels of free 18:3n-3, the precursor of 22:6n-3. Since D6D can utilize either 
precursor, competition between the more abundant n-6 PUFA substrate for conversion by 
ectopically expressed enzyme may account for the lack of effect on 22:6n-3 levels (Harnack, 
Andersen, and Somoza, 2009). Rats accumulate more 22:6n-3 in plasma and liver lipids when 
the proportion of 18:3n-3 increases from 0.2% of the total dietary lipids to 1.0%, when 18:2n-6 
levels are kept constant at 1% of total dietary lipids (Tu et al., 2010), further suggesting the 
competition between n-6 and n-3 PUFA for D6D activity. Since we did not presently supplement 
the media the HEK 293 cells were grown in with additional 18:3n-3, it is possible that 18:2n-6 
outcompeted 18:3n-3 for D6D.   
8.5 Conclusions  
This study is the first to characterize the D6D.2 isoform. This isoform does not synthesize 
the usual D6D products, 20:4n-6 or 22:6n-3. This suggests that the missing cytochrome b5-heme 
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binding domain is important in mammalian D6D, which has been shown in the plant (Sayanova, 
Shewry, and Napier, 1999) and rat (Guillou et al., 2004) form of D6D, but not human D6D. 
Future studies should target this domain to determine its role in D6D activity and synthesis of 
20:4n-6 and 22:6n-3. D6D.2 also appears to be a negative inhibitor of D6D.1 activity, since no 
increases in 20:4n-6 or 22:6n-3 were observed in HEK cells electroporated with equal amounts 
of FADS2_v0/1 and FADS2_v2 DNA. Since transfecting equal copies of these two transcript 
variants had an apparent negative effect on D6D activity in HEK cells, I propose that the reason 
MCF7 cells do not synthesize D6D products in MCF7 cells is because of FADS2_v2 is expressed 
at levels 6-fold greater than that of FADS2_v0/1, and FADS2_v2 is negatively inhibiting activity. 
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Table 8.1 Summary of human FADS2 transcript variant sequence information and primer sequences for reverse transcriptase 
real-time PCR 
 
Transcript 
Variant 
Transcript 
Annotation 
Transcript 
Accession 
Number 
Protein 
Annotation 
Protein Accession 
Number 
Protein 
length 
Primer Sequence (5’-3’) 
0 FADS2_v0 AF084559.1 D6D.1 AAG23121.1 432 amino 
acids 
Forward: 5’- 
CAGCTGGGAGGAGATTCAGA-3’  
Reverse: 5’-
GGAAGGCGCGGAAGGCATCC-3’ 
1 FADS2_v1 NM_004265.3 D6D.1 NP_004256.1 432 amino 
acids 
Forward: 5’- 
CAGCTGGGAGGAGATTCAGA-3’  
Reverse: 5’-
GGAAGGCGCGGAAGGCATCC-3’ 
2 FADS2_v2 NM_001281501.1 D6D.2 NP_0012684301.1 389 amino 
acids 
Forward: 5’-
ATGCACGGCAGGGAGGCGGG-3’  
Reverse: 5’-
GGAAGGCGCGGAAGGCATCC-3’ 
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D6D.1              1 MGKGGNQGEGAAERE-----------VSVPTFSWEEIQKHNLRTDRWKVI     39 
                                  ||            | ||      |            
D6D.2              1 ----------MHGREAGPFVCVCVLLASIPTPQTPLLQAS---------L     31 
 
D6D.1              0 DPKVWNITKWSIQHPGGQRVIGHY-AGEDATDAFRAFHPDLEFVGKFLKP     88 
                      |           ||      ||   |    ||||||||||||||||||| 
D6D.2             32 PP----------FHPAS---AGHHITGQQ--DAFRAFHPDLEFVGKFLKP     66 
 
D6D.1             89 LLIGELAPEEPSQDHAKNSKITEDFRALRRTAEDMNLFKTNHVFFLLLLA    138 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
D6D.2             67 LLIGELAPEEPSQDHAKNSKITEDFRALRRTAEDMNLFKTNHVFFLLLLA    116 
 
D6D.1            139 HIIALESIAWFTVFYFGNGWIPTLITAFVLATSQAQAGWLEHDYGHLSVY    188 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
D6D.2            117 HIIALESIAWFTVFYFGNGWIPTLITAFVLATSQAQAGWLEHDYGHLSVY    166 
 
D6D.1            189 RKPKWNHLVHKFVIGHLKGASANWWNHRHFQHHAKPNIFHKDPDVNMLHV    238 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
D6D.2            167 RKPKWNHLVHKFVIGHLKGASANWWNHRHFQHHAKPNIFHKDPDVNMLHV    216 
 
D6D.1            239 FVLGEWQPIEYGKKKLKYLPYNHQHEYFFLIGPPLLIPMYFQYQIIMTMI    288 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
D6D.2            217 FVLGEWQPIEYGKKKLKYLPYNHQHEYFFLIGPPLLIPMYFQYQIIMTMI    266 
 
D6D.1            289 VHKNWVDLAWAVSYYIRFFITYIPFYGILGALLFLNFIRFLESHWFVWVT    338 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
D6D.2            267 VHKNWVDLAWAVSYYIRFFITYIPFYGILGALLFLNFIRFLESHWFVWVT    316 
 
D6D.1            339 QMNHIVMEIDQEAYRDWFSSQLTATCNVEQSFFNDWFSGHLNFQIEHHLF    388 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
D6D.2            317 QMNHIVMEIDQEAYRDWFSSQLTATCNVEQSFFNDWFSGHLNFQIEHHLF    366 
 
D6D.1            389 PTMPRHNLHKIAPLVKSLCAKHGIEYQEKPLLRALLDIIRSLKKSGKLWL    438 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
D6D.2            367 PTMPRHNLHKIAPLVKSLCAKHGIEYQEKPLLRALLDIIRSLKKSGKLWL    416 
 
D6D.1            439 DAYLHK    444 
                     |||||| 
D6D.2            417 DAYLHK    422 
 
Figure 8.1. Sequence alignment of human D6D.1 and D6D.2 enzymes. Sequence alignment was performed using EMBOSS Needle 
(Rice, Longden, and Bleasby, 2000). The beginning of the cytochrome b5-heme binding domain is bolded, italicized and highlighted 
in green. The four-amino acid sequence that is bolded, italicized and highlighted in yellow is required for heme binding and represents 
a sharp β-turn. The end of the heme binding domain is highlighted in blue. 
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Figure 8.2.  Expression of transcripts coding for either wildtype D6D.1 (FADS2_v0/1) or D6D.2 
(FADS2_v2) in MCF7 cells, in response to treatment with increasing concentrations of estradiol 
for 8 hours. Data are means ± s.e.m.. *p<0.05 versus expression of the Fads2_v0/1 at the same 
concentration of estradiol. Within a transcript variant, means with a different letter are significantly 
different by Newman-Keul’s post hoc test following a significant one-way ANOVA F-value. 
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Figure 8.3 Relative proportion of 20:4n-6 and 22:6n-3 in phospholipids from HEK 293 cells 
electroporated with pCMV (empty vector control), or a plasmid expression vector containing the 
coding sequence for either D6D.1 (i.e. pc-FADS2_v0/1) or. D6D.2 (i.e. pc-FADS2_v2). Data are 
means ± s.d. Within a fatty acid, means with a different letter are significantly different by 
Newman-Keul’s post hoc test following a significant one-way ANOVA F-value. 
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Figure 8.4 D6D.1 and D6D.2 co-immunoprecipitate when expressed together in HEK293 cells. A: 
Immunoprecipitation using a secondary antibody, an anti-His antibody or a HA antibody, and 
detected after running on the same gel using an anti-HA antibody. B:  Immunoprecipitation using a 
secondary antibody, anti-His antibody or a HA antibody, and detected after running on the same 
gel using an anti-His antibody. 
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Figure 8.5 Relative proportion of 20:4n-6 and 22:6n-3 in phospholipids from HEK 293 cells 
electroporated with pCMV (empty vector control), or a plasmid expression vector containing the 
coding sequence for either D6D.1 (i.e. pc-FADS2_v0/1) and increasing amounts of D6D.2 (i.e. pc-
FADS2_v2). Data are means ± s.d. Within a fatty acid, means with a different letter are 
significantly different by Newman-Keul’s post hoc test following a significant one-way ANOVA 
F-value. 
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Chapter 9. 
General Discussion 
There were four main objectives of this thesis. The first was to confirm if small 
physiological changes in estrogen over the menstrual cycle are associated with changes in blood 
fatty acid composition by measuring blood fatty acids at two time points over the menstrual cycle. 
We hypothesized that levels of 18:0, 16:1n-7 and 22:6n-3 would be higher during the luteal phase 
compared with the follicular phase. Contrary to our hypotheses, levels of 18:0 did not change with 
time over the menstrual cycle, and 16:1n-7 was lower during the luteal phase. However, increased 
levels of 22:6n-3 were observed as expected. We also hypothesized that these three fatty acids 
would be higher in plasma of oral contraceptive users compared with women not taking oral 
contraceptives and men. As expected, 16:1n-7 and 22:6n-3 levels were higher in oral contraceptive 
users, but 18:0 was actually lowest in this group. It appears that increasing levels of estrogen 
increases 22:6n-3 levels, but the relationship is not as straightforward when examining 16:1n-7. 
Other models of increasing estrogen increase 18:0 levels (Marks, Kitson, and Stark, 2013; Stark et 
al., 2005), but the opposite pattern was observed presently, suggesting the relationship between 
SFA and estrogen is not straightforward. 
The second objective in this thesis was to further examine the effects of physiological 
changes in estrogen concentrations in naturally cycling animals by using a rat model to measure 
hepatic enzyme expression over the four-day estrous cycle. We hypothesized that mRNA and 
protein levels of elongase 6, elongase 2 and Fads2 would be highest during proestrus, when 
estrogen is highest. These hypotheses were all incorrect. Elongase 6 levels were consistently 
highest in females, but the estrous cycle had no effect on mRNA or protein levels. Elongase 2 
mRNA was not different over the estrous cycle, and protein levels were highest in males and 
proestrus. Finally, Fads2 mRNA was highest during estrus, but protein levels were not different at 
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all. It appears that regulation of these enzymes in vivo is controlled by multiple mechanisms. 
Estrogen may be one of these factors, but is not the only one.  
Therefore, the third objective was to confirm the effects of estrogen on gene expression 
changes in MCF7 cells, an ERα-positive cell line without the additional considerations of diet, 
other hormone changes, fatty acid feedback regulation and multiple sources of estrogen required 
for an in vivo model. We hypothesized that estrogen treatment would increase mRNA expression 
of FASN, ELOVL6, ELOVL2 and FADS2, and levels of 18:0, 16:1n-7 and 22:6n-3. As expected, 
mRNA levels of ELOVL6, ELOVL2 and FADS2 increased, confirming that estrogen has a role in 
regulating mRNA expression of these genes. FASN was not increased with estrogen. Levels of 
16:1n-7 increased as predicted, but few other changes were observed, unlike our hypotheses. 
FADS2 has been previously been predicted to be non-functional in MCF7 cells, so it is likely that 
this is why no changes in 22:6n-3 levels were observed. 
Therefore, the final purpose of this thesis was to examine perturbations in MCF7 fatty acid 
metabolism. Two transcript variants were identified, and the ability of each to synthesize 20:4n-6 
and 22:6n-3 when overexpressed in HEK 293 cells was determined. We hypothesized that 
overexpressing FADS2_v0/1 in HEK 293 cells would increase the levels of these two fatty acids, 
but FADS2_v2 overexpression would not, compared with controls. These hypotheses were what 
was observed. We hypothesized that the two variants would interact when both are overexpressed 
in HEK293 cells to inhibit synthesis of 20:4n-6 and 22:6n-3 by the wild-type variant, which is 
what was observed, suggesting that FADS2_v2 acts as a dominant negative inhibitor on 
FADS2_v0/1.  
The relationship between estrogen and fatty acid composition was examined in several 
models, including the human menstrual cycle, rat estrous cycle and in cell lines. Higher levels of 
22:6n-3 and lower levels of 22:5n-3 during the menstrual cycle when estrogen is highest suggested 
estrogen regulation of the expression and/or activity of ELOVL2 or FADS2.  Follow up work in 
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rats confirmed the fatty acid results but hepatic Elovl2 was not different across the estrous cycle, 
while Fads2 was highest at estrus and diestrus stage in rats, but not during proestrus when estrogen 
is highest. However, ELOVL2 and FADS2 did increase with estradiol treatment in MCF7 cells. It is 
possible that other changes in rats that are not occurring in MCF7 cells contribute to the 
differences between the two studies. For example, progesterone also increases during the estrous 
cycle in rats, and has been previously reported to have effects on PUFA biosynthesis and 
potentially interfering with the effects of estradiol (Childs et al., 2012; Sibbons et al., 2014; Wade, 
1975).  The estrogen:progesterone ratio is also an important determinant of signaling and 
estrogenic effects (Sinchak and Wagner, 2012). Progesterone is at its highest during proestrus in 
the rat, while it is low during estrus when there is a secondary peak in estradiol (Smith, Freeman, 
and Neill, 1975).  Progesterone was not examined in the MCF7 experiments. It may also be 
possible that when levels of 22:6n-3 are high, feedback regulation occurs to shut off expression of 
desaturases and elongases, which may have been happening during proestrus in rats, since 22:6n-3 
levels were highest. This would not have happened in MCF7 cells, because there were no 
differences in cellular PUFA levels.  
Fads1 and Elovl5 also changed over the estrous cycle in rats, but did not change with 
estradiol treatment in cells, suggesting that they are not directly regulated by estrogen, but possibly 
by additional hormones and gene-regulatory factors present in complex organism systems. It is 
also possible that eight hours of estradiol treatment was not long enough to elicit changes in 
expression of these genes in MCF7 cells, because some genes have been demonstrated to require 
twenty-four hours to show changes in MCF7 cells treated with estradiol (Frasor et al., 2003). 
Future studies should examine a time course of estrogen treatment, to determine if these genes are 
induced or repressed by estrogen after a longer time period.  
Levels of 20:4n-6 and 22:6n-3 were highest in the blood of proestrus rats and women in the 
luteal phase, when estrogen peaks. However, levels of these fatty acids were not higher in MCF7 
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cells treated with estradiol. Expression of FADS2, which codes for D6D (the rate-limiting enzyme 
in the synthesis of these two PUFA species) is induced by estrogen in MCF7 cells. However, this 
may be explained by the alternate splice variant (FADS2_v2) that I characterized in MCF7 cells.  
This variant codes for a shorter protein that is unable to synthesize 20:4n-6 and 22:6n-3. 
Expression of FADS2_v2 was higher in MCF7 cells compared with the wild type FADS2_v0/1. 
Introduction of higher levels of FADS2_v2 into HEK 293 cells caused an inhibition of 20:4n-6 
biosynthesis by co-expressed FADS2_v0/1. Since a direct interaction between D6D.1 and D6D.2 
was observed, it is possible that D6D.2 directly inhibits the activity of the wildtype enzyme, 
although additional work will be required to confirm this. Importantly, these studies suggest a 
mechanism to explain why FADS2 has been reported to be non-functional in MCF7 and 
potentially other cancer cells. My results suggest D6D activity may still be possible in these cells, 
but is largely inhibited.  
In this thesis, we also report that 16:1n-7 was higher in women who take oral 
contraceptives compared with both women who do not receive oral contraceptives and men and in 
total lipid extracts from MCF7 cells treated with estradiol compared with controls, which agrees 
with prior reports in postmenopausal women taking and not taking hormone therapy (Stark, Park, 
and Holub, 2003; Tworek et al., 2000). When estrogen concentrations are fluctuating, such as in 
women who do not receive oral contraceptives and in the estrous cycle in rats, 16:1n-7 is not 
increased as predictably.  The effect of estrogen on 16:1n-7 seems to be reserved for large 
differences in estrogen exposure that are typically observed with exogenous treatment that is 
pharmacological versus physiological. 
There are several strengths to the studies in this thesis. Firstly, the studies in rats and 
humans specifically examined estrous or menstrual cycle stage, respectively, as well as birth 
control use in humans. Often females are under studied because menstrual cycle and estrogen-
based changes may complicate analyses, or if females are included, the menstrual cycle is not 
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considered during analyses. I have shown there are differences in both hepatic expression of fatty 
acid elongases and desaturases and blood fatty acid composition over the cycle in rats and humans. 
Researchers should consider these factors when designing experiments in the future, and 
potentially take multiple experimental measurements in women to account for menstrual cycle to 
get an accurate representation. Finally, whenever cells were treated with estradiol, this was the 
only source of estrogen signalling, because the media did not contain phenol red, and charcoal-
stripped FBS was used. For plasmid experiments, cells were grown in media containing FBS that 
had been charcoal-stripped to remove any sources of long chain PUFA, thereby minimizing 
confounding from exogenous lipids when determining effects of the different FADS2 transcript 
variants on fatty acid levels. Additionally, for the plasmid experiments, TLC was performed to 
isolate phospholipids, the major complex lipid type incorporating 20:4n-6 and 22:6n-3.  
However, there are some limitations to these studies as well. While menstrual cycle and 
birth control use were controlled for and analyzed separately in Chapter 5, data on the timing of 
when women were taking the oral contraceptives was not collected, so when women may have 
been exposed to different hormone levels at the time of the blood collections. Future studies should 
examine the effect of hormone timing on fatty acid composition, in addition to other dosing and 
delivery methods, such as a triphasic birth control or transdermal patch. Similarly, the timing of 
the rat estrous cycle was difficult to determine. Both estrogen and progesterone change rapidly 
over the estrous cycle, particularly during proestrus (Smith, Freeman, and Neill, 1975). We tried to 
minimize variability by sacrificing rats at the same time of day, but it is possible that the rats were 
not entirely timed perfectly. This is supported by some of the vaginal stains that appeared to be in 
between two different cycle stages and the variability in the hormone data, despite measuring 
steroid hormones by UHPLC-MS/MS. A tighter timeline in rats or allowing them to acclimate 
longer prior to sacrifice may alleviate some of these limitations. Additionally, the rats were fasted. 
This minimized the within-experiment variability, but limits the applicability to fed and refed 
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models since both mRNA expression of Scd1 and Elovl6 (Turyn, Stojek, and Swierczynski, 2010) 
and hepatic fatty acid composition (Marks et al., 2015) have been demonstrated to be regulated by 
fasting and feeding. Using cell culture allows for specific parameters to be manipulated. However, 
the FBS in the cell culture media contains factors required for cell growth including fatty acids, 
specifically HUFA. Although stripped serum was used prior to hormone and plasmid experiments, 
it is unknown what proportion of the fatty acids measured after treatments were due to the 
experimental manipulation and what was taken up and incorporated into the cells prior to 
treatment, when cells were still exposed to regular FBS. It took a lot of time to fully identify the 
FADS2 variants and develop a method for examining the effects of the variants on 20:4n-6 and 
22:6n-3 levels. As such, many of the conclusions regarding the transfected cells and functionality 
of the FADS2 variants are based on fatty acid composition only. Future studies using radiolabeled 
fatty acids in conjunction with overexpression of the FADS2 variants and/or an enzyme assay will 
allow for a more specific measure of the activity of the different variants. Additionally, confirming 
the role of FADS2_v2 in dominantly inhibiting FADS2_v0/1 in MCF7 cells should be completed. 
This could be achieved by overexpressing FADS2_v0/1 in these cells to determine if increasing 
levels of this variant to levels greater than those of FADS2_v2 can overcome the inhibition, or 
silencing FADS2_v2 and determining if activity of FADS2_v0/1 is no longer repressed. 
The work from this thesis expands the current state of knowledge of the effects of sex and 
estradiol on fatty acid metabolism. 22:6n-3 biosynthesis appears to be upregulated by estrogen, but 
the expression of enzymes in 22:6n-3 biosynthesis appears to have multiple control factors in vivo. 
Measuring expression levels of multiple transcript variants of FADS2 is a novel concept employed 
herein.  This is important for future research, as I have characterized D6D.2 as non-functional and 
inhibitory with regards to the function of the wildtype D6D.1 enzyme.  This could be important for 
understanding the impact of genetics on fatty acid metabolism particularly polymorphisms in 
populations but also mutations in metabolic disorders and cancer.  I have also demonstrated that 
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some of the inconsistent findings with fatty acid metabolism in sex comparisons may be due to a 
failure to categorize women and female animal models based on menstrual or estrous cycle stage, 
as well as exogenous hormone use.  Future dietary recommendations for fatty acid intake and 
requirements for men and women, and women at different life stages (such as monthly 
recommendations during the menstrual cycle, pregnancy, and menopause) should be considered.  
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Appendix 1.1. Advertisements for Chapter 5 
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Appendix 1.2. Chapter 5 Email Recruitment Script 
 
Mailing Lists Targeted: Applied Health Science Listservs 
 
Email Subject Line: Seeking Participants for a Blood Lipids Research Study  
 
Email Text: 
 
The Laboratory of Nutritional and Nutraceutical Research in the Department of Kinesiology is looking for 
male and female participants between the ages of 18 and 35 for a blood lipids research study. 
 
Study description: 
Sex hormones play a role in lipid levels in the body. It has been shown that there is an increased level of 
docosahexaenoic acid in females than males. This study is examining the changes in blood lipid levels 
during the menstrual cycle, which has changing levels of sex hormones. These fluctuating levels of sex 
hormones result in changes in blood lipid composition. This study will identify these changes.  
 
Participants in this study will be asked to: 
 
 Visit the Department of Kinesiology at the University of Waterloo 2 times over 1 month for female 
participants and 1 time per month for male participants 
 Provide a venous blood sample collected by a certified technician on 2 occasions for female 
participants and 1 occasion for male participants 
 Complete a nutritional questionnaire at baseline 
 
Benefits to the participant: 
 
 Receive up to $10 remuneration 
 
We are seeking participants (ages 18-25) who: 
 
 Eat fish less than once a week and do not take fish oil supplements 
 Females with a regular menstrual cycle between 28-35 days for the last 3 months  
 Males for comparison 
 Women cannot be taking oral medications other than Alesse birth control 
o Other oral contraceptives are not allowed 
 No conditions that would affect hormone levels 
 
For more information or to volunteer please contact: 
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The Laboratory of Nutritional and Nutraceutical Research 
Department of Kinesiology, University of Waterloo 
Phone – (519) 888-4567 ext 37873 
Email – k2marks@uwaterloo.ca 
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Appendix 1.3. Chapter 5 Class Announcement Slide 
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Appendix 1.4. Information and Consent Forms for Chapter 5 
Information and Consent Form 
 
Laboratory of Nutritional and Nutraceutical Research  
Department of Kinesiology 
University of Waterloo 
 
Title of Project The Effect of Sex Hormones on Blood Lipidomics 
 
Principal Investigator: Professor Ken D. Stark 
 University of Waterloo, Department of Kinesiology 
 (519) 888 – 4567 ext. 37738 
 
Student Investigators: Kristin Marks, PhD Student 
 University of Waterloo, Department of Kinesiology 
 (519) 888 – 4567 ext. 37873 
 k2marks@uwaterloo.ca  
 
 Chloe Kurtin 
 University of Waterloo, Department of Kinesiology 
 (519) 888 – 4567 ext. 37873 
 ckurtin@uwaterloo.ca  
 
Purpose of Study: 
 
Sex differences in fatty acid levels in the blood have been documented in both humans and rats. 
These sex differences can have numerous effects on the body. Polyunsaturated fatty acids (PUFA) 
have shown a cardioprotective effect in regards to eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA). It has been seen in humans that women tend to have higher DHA 
levels than men. It has been seen in rat models that estradiol contributes strongly to this difference.   
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The goal of the study is to examine the differences in blood lipid composition during the menstrual 
cycle. This study is also examining the difference in blood lipid composition between women on 
hormonal contraceptives and women experiencing normal fluctuating hormone levels. A secondary 
goal of this study is to examine the sex differences between blood lipid levels. In the study, you 
will be asked to give two blood samples if you are female and one blood sample if you are male. 
The first blood sample for females will be taken at day 6-8 of your menstrual cycle and the second 
blood sample will be taken at day 21-23 of your menstrual cycle. Males will give one blood 
sample at the beginning of the study.  
 
The results of this study will be helpful in determining the pathway that estrogen modulates to 
change blood lipid composition. The results will also be used to better understand the effects of 
birth control and hormone treatments on blood lipid levels. This could help us better understand 
the change in blood lipid composition in the bodies of women using hormone based birth controls. 
Specific details about the study procedures are provided in the following section. 
 
Procedures Involved in this Study: 
 
As a female study participant, you will be asked to do the following: 
 
1. Complete a health status questionnaire, food frequency questionnaire, and menstrual cycle 
questionnaire to determine study eligibility  
2. During the study, do not vary your diet from normal. It is important to continue your diet as normal. 
Do not make significant changes to your daily exercise. 
3. Ensure researchers are told of any changes to medications or oral contraceptives. 
4. Arrange for venous blood samples to be taken on day 6-8 of menstrual cycle (from start of the cycle) 
and days 21-23 of the menstrual cycle. 
5. Fast overnight (including no drinking and eating, water is allowed) before the blood sample is taken. 
6. Provide venous blood samples two times over the study period for female participants.  
7. Allow your blood to be analyzed for whole blood lipid composition and assessing levels of various 
enzymes involved in lipid synthesis. 
 
As a male study participant, you will be asked to do the following: 
 
1. Complete a health status questionnaire, and food frequency questionnaire to determine study 
eligibility 
2. During the study, do not vary your diet from normal. It is important to continue your diet as normal. 
Do not make significant changes to your daily exercise. 
3. Ensure researchers are told of any changes to medications. 
4. Arrange for a venous blood samples to be taken. 
5. Fast overnight (including no drinking and eating, water is allowed) before the blood sample is taken. 
6. Provide one venous blood sample.  
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7. Allow your blood to be analyzed for whole blood lipid composition and assessing levels of various 
enzymes involved in lipid synthesis. 
 
Information is provided on each of the tests. The tests will all be completed at the Laboratory of 
Nutritional and Nutraceutical research at the University of Waterloo. 
 
Time Commitment: 
 
Each visit to the laboratory should be 15-20 minutes. This will include the initial screening visit to 
determine eligibility to the study as well as the venous blood collections.  
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Study Timeline - Females: 
 
Eligibility Screening 
 
 Health status questionnaire 
 Menstrual cycle questionnaire 
 Food Frequency Questionnaire 
 
Eligible participants will be invited to participate in the following: 
 
Day 6-8 from beginning of menstrual cycle:  
 
 Venous blood sample completed by a trained personnel 
 Only one sample will be collected on one of the days. One visit only. 
 
Day 21-23 from beginning of menstrual cycle: 
 
 Venous blood sample completed by a trained personnel 
 Only one sample will be collected on one of the days. One visit only. 
 
Study Timeline - Males: 
 
Eligibility Screening 
 
 Health status questionnaire 
 Food Frequency Questionnaire 
 
Eligible participants will be invited to participate in the following: 
 
 Venous blood sample completed by a trained personnel 
 Only one sample will be collected on one of the days. One visit only. 
 
Personal Benefits of Participation: 
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You will receive information on your blood lipid composition including the omega-3 status in 
comparison to current health recommendations. During the study, a food frequency questionnaire 
will be completed. These results may give you information on your dietary habits.  
 
Detailed Explanation of Procedures and Risks: 
Venous Blood Sampling – This is similar to blood samples taken by your physician. Venous blood 
will be collected under sterile conditions with an 18-21 gauge needle from a vein in your arm and 
will be collected into sterile glass tubes. For each visit approximately 15mL or 3tsp of blood will 
be collected.  This procedure may result in slight bruising and bleeding.  This can be minimized by 
the application of direct pressure to the point of needle entry into the vein.  The use of sterile gauze 
and alcohol swipes minimizes the risk of infection.  Blood fatty acid levels will be determined. 
Venous blood sampling will be performed by trained and competent laboratory personnel 
following universal guidelines for handling blood and blood products. This procedure is being 
done under the delegation of Dr. John Moule. 
Special Instructions: 
 
Participants are asked to continue their regular diet and exercise regime. If you make significant 
changes to your diet or exercise regime, we ask that you inform the researchers of this change.  
Any change to your medication, including oral contraceptives, is asked to be reported to the 
researcher. It is asked that you do not participate in other studies or donate blood during your 
participation in this study. Participants are asked to fast overnight before the blood tests, including 
no food or drink other than water. Please refrain from alcohol consumption two days before the 
scheduled blood draws. 
 
Health Screening Form: 
 
The Health Screening questionnaire asks questions about your current health status. This form 
guides the researchers with the eligibility into the study and ensures you are a suitable candidate 
for the study. If you have disorders resulting in abnormal hormone levels, lipid metabolism 
disorders, or cardiovascular disease, you will not be eligible to participate in the study. 
 
Menstrual Cycle Screening Form (females only): 
 
This questionnaire provides researchers with information regarding the regularity and other aspects 
of your menstrual cycle. This information is used to guide eligibility into the study. If you have a 
menstrual cycle outside of 28-35 days, abnormal cycles within the last 3 months, or use hormonal 
contraceptives other than Alesse, you will not be eligible for this study. 
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Changing Your Mind about Participation: 
 
Participation is voluntary; therefore, you may withdraw from the study at any point. Please 
indicate to one of the researchers that you no longer want to participate in this study. If you 
withdraw, we will ask why you wanted to withdraw, if you agree to provide the information. You 
do not have to provide us with this information. 
 
Confidentiality: 
 
Confidentiality will be ensured by each participant having an identification code known only by 
the primary researcher and his research assistants. This will include all data, including 
questionnaires and blood samples, to be identified by this code. This code will be kept on a paper 
copy in a locked filing cabinet only accessible by the researchers. The participant codes will be 
shredded once all data has been entered under anonymous code and feedback provided to 
participants. The coded participant specimens will be kept in a - 80°C freezer in a locked 
laboratory in the Department of Kinesiology.  Specimens are destroyed during the analytical 
procedures with any remaining specimens being destroyed at the completion of the study (March 
1st, 2016). 
 
Handling of Results and Participant Feedback: 
 
Anonymous data will be analyzed to determine the role of sex hormones on blood lipidomics.  The 
data will be used to make tables and/or graphs and presented in scientific articles and/or at 
scientific conferences.  After the completion of the study, you will be provided with a thank you 
letter.  Also, if you choose to receive your individual results, you will receive a feedback sheet that 
will include your omega-3 index level (amount of EPA+DHA in your blood) as well as sources of 
information on how to interpret the number in regards to your health.  In this study it is unlikely, 
but in looking at the fatty acid and lipidomic values of your blood, we may observe an unforeseen 
or incidental finding that was not the intention of the study.  If we observe such a finding, we will 
send you a letter asking if you want to receive this finding and outlining your options. 
 
Remuneration: 
 
Participants will be provided with $5 per visit to the lab as remuneration. This is to cover the time 
commitment of the participants. The amount received is taxable. It is your responsibility to report 
this amount for income tax purposes.  
 147 
 
 
Contact Information: 
 
If you have any questions, contact Professor Ken Stark at (519)–888–4567 ext. 37738, Kristin 
Marks at k2marks@uwaterloo.ca, or Chloe Kurtin at ckurtin@uwaterloo.ca. 
 
Concerns about Your Participation: 
I would like to assure you that this study has been reviewed and received ethics clearance through 
a University of Waterloo Ethics Committee. However, the final decision about participation is 
yours. If you have any comments or concerns resulting from your participation in this study, you 
may contact M. Nummelin, Chief Ethics Officer by calling (519) 888-4567 ext. 36005 or emailing 
maureen.nummelin@uwaterloo.ca. 
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Health Screening Form 
 
Present Health Problems 
Past Health Problems: 
 
Rheumatic Fever (  )  Epilepsy   (  ) 
Heart Murmur (  )  Varicose Veins  (  ) 
High Blood Pressure (  )  Disease of Arteries  (  ) 
High Cholesterol (  )  Emphysema, Pneumonia, 
Congenital Heart Disease (  )   Asthma, Bronchitis (  ) 
Heart Attack (  )  Back Injuries   (  ) 
Heart Operation (  )  Kidney and liver disease (  ) 
Diabetes (diet or insulin) (  )  Heartburn   (  ) 
Ulcers (  )  Bleeding disorders  (  ) 
Bleeding from Intestinal Tract (  )  Lipid Metabolism disorders (  ) 
Enteritis/colitis/diverticulitis    (  )  Other (describe overleaf) (  ) 
 
Age: ______________________________________________ 
 
Smoking: 
 
Never (   ) Ex-smoker (   )  Regular (   ) Amt/day:_______ 
 
List Current Health Problems: 
 
1.   
 
 
2.   
 
 
3.  
List medications taken in the last 6 months 
 
1.   
 
 
2.   
 
 
3.  
 149 
 
Alcohol Intake: 
 
A standard drink is:  
 -1  can/bottle of beer (355 ml/12 oz) 
 -1 glass of wine (150 ml/5 oz) 
 -1 shot of 40% hard liquor or spirits (44 ml/1.5 oz) 
 
 
 
 
How often do you have 10 or more standard drinks on 1 occasion? 
 (   ) Never 
 (   ) Less than Monthly 
 (   ) Monthly 
 (   ) Weekly 
 (   ) Daily or Almost Daily 
 
 
Dietary Supplements: 
Do you take vitamin-mineral or other supplements regularly? Yes (  ) No (  ) 
 
 If yes, please list:  
  
Type 
(eg: multivitamin) 
Brand  
(eg: Centrum) 
Frequency  
(eg: daily) 
Amount 
(eg: 1,  500mg 
capsule) 
    
    
    
    
    
 
 
Do you follow a vegetarian, vegan or restricted diet?   Yes (  ) No (  ) 
 If yes, please list all foods restricted from your diet (eg: fish): 
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Do you have any food allergies/intolerances?    Yes (  ) No (  ) 
 If yes, please list: 
 
 
 
 
 
 
 
 
Have you made any major changes to your diet over the past year?  Yes (  ) No (  ) 
 If yes, please list changes and when they took place: 
 
 
 
 
 
 
 
 
Have you lost or gained weight in the past year?   Yes (  ) No (  ) 
 If yes, please describe changes and when they took place: 
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Current Physical Activity Status: 
I consider my physical activity status to be: High (  ), Average (  ), Low (  ). 
List the physical activities that you do on a regular basis:   
Type (eg: jogging) Frequency (eg: 3x/week) Duration (eg:30 min) 
   
   
   
   
   
 
Signature of Participant:_________________________________ 
Witness:___________________________________________ 
Date:______________________________________________ 
------------------------------------------------------------------------------------------------------------ 
The current study has been identified as requiring medical clearance:    
Yes_____  No___X__ 
Menstrual Health Questionnaire  
1. At present, what best describes your menstrual cycle? 
 I have regular periods 
 I have irregular periods 
 My periods have stopped due to menopause, surgery, medications, or other reasons 
 Other: ____________________________________________________________________ 
 
2. What is the average length of your menstrual cycle? ____________ 
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3. What was the date of your last period? _______________________________________ 
 
4. Have you been pregnant in the last 6 months? 
 Yes 
 No 
 
5. Have you taken any form of hormonal birth control in the last 6 months? 
 Yes 
 No 
If you said yes to the above question, please indicate the type and brand of the birth control: 
_____________________________________________________ 
 
6. Have you ever been diagnosed with the following: 
 Addison’s disease 
 Polycystic Ovarian Syndrome 
 Amenorrhea  
 Turner’s Syndrome 
 Syndromes that cause pituitary to release to much prolactin (i.e. pituitary tumor) 
 Cancer 
 Other 
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CONSENT FORM 
I agree to take part in a research study being 
conducted by Professor Ken Stark and Chloe Kurtin and Kristin Marks of the Department of 
Kinesiology, University of Waterloo. 
I have made this decision based on the information I have read in the Information letter. All the 
procedures, any risks and benefits have been explained to me. I have had the opportunity to ask 
any questions and to receive any additional details I wanted about the study.  If I have questions 
later about the study, I can ask one of the researchers (Professor Ken Stark at his office (519) 888-
4567 ext. 37738 or Chloe Kurtin at extension 37873) or by emailing ckurtin@uwaterloo.ca. 
I understand that I may withdraw from the study at any time without penalty by telling the 
researcher.  
By signing this consent form the participant does not waive any legal rights that they would 
otherwise and that any offers of compensation in the event of injury will not limit recourse to other 
legal remedies. 
This project has been reviewed by, and received ethics clearance through a University of Waterloo 
ethics board at the University of Waterloo.  I am aware that I may contact this office (888-4567, 
ext. 36005) if I have any concerns or questions resulting from my involvement in this study. 
 
Printed Name:   
 
Local Address:   
 
Please indicate if you would like to receive your individual results: 
 
Yes:________     No:_________ 
 
Signature:   
 
_______________________________ ___________________________________ 
Dated at Waterloo, Ontario   Witnessed 
 
 
Participant Code (Office use): _________________ 
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Appendix 1.5. Food Frequency Questionnaire for Chapter 5 
 
    
   Laboratory of Nutritional and Nutraceutical Research 
    
Food Frequency Questionnaire 
 
INSTRUCTIONS:  Please answer the following background questions and subsequent 48 questions 
about your usual eating habits over the past 12 months.  
 
Date you answered this questionnaire: ______________________ 
 
Age:
(  ) Under 19 years (  ) 30-34 years (  ) 45-49 years (  ) 60-64 years 
(  ) 19-24 years (  ) 35-39 years (  ) 50-54 years (  ) 65 years and over 
(  ) 25-29 years (  ) 40-44 years (  ) 55-59 years 
  
Gender:  (  ) Male     (  ) Female 
 
Sociodemographic  
 
1.  What is your cultural/racial background? 
 
(  ) Caucasian 
(  ) Chinese 
(  ) South Asian (ex: East Indian, Pakistani, 
      Sri Lankan) 
(  ) African 
(  ) Filipino 
(  ) Latin American 
(  ) Southeast Asian (ex: Cambodian, 
Indonesian, Laotian, Vietnamese) 
(  ) Arab 
(  ) West Asian (ex: Afgan, Iranian) 
(  ) Japanese 
(  ) Korean 
(  ) Aboriginal  
(  ) Other: __________________________  
 
 
 
 
 
 
 
Participant Code (Office Use): _________ 
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2. What is the highest level of education you 
have attained? 
 
(  ) Some High School 
(  ) High School Diploma 
(  ) Diploma/Certificate from trade, technical or 
vocational school or business college 
(  ) Diploma/Certificate from community 
college, CEGEP or nursing school 
(  ) Bachelor’s undergraduate degree or 
teacher’s college 
(  ) Master’s degree 
(  ) Degree in Medicine, Dentistry, Veterinary 
Medicine, Optometry or Law 
(  ) Earned doctorate (ex: Ph.D.) 
(  ) Other: __________________________ 
 
3.  What is your annual household income? 
 
(  ) less than $25,000 
(  ) $25,000 - $49,999 
(  ) $50,000 - $74,999 
(  ) $75,000 - $99,999 
(  ) more than $100,000
 
Diet 
 
4.  What type of milk do you usually use? 
 
(  ) I do not drink milk 
(  ) Regular cow’s milk (non-omega-3) 
(  ) Regular soy milk (non-omega-3) 
(  ) Nielson, Dairy Oh! 1% or 2% milk 
 
 
 
(  ) Nielson, Dairy Oh! Homogenized milk 
(  ) Silk Plus, Omega-3 DHA soy milk 
(  ) So Good, Omega-3 DHA soy milk 
(  ) Other Omega-3 enriched milk 
Please specify Brand:       
_____________________________ 
 
5. How much omega-3 milk do you usually 
use per day (including milk added to tea, 
coffee, cereal, etc.)?  
 
(  ) None 
(  ) 1 tablespoon 
(  ) 2 tablespoons 
(  ) ¼ cup (62.5 mL) 
(  ) ½ cup (125 mL) 
(  ) 1-2 cups (250-500 mL) 
(  ) 2-3 cups (500-750 mL) 
(  ) 3 cups (750 mL) or more 
 
6. What kinds of margarine/spread do you 
usually use? (ex: On bread, vegetables, in 
cooking and baking, etc.) 
 
(  ) I don’t use any margarine/spread 
(  ) Regular margarine (non-omega-3) 
(  ) Becel, Omega-3 Plus Margarine 
(  ) Other Omega-3 enriched margarine 
Please specify brand:   
______________________________ 
 
7. How much omega-3 margarine/spread 
do you usually use per day?  
 
(  ) None 
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(  ) 1-2 teaspoons 
(  ) 1 tablespoon 
(  ) 2 tablespoons 
(  ) 3 tablespoons 
(  ) 4 tablespoons 
(  ) 5-7 tablespoons 
(  ) 8 or more tablespoons 
 
8. What kinds of eggs do you usually eat 
(include eggs in baked goods/cooking)? 
 
(  ) Naturegg Breakfree omega-3 liquid 
eggs 
(  ) Naturegg Omega-3 eggs (in shell) 
(  ) Naturegg Omega-3 Pro eggs (in shell) 
(  ) Complements Omega-3 eggs  
(  ) President’s Choice Omega-3 eggs 
(  ) Gray Ridge Omega-3 large eggs 
(  ) Gray Ridge Omega-3 extra-large eggs 
(  ) Regular Chicken eggs 
(  ) Duck eggs 
(  ) Other Omega-3 enriched eggs 
Please specify brand:  
_______________________________ 
 
 
9. On average, how many eggs do you 
usually eat per week (including eggs in 
baked goods/cooking)?   
 
(  ) I don’t eat eggs 
(  ) Less than 1 egg   
(  ) 1 to 2 eggs            
(  ) 3 to 5 eggs           
(  ) 6 or more eggs  
 
10. What kind of juice do you usually drink? 
 
(  ) I don’t drink juice 
(  ) Regular juice (non-omega-3) 
(  ) Tropicana Essentials, Omega-3 orange 
juice 
(  ) Minute Maid Fruit Solutions, Omega-3 
mango, orange & passion juice 
(  ) President’s Choice, Oh Mega J orange 
juice 
(  ) Other Omega-3 enriched juice 
Please specify brand:  
___________________________ 
  
11. How much omega-3 juice do you 
usually drink per day?  
 
(  ) None 
(  ) less than one cup (<250 mL) 
(  ) 1 cup (250 mL) 
(  ) 1-2 cups (250-500 mL) 
(  ) 2-3 cups (500-750 mL) 
(  ) 3 cups (750 mL) or more 
 
12. What kind of yogurt do you usually eat? 
 
(  ) I don’t eat yogurt 
(  ) Regular yogurt (non-omega-3) 
(  ) Danone Danino yogurt 
(  ) Danone Danino Go yogurt drink  
 157 
 
(  ) Other Omega-3 enriched yogurt 
Please specify brand:         
_____________________________ 
 
13. How much omega-3 yogurt do you 
usually eat per week?   
 
(  ) none 
(  ) less than 1, 100 g pot 
(  ) 1, 100 g pot 
(  ) 2 to 3, 100 g pots 
(  ) 4 to 5, 100 g pots 
(  ) 6 to 7, 100 g pots 
(  ) 8 or more 100 g pots 
14. What kind of bread do you usually eat? 
 
(  ) I don’t eat bread 
(  ) Regular bread (non-omega-3) 
(  ) Wonder+ Omega-3 bread with DHA 
(  ) Other Omega-3 enriched bread 
Please specify brand/type:  
 
 
15. How much omega-3 bread do you 
usually eat per day (fresh and toasted)? 
 
(  ) none 
(  ) less than 1 piece 
(  ) 1 piece 
(  ) 2 pieces 
(  ) 3 pieces 
(  ) 4 pieces 
(  ) 5-7 pieces 
(  ) 8 or more pieces 
 
16. What kind of cheese do you usually 
eat?  
 
(  ) I don’t eat cheese 
(  ) Regular cheese (non-omega-3) 
(  ) Black Diamond, Smart Growth Cheese 
Strings with DHA 
(  ) Other omega-3 enriched cheese 
Please specify brand:  
 _______________________________ 
 
17. How much omega-3 cheese do you 
usually eat per week? 
 
(  ) None 
(  ) less than 1oz (~1 cheese string) 
(  ) 1 oz (~1 cheese string) 
(  ) 2-3 oz (2-3 cheese strings) 
(  ) 4-5 oz (4-5 cheese strings) 
(  ) 6-7 oz (6-7 cheese strings) 
(  ) 8 or more oz (8+ cheese strings) 
 
18.  What kind of nut butter (ex: peanut) do 
you usually eat? 
 
(  ) I don’t eat nut butter 
(  ) Regular nut butter (non-omega-3) 
(  ) Life Brand, Omega-3 Peanut Butter 
(  ) Other omega-3 enriched nut butter 
 Please specify brand:  
_______________________________ 
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19.  How much omega-3 nut butter do you 
eat per week? 
 
(  ) None 
(  ) less than 1 tablespoon (tbsp) 
(  ) 1 tbsp 
(  ) 2-3 tbsp 
(  ) 4-5 tbsp 
(  ) 6-7 tbsp 
(  ) 8 or more tbsp 
 
20.  On average, how often do you eat fish 
paste? (ex: Surimi, often in Asian dishes) 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Specify the type of fish paste, brand and 
amount usually eaten (number of 
teaspoons) 
Type of fish paste Brand  #tsp 
__________________________________ 
 
21.  On average, how often do you eat 
seaweed? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of seaweed (or 
dish containing seaweed) and amount 
eaten on a typical occasion 
Type of seaweed/Dish  Amount 
 
 
 
 
 
 
 
 
 
22.  On average, how often do you eat 
seafood-containing sauce? (ex: fish sauce 
oyster sauce, etc (often in Asian dishes))? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
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Please specify the type of seafood sauce, 
brand and amount usually eaten (# tsp) 
Type of sauce           Brand  #tsp 
_________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
23. On average, how often do you eat fish-
based broth (ex: fish broth-based soup)? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the brand (or ‘homemade’) 
and amount of fish broth usually eaten  
Brand    Amount 
_________________________________ 
 
24.  How many fish oil supplements 
(ex:capsules) do you usually take per day  
 
(  ) None 
(  ) Number: _____ 
 
Please Specify brand and name of fish oil 
capsules: (ex: Jamieson, omega-3 
Complete) 
Brand   Product Name 
__________________________________ 
__________________________________
25.  When you eat meat or poultry, what size serving do you usually eat? 
 
 
A: Deck of cards sized 
portion = 3oz / 90g 
B: 5oz / 150g C: 7oz / 200g 
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(  ) Less than A  (  ) B    (  ) C 
(  ) A    (  ) Between B and C  (  ) More than C 
(  ) Between A and B 
 
 
26. On average, how often do you eat 
chicken or turkey?  
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the types of chicken/turkey 
eaten most frequently and whether the 
skin is eaten (ex: Turkey thigh, with skin) 
__________________________________ 
__________________________________ 
 
27. On average, how often do you eat duck 
or goose? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of duck/goose 
eaten most frequently and whether the 
skin in eaten. (ex: Duck breast, without 
skin) 
 
 
28. How often do you usually eat beef? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of beef most often 
eaten (ex: Rump steak): 
__________________________________ 
 
 
29. On average, how often do you eat 
lamb? 
 
(  ) Never 
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(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
 
 
Please specify the type of lamb most often 
eaten (ex: Loin chop): 
 
 
30. On average, how often do you eat 
veal? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of veal most often 
eaten (ex: Veal steak): 
 
 
31. On average, how often do you eat 
pork? (do not include ham or bacon) 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type of pork most often 
eaten (ex: Pork chop): 
 
 
32. On average, how often do you eat 
bacon?  
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the number of slices of 
bacon usually eaten on each occasion: 
 
 
 
33. On average, how often do you eat ham 
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(not deli/sandwich meat)? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the number of slices of 
ham usually eaten on each occasion: 
 
 
34. On average, how often do you usually 
eat sliced deli meat (ex: luncheon meats or 
salami)? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type (ex: lean turkey 
breast), brand and the number of slices 
of sliced deli meat most often eaten: 
Type  Brand  # slices 
 
__________________________________ 
 
35. On average, how often do you eat 
sausages? 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type (ex: Beef, pork, 
turkey) and number of sausages usually 
eaten on each occasion: 
Type    Number 
 
36. On average, how often do you eat 
canned fish? (ex: canned tuna, salmon, 
sardines, etc.) 
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify up to 4 types of canned fish 
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that you regularly eat, including the brand 
and the amount typically eaten. (ex: White 
tuna in water, Goldseal, ½ 120g tin) 
 
Type of Fish       Brand           Amount 
 
__________________________________
__________________________________
__________________________________ 
 
37. On average, how often do you eat fresh 
or frozen fish? (Include fish meals at home, 
at a restaurant and take out).  
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify up to 4 types of fresh or 
frozen fish that you regularly eat and the 
amount typically eaten  
 
(Include the brand for frozen fish. If type of 
fish is unknown for restaurant fish please 
write ‘restaurant fish’).  
(ex: Wild Atlantic Salmon, Highliner, 150g) 
 
Type of Fish       Brand              Amount 
 
__________________________________
__________________________________
__________________________________ 
 
 
 
38. How often do you eat fresh, frozen or 
canned shellfish? (ex: shrimp, oysters, 
scallops, crab, calamari, lobster, etc).  
 
(  ) Never 
(  ) less than once per month 
(  ) 1 to 3 times a month 
(  ) once per week 
(  ) 2 to 3 times per week 
(  ) 4 to 6 times per week 
(  ) once per day 
(  ) 2 or more times per day 
 
Please specify the type and amount of 
shellfish eaten on a typical occasion: 
Type of Shellfish  Amount 
 
__________________________________
__________________________________ 
 
39. Are there any other meat, poultry or 
fish products that you eat regularly?  
 
Please specify the type, amount and how 
often other meat or fish products are eaten 
 
Type  Amount How often  
__________________________________ 
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__________________________________ 
__________________________________ 
 
 
 
Food Preparation 
 
40. On average, how many meals prepared 
outside of your home do you eat? Include 
restaurant, fast food, take out and cafeteria 
meals.  
 
(  ) None 
(  ) 1 or 2 a month 
(  ) 1 per week 
(  ) 2 per week 
(  ) 3 to 4 per week 
(  ) 5 to 6 per week 
(  ) 1 per day 
(  ) 2 per day 
(  ) 3 per day 
 
 
 
 
 
41. On average, how often do you eat pre-
prepared / heat-and-serve meals? 
 
(  ) Never 
(  ) once or twice a month 
(  ) once a week 
(  ) twice a week 
(  ) 3 to 4 times per week 
(  ) 5 to 6 times per week 
(  ) once a day 
(  ) twice a day 
(  ) three times a day 
 
42.  On average, how often do you eat 
home-prepared meals? 
 
(  ) Never 
(  ) once or twice a month 
(  ) once a week 
(  ) twice a week 
(  ) 3 to 4 times per week 
(  ) 5 to 6 times per week 
(  ) once a day 
(  ) twice a day 
(  ) three times a day 
 
43. Who usually prepares meals in your 
home? 
 
(  ) Myself 
(  ) Shared 
(  ) Spouse/Partner 
(  ) Other:______________________ 
 
44. Who usually purchases food? 
 
(  ) Myself 
(  ) Spouse/Partner 
(  ) Shared 
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(  ) Other:______________________ 
 
45.  On average, how much money do you 
spend on groceries per person in your 
household per week? 
 
(  ) less than $15 
(  ) $15-$25 
(  ) $25-$35 
(  ) $35-$50 
(  ) $50-$75 
(  ) more than $75 
 
 
 
46. On average, how much time do you 
spend preparing all meals for your 
household per day 
 
(  ) less than 15 minutes 
 
(  ) 15 to 30 minutes 
(  ) 30 to 35 minutes 
(  ) 45 minutes to 1 hour 
(  ) 1 hour to 1 ½ hours 
(  ) more than 1 ½ hours 
 
47.  How frequently is the food in your home is purchased from the following sources?
  
Full-service supermarket (ex: Zehrs, 
Sobeys): 
 
(  ) Never 
(  ) less than once a month 
(  ) once a month 
(  ) 2 to 3 times a month 
(  ) weekly 
(  ) more than once a week  
List full-service supermarkets: 
__________________________________
__________________________________ 
 
Discount grocery store (ex: Food Basics, 
Price Chopper, No Frills): 
 
(  ) Never 
(  ) less than once a month 
(  ) once a month 
(  ) 2 to 3 times a month 
(  ) weekly 
(  ) more than once a week 
List discount grocery stores: 
__________________________________
__________________________________ 
 
Farmer’s Market: 
 
(  ) Never 
(  ) less than once a month 
(  ) once a month 
(  ) 2 to 3 times a month 
(  ) weekly 
(  ) more than once a week 
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List types of vendors (ex: fruit, fish): 
__________________________________
__________________________________ 
 
 
 
 
 
 
 
 
Gourmet stores (including specialty delis 
and bakeries): 
 
(  ) Never 
(  ) less than once a month 
(  ) once a month 
(  ) 2 to 3 times a month 
(  ) weekly 
(  ) more than once a week 
List gourmet stores: 
__________________________________
__________________________________ 
 
Natural health food stores: 
 
(  ) Never 
(  ) less than once a month 
(  ) once a month 
(  ) 2 to 3 times a month 
(  ) weekly 
(  ) more than once a week 
List natural health food stores: 
__________________________________
__________________________________ 
 
 
Specialty ethnic grocery stores: 
 
(  ) Never 
(  ) less than once a month 
(  ) once a month 
(  ) 2 to 3 times a month 
(  ) weekly 
(  ) more than once a week 
List ethnic grocery stores: 
__________________________________
__________________________________ 
 
 
 
 
 
 
 
 
Take out: 
 
(  ) Never 
(  ) less than once a month 
(  ) once a month 
(  ) 2 to 3 times a month 
(  ) weekly 
(  ) more than once a week 
List frequent take out suppliers: 
__________________________________
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__________________________________ 
__________________________________ 
 
Other Locations: 
 
(  ) Never 
(  ) less than once a month 
(  ) once a month 
(  ) 2 to 3 times a month 
(  ) weekly 
(  ) more than once a week 
List stores: 
__________________________________
________________________________ 
________________________________
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48.  Have you changed your diet in any significant way over the past year?  
  
(  ) Yes 
 (  ) No 
 
If yes, please specify the changes:  
________________________________________________________________________________
________________________________________________________________________________
_______________________________________________________________________ 
 
 
 
Thank you for completing this survey 
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Table A1.1 Plasma fatty acid concentrations in men and women who take or do not take oral contraceptives. 
Plasma Fatty Acids 
µg fatty acid/100 µl plasma 
Name Men 
Women taking oral 
contraceptives Women with natural cycles 
C 10:0 0.04 ± 0.02 0.08 ± 0.07 0.07 ± 0.06 
C 12:0 0.40 ± 0.21 0.40 ± 0.17 0.47 ± 0.25 
C 14:0 3.15 ± 1.14 3.72 ± 1.47 2.94 ± 0.76 
C 16:0 75.36 ± 13.38 92.64 ± 28.56 77.73 ± 15.10 
C 18:0 23.34 ± 4.45 23.06 ± 4.51 23.83 ± 2.78 
C 20:0 0.57 ± 0.09 0.65 ± 0.11 0.65 ± 0.11 
C 22:0 1.31 ± 0.30 1.47 ± 0.22 1.45 ± 0.21 
C 24:0 1.20 ± 0.25 1.28 ± 0.20 1.20 ± 0.19 
SFAs 106.20 ± 18.88 123.90 ± 33.30 108.82 ± 17.26 
C 12:1 0.04 ± 0.03 0.02 ± 0.01 0.03 ± 0.01 
C 14:1 0.13 ± 0.09a 0.23 ± 0.12b 0.21 ± 0.09ab 
C 16:1n-7 4.62 ± 1.93a 7.53 ± 3.58b 4.76 ± 1.17a 
C 18:1n-7 5.61 ± 1.15 6.47 ± 1.32 5.58 ± 1.06 
C 18:1n-9 62.20 ± 14.26 65.90 ± 15.52 64.61 ± 10.46 
C 20:1n-9 0.46 ± 0.11a 0.60 ± 0.17b 0.48 ± 0.10a 
C 22:1n-9 0.21 ± 0.07a 0.42 ± 0.12b 0.38 ± 0.08b 
C 24:1n-9 1.80 ± 0.39a 2.34 ± 0.46b 2.05 ± 0.41ab 
MUFAs 75.04 ± 16.82 83.51 ± 19.61 78.09 ± 12.12 
C 18:2n-6 96.39 ± 15.80 100.64 ± 21.62 99.50 ± 16.91 
C 18:3n-6 1.17 ± 0.46 1.09 ± 0.42 1.17 ± 0.40 
C 20:2n-6 0.54 ± 0.16a 0.71 ± 0.23b 0.50 ± 0.18a 
C 20:3n-6 4.12 ± 1.52a 5.69 ± 1.40b 4.17 ± 1.17a 
C 20:4n-6 22.79 ± 4.01 24.01 ± 6.96 21.95 ± 4.25 
C 22:2n-6 0.07 ± 0.05 0.09 ± 0.03 0.07 ± 0.03 
C 22:4n-6 0.57 ± 0.16 0.66 ± 0.20 0.54 ± 0.15 
C 22:5n-6 0.40 ± 0.16 0.47 ± 0.19 0.46 ± 0.15 
N-6 125.92 ± 19.80 133.23 ± 27.50 128.18 ± 19.12 
C 18:3n-3 2.06 ± 0.71 2.47 ± 1.02 2.20 ± 0.68 
C 20:3n-3 0.12 ± 0.04ab 0.15 ± 0.04a 0.09 ± 0.04b 
C 20:5n-3 1.64 ± 0.63 1.83 ± 0.54 1.73 ± 0.55 
C 22:5n-3 1.41 ± 0.38 1.14 ± 0.29 1.32 ± 0.26 
C 22:6n-3 3.90 ± 0.91a 5.59 ± 1.62b 4.52 ± 1.38ab 
N-3 9.14 ± 1.80a 11.18 ± 2.77b 9.86 ± 2.13ab 
EPA+DHA 5.54 ± 1.21a 7.42 ± 1.95b 6.26 ± 1.62ab 
Total 316.58 ± 52.96 352.03 ± 76.52 325.13 ± 46.81 
Values are means ± SD. Means with different letters are significantly different by Tukey’s post-hoc test, following a 
significant F-value for one way ANOVA. 
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Table A1.2 Concentration of fatty acids in erythrocytes of men and women taking or not taking oral contraceptives. 
Erythrocyte Fatty Acids 
µg fatty acid/200 mg erythrocytes 
Name Men 
Women taking oral 
contraceptives Women with natural cycles 
C 12:0 0.33 ± 0.07 0.46 ± 0.18 0.39 ± 0.18 
C 14:0 6.85 ± 0.94 6.81 ± 2.04 5.96 ± 1.62 
C 16:0 130.54 ± 10.16 134.52 ± 16.96 123.53 ± 13.37 
C 18:0 85.21 ± 8.94 79.38 ± 9.10 81.94 ± 9.38 
C 20:0 1.86 ± 0.22 1.83 ± 0.37 1.89 ± 0.22 
C 22:0 7.56 ± 0.92a 6.42 ± 1.30b 7.29 ± 1.29ab 
C 23:0 0.36 ± 0.29 0.41 ± 0.15 0.55 ± 0.39 
C 24:0 23.97 ± 3.72a 18.78 ± 3.71b 21.62 ± 4.19ab 
SFAs 255.26 ± 20.86 248.68 ± 29.01 243.26 ± 27.88 
C 12:1 0.16 ± 0.06 0.31 ± 0.35 0.28 ± 0.30 
C 14:1 2.61 ± 0.46 2.36 ± 1.01 1.99 ± 0.74 
C 16:1n-7 1.39 ± 0.23a 1.92 ± 0.58b 1.33 ± 0.26a 
C 18:1n-7 7.51 ± 0.66 7.31 ± 1.09 6.70 ± 0.92 
C 18:1n-9 73.40 ± 5.49a 67.61 ± 8.84ab 65.55 ± 9.92b 
C 20:1n-9 1.40 ± 0.18 1.29 ± 0.27 1.23 ± 0.27 
C 22:1n-9 0.76 ± 0.12ab 0.69 ± 0.12a 0.86 ± 0.19b 
C 24:1n-9 21.86 ± 2.91 20.63 ± 4.16 20.93 ± 3.80 
MUFAs 109.09 ± 7.39 102.12 ± 14.01 98.86 ± 13.92 
C 18:2n-6 60.31 ± 8.46 55.54 ± 9.10 52.85 ± 6.56 
C 18:3n-6 0.27 ± 0.08 0.28 ± 0.17 0.33 ± 0.12 
C 20:2n-6 1.58 ± 0.24 1.49 ± 0.36 1.29 ± 0.38 
C 20:3n-6 8.61 ± 1.68 8.69 ± 2.11 7.23 ± 2.44 
C 20:4n-6 85.35 ± 4.96 77.69 ± 12.40 76.70 ± 10.89 
C 22:2n-6 0.40 ± 0.20 0.39 ± 0.18 0.40 ± 0.18 
C 22:4n-6 18.39 ± 3.10 18.07 ± 4.79 15.77 ± 4.14 
C 22:5n-6 3.26 ± 0.67 2.71 ± 1.69 2.81 ± 0.60 
N-6 178.18 ± 14.36a 164.84 ± 25.76ab 157.00 ± 22.38b 
C 18:3n-3 0.90 ± 0.21 0.89 ± 0.36 0.84 ± 0.23 
C 20:3n-3 0.22 ± 0.17 0.23 ± 0.09 0.25 ± 0.17 
C 20:5n-3 3.07 ± 0.84 2.75 ± 0.72 2.63 ± 0.64 
C 22:5n-3 13.49 ± 2.13a 10.49 ± 1.76b 11.05 ± 2.20b 
C 22:6n-3 20.89 ± 4.85 24.92 ± 6.65 21.02 ± 4.65 
N-3 38.57 ± 4.81 39.28 ± 8.03 35.80 ± 6.29 
EPA+DHA 23.96 ± 5.32 27.67 ± 6.94 23.65 ± 5.07 
Total 581.11 ± 39.26 554.47 ± 72.11 534.93 ± 63.84 
Values are means ± SD. Means with different letters are significantly different by Tukey’s post-hoc test, following a 
significant F-value for one way ANOVA. 
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Table A1.3 Proportion of fatty acids in erythrocytes of men and women taking or not taking oral contraceptives. 
Erythrocyte Fatty Acids 
% weight total fatty acids 
Name Men 
Women taking oral 
contraceptives Women with natural cycles 
C 12:0 0.05 ± 0.01a 0.08 ± 0.03b 0.07 ± 0.03ab 
C 14:0 1.14 ± 0.16 1.17 ± 0.29 1.07 ± 0.26 
C 16:0 21.86 ± 0.72a 23.35 ± 1.21b 22.23 ± 0.88a 
C 18:0 14.31 ± 1.03ab 13.77 ± 0.69a 14.74 ± 0.72b 
C 20:0 0.31 ± 0.04 0.32 ± 0.06 0.34 ± 0.03 
C 22:0 1.26 ± 0.16ab 1.12 ± 0.21a 1.31 ± 0.19b 
C 23:0 0.06 ± 0.04 0.07 ± 0.03 0.10 ± 0.07 
C 24:0 3.93 ± 0.55a 3.25 ± 0.49b 3.88 ± 0.62a 
SFAs 42.70 ± 0.96 43.15 ± 1.24 43.76 ± 1.92 
C 12:1 0.03 ± 0.01 0.06 ± 0.07 0.05 ± 0.07 
C 14:1 0.43 ± 0.08 0.40 ± 0.16 0.36 ± 0.13 
C 16:1n-7 0.24 ± 0.05a 0.34 ± 0.10b 0.24 ± 0.04a 
C 18:1n-7 1.25 ± 0.08 1.27 ± 0.13 1.21 ± 0.12 
C 18:1n-9 12.27 ± 0.56 11.75 ± 1.03 11.77 ± 1.10 
C 20:1n-9 0.23 ± 0.03 0.22 ± 0.04 0.22 ± 0.04 
C 22:1n-9 0.13 ± 0.02a 0.12 ± 0.02a 0.15 ± 0.03b 
C 24:1n-9 3.61 ± 0.48 3.57 ± 0.56 3.77 ± 0.53 
MUFAs 18.18 ± 0.80 17.74 ± 1.54 17.77 ± 1.47 
C 18:2n-6 9.93 ± 0.91 9.64 ± 1.17 9.52 ± 0.70 
C 18:3n-6 0.05 ± 0.01 0.05 ± 0.04 0.06 ± 0.03 
C 20:2n-6 0.26 ± 0.04 0.26 ± 0.05 0.23 ± 0.07 
C 20:3n-6 1.47 ± 0.30 1.51 ± 0.34 1.30 ± 0.43 
C 20:4n-6 14.33 ± 0.64 13.46 ± 1.25 13.79 ± 1.20 
C 22:2n-6 0.07 ± 0.03 0.07 ± 0.03 0.07 ± 0.03 
C 22:4n-6 3.05 ± 0.48 3.12 ± 0.68 2.83 ± 0.65 
C 22:5n-6 0.54 ± 0.11 0.45 ± 0.27 0.45 ± 0.16 
N-6 29.69 ± 1.10 28.56 ± 2.63 28.34 ± 2.53 
C 18:3n-3 0.15 ± 0.03 0.15 ± 0.05 0.15 ± 0.03 
C 20:3n-3 0.04 ± 0.03 0.04 ± 0.01 0.04 ± 0.03 
C 20:5n-3 0.52 ± 0.14 0.48 ± 0.12 0.48 ± 0.09 
C 22:5n-3 2.24 ± 0.37a 1.83 ± 0.27b 2.05 ± 0.24ab 
C 22:6n-3 3.53 ± 0.84 4.30 ± 0.93 3.78 ± 0.79 
N-3 6.47 ± 0.89 6.80 ± 1.04 6.51 ± 0.92 
EPA+DHA 4.04 ± 0.93 4.78 ± 0.97 4.26 ± 0.85 
Values are means ± SD. Means with different letters are significantly different by Tukey’s post-hoc test, following a 
significant F-value for one way ANOVA.  
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Table A1.4 Plasma fatty acid content in women taking and not taking oral contraceptives during the follicular and 
luteal phase of the menstrual cycle 
Plasma Fatty acids 
µg fatty acid/100 µl plasma 
 Women taking oral contraceptives Women with natural cycles 
Name 
Day 6-8  
(no hormone phase) 
Day 21-23 
(active hormone phase) 
Day 6-8  
(follicular phase) 
Day 21-23 
(luteal phase) 
C 16:01 97.80 ± 31.22 87.48 ± 27.46 81.36 ± 16.04 74.11 ± 17.73 
C 18:01 24.30 ± 5.81 21.83 ± 3.98 24.64 ± 3.30 23.02 ± 3.32 
C 20:0 0.65 ± 0.14 0.66 ± 0.10 0.65 ± 0.11 0.65 ± 0.13 
C 22:0 1.47 ± 0.19 1.47 ± 0.29 1.43 ± 0.22 1.48 ± 0.25 
C 24:0 1.24 ± 0.18 1.32 ± 0.24 1.18 ± 0.21 1.22 ± 0.22 
SFAs1 130.76 ± 37.86 117.04 ± 30.96 113.64 ± 18.92 104.01 ± 20.54 
C 16:1n-71,2 8.25 ± 3.31 6.81 ± 4.05 5.40 ± 1.65 4.12 ± 1.17 
C 18:1n-7 6.37 ± 1.44 6.57 ± 1.48 5.70 ± 1.04 5.46 ± 1.30 
C 18:1n-9 67.38 ± 16.42 64.42 ± 16.79 66.39 ± 11.52 62.83 ± 12.42 
C 20:1n-91,2 0.50 ± 0.16a 0.71 ± 0.21b 0.46 ± 0.10a 0.50 ± 0.13a 
C 22:1n-91 0.36 ± 0.14a 0.48 ± 0.13b 0.37 ± 0.10a 0.39 ± 0.07a 
C 24:1n-9 2.27 ± 0.51 2.40 ± 0.47 2.05 ± 0.43 2.05 ± 0.45 
MUFAs 85.42 ± 20.20 81.60 ± 21.55 80.59 ± 13.48 75.58 ± 14.54 
C 18:2n-6 102.29 ± 24.41 98.99 ± 20.76 101.30 ± 16.67 97.69 ± 19.57 
C 18:3n-61 1.28 ± 0.54 0.90 ± 0.37 1.33 ± 0.57 1.01 ± 0.32 
C 20:2n-61,2 0.62 ± 0.18 0.81 ± 0.31 0.50 ± 0.19 0.50 ± 0.18 
C 20:3n-61 5.56 ± 1.51 5.82 ± 1.48 4.44 ± 1.38 3.91 ± 1.08 
C 20:4n-6 24.49 ± 7.86 23.53 ± 6.58 22.09 ± 4.54 21.81 ± 4.68 
C 22:2n-6 0.10 ± 0.05 0.08 ± 0.03 0.09 ± 0.05 0.06 ± 0.03 
C 22:4n-6 0.63 ± 0.19 0.69 ± 0.24 0.56 ± 0.17 0.52 ± 0.17 
C 22:5n-6 0.40 ± 0.12 0.53 ± 0.27 0.51 ± 0.14 0.46 ± 0.14 
N-6 135.26 ± 31.46 131.21 ± 25.83 130.61 ± 19.39 125.74 ± 22.29 
C 18:3n-3 2.41 ± 1.08 2.52 ± 1.09 2.19 ± 0.63 2.21 ± 0.90 
C 20:3n-32 0.13 ± 0.05 0.16 ± 0.05 0.09 ± 0.05 0.09 ± 0.05 
C 20:5n-3 2.02 ± 0.64 1.64 ± 0.67 1.68 ± 0.49 1.79 ± 0.85 
C 22:5n-3 1.20 ± 0.32 1.08 ± 0.31 1.39 ± 0.35 1.24 ± 0.30 
C 22:6n-3 5.41 ± 1.53 5.78 ± 1.85b 4.49 ± 1.22 4.56 ± 1.71 
N-3 11.18 ± 2.58 11.18 ± 3.22 9.83 ± 1.61 9.89 ± 3.20 
EPA+DHA 7.43 ± 1.83 7.42 ± 2.32 6.17 ± 1.23 6.34 ± 2.29 
N-6/N-3 12.33 ± 2.11 12.17 ± 2.19 13.37 ± 1.35 13.30 ± 2.45 
Total1 362.81 ± 83.68 341.24 ± 75.64 334.87 ± 48.69 315.39 ± 57.37 
Values are mean ± sd. Means with different letters are significantly different by Tukey’s post-hoc test, following a 
significant F-value for birth control status x time by the linear mixed models procedure. 
1 significant main effect of time 
2 significant main effect of birth control status 
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Table A1.5 Erythrocyte fatty acid content in women taking and not taking oral contraceptives during the follicular 
and luteal phase of the menstrual cycle 
Erythrocyte Fatty Acids 
µg fatty acid/200 mg cells 
 Women taking oral contraceptives Women with natural cycles 
Name 
Day 6-8  
(no hormone phase) 
Day 21-23 
(active hormone 
phase) 
Day 6-8  
(follicular phase) 
Day 21-23 
(luteal phase) 
C 14:0 6.54 ± 2.33 7.07 ± 2.16 5.94 ± 1.61 5.98 ± 1.76 
C 16:0 130.18 ± 18.61 138.87 ± 19.60 122.07 ± 11.10 125.00 ± 20.35 
C 18:0 77.68 ± 11.86 81.07 ± 13.05 80.03 ± 9.69 83.85 ± 14.42 
C 20:0 1.73 ± 0.33 1.93 ± 0.47 1.88 ± 0.20 1.89 ± 0.33 
C 22:0 6.12 ± 1.27 6.72 ± 1.51 7.30 ± 1.00 7.29 ± 1.71 
C 23:0 0.38 ± 0.15 0.44 ± 0.19 0.52 ± 0.42 0.62 ± 0.46 
C 24:0 17.96 ± 3.25 19.61 ± 4.62 21.50 ± 3.54 21.74 ± 5.24 
SFAs 241.18 ± 32.44 256.19 ± 36.42 239.77 ± 22.76 246.74 ± 41.72 
C 16:1n-72 1.99 ± 0.63 1.85 ± 0.59 1.36 ± 0.28 1.29 ± 0.28 
C 18:1n-7 7.31 ± 1.44 7.32 ± 1.02 6.71 ± 0.99 6.69 ± 1.06 
C 18:1n-9 67.24 ± 9.51 67.99 ± 10.76 65.02 ± 8.55 66.07 ± 12.79 
C 20:1n-9 1.27 ± 0.29 1.31 ± 0.29 1.21 ± 0.27 1.25 ± 0.30 
C 22:1n-92 0.68 ± 0.16 0.69 ± 0.14 0.82 ± 0.18 0.89 ± 0.27 
C 24:1n-9 19.62 ± 3.79 21.64 ± 4.93 21.02 ± 3.58 20.84 ± 4.67 
MUFAs 100.60 ± 14.42 103.64 ± 16.37 98.40 ± 12.38 99.32 ± 17.62 
C 18:2n-6 54.28 ± 10.00 56.80 ± 9.46 51.99 ± 5.62 53.71 ± 9.27 
C 18:3n-6 0.31 ± 0.19 0.28 ± 0.14 0.33 ± 0.11 0.33 ± 0.15 
C 20:2n-6 1.48 ± 0.37 1.50 ± 0.36 1.22 ± 0.32 1.36 ± 0.58 
C 20:3n-6 8.62 ± 2.47 8.75 ± 1.95 7.19 ± 2.34 7.27 ± 2.65 
C 20:4n-6 77.05 ± 14.69 78.33 ± 12.17 75.75 ± 10.12 77.64 ± 14.44 
C 22:2n-6 0.34 ± 0.10 0.44 ± 0.29 0.36 ± 0.11 0.45 ± 0.30 
C 22:4n-6 18.06 ± 5.32 18.08 ± 4.45 15.52 ± 3.43 16.02 ± 5.11 
C 22:5n-6 3.31 ± 1.02 3.30 ± 1.31 2.76 ± 0.65 2.86 ± 0.62 
N-6 162.81 ± 30.21 166.87 ± 25.18 154.74 ± 18.58 159.25 ± 30.44 
C 18:3n-3 0.90 ± 0.32 0.95 ± 0.40 0.79 ± 0.19 0.89 ± 0.34 
C 20:3n-3 0.21 ± 0.10 0.25 ± 0.14 0.22 ± 0.18 0.28 ± 0.21 
C 20:5n-3 2.80 ± 0.81 2.69 ± 0.70 2.64 ± 0.58 2.63 ± 0.84 
C 22:5n-3 10.57 ± 2.07 10.42 ± 1.79 11.07 ± 1.93 11.04 ± 2.63 
C 22:6n-3 24.93 ± 7.39 24.92 ± 6.49 21.00 ± 5.19 21.04 ± 4.73 
N-3 39.33 ± 9.13 39.23 ± 8.01 35.73 ± 6.48 35.87 ± 7.24 
EPA+DHA 27.73 ± 7.73 27.61 ± 6.82 23.65 ± 5.49 23.66 ± 5.37 
N-6/N-31 4.24 ± 0.85 4.37 ± 0.91 4.45 ± 0.86 4.54 ± 0.90 
Total 542.91 ± 83.68 566.02 ± 79.56 528.66 ± 52.23 541.21 ± 91.76 
Values are mean ± sd.  
1 significant main effect of time 
2 significant main effect of birth control status  
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Table A1.6 Erythrocyte fatty acid composition in women taking and not taking oral contraceptives during the 
follicular and luteal phase of the menstrual cycle 
Erythrocyte Fatty Acids 
% weight total fatty acids 
 Women taking oral contraceptives Women with natural cycles 
Name 
Day 6-8  
(no hormone phase) 
Day 21-23 
(active hormone 
phase) 
Day 6-8  
(follicular phase) 
Day 21-23 
(luteal phase) 
C 14:0 1.15 ± 0.34 1.20 ± 0.32 1.08 ± 0.29 1.05 ± 0.28 
C 16:0 23.01 ± 1.16ab 23.68 ± 1.34a 22.28 ± 0.81b 22.19 ± 1.07b 
C 18:02 13.73 ± 0.90 13.82 ± 1.10 14.59 ± 1.01 14.89 ± 0.85 
C 20:0 0.31 ± 0.06 0.33 ± 0.07 0.35 ± 0.04 0.34 ± 0.04 
C 22:02 1.09 ± 0.24 1.15 ± 0.20 1.33 ± 0.17 1.29 ± 0.22 
C 23:0 0.07 ± 0.03 0.07 ± 0.03 0.09 ± 0.07 0.11 ± 0.07 
C 24:02 3.18 ± 0.48 3.33 ± 0.59 3.93 ± 0.61 3.84 ± 0.69 
SFAs 42.65 ± 1.17 43.65 ± 1.57 43.76 ± 1.65 43.77 ± 2.36 
C 16:1n-71,2 0.35 ± 0.10 0.32 ± 0.11 0.25 ± 0.05 0.23 ± 0.04 
C 18:1n-7 1.29 ± 0.16 1.25 ± 0.12 1.22 ± 0.13 1.19 ± 0.12 
C 18:1n-91 11.91 ± 1.06 11.59 ± 1.11 11.86 ± 1.11 11.69 ± 1.14 
C 20:1n-9 0.22 ± 0.04 0.22 ± 0.05 0.22 ± 0.05 0.22 ± 0.04 
C 22:1n-92 0.12 ± 0.03 0.12 ± 0.02 0.15 ± 0.03 0.16 ± 0.04 
C 24:1n-9 3.47 ± 0.56 3.67 ± 0.67 3.83 ± 0.51 3.70 ± 0.64 
MUFAs 17.81 ± 1.53 17.66 ± 1.66 17.94 ± 1.49 17.60 ± 1.53 
C 18:2n-6 9.60 ± 1.33 9.68 ± 1.06 9.49 ± 0.61 9.55 ± 0.86 
C 18:3n-6 0.06 ± 0.04 0.05 ± 0.03 0.06 ± 0.02 0.06 ± 0.03 
C 20:2n-6 0.26 ± 0.06 0.26 ± 0.06 0.22 ± 0.06 0.25 ± 0.11 
C 20:3n-6 1.52 ± 0.35 1.50 ± 0.34 1.33 ± 0.47 1.28 ± 0.40 
C 20:4n-6 13.56 ± 1.37 13.37 ± 1.19 13.81 ± 1.24 13.77 ± 1.28 
C 22:2n-6 0.06 ± 0.01 0.07 ± 0.05 0.06 ± 0.02 0.08 ± 0.04 
C 22:4n-61 3.16 ± 0.73 3.08 ± 0.65 2.84 ± 0.64 2.81 ± 0.67 
C 22:5n-6 0.56 ± 0.14 0.55 ± 0.18 0.50 ± 0.12 0.49 ± 0.10 
N-6 28.66 ± 2.95 28.45 ± 2.39 28.79 ± 25.06 28.09 ± 3.14 
C 18:3n-3 0.16 ± 0.05 0.16 ± 0.06 0.15 ± 0.03 0.16 ± 0.04 
C 20:3n-3 0.04 ± 0.02 0.04 ± 0.02 0.04 ± 0.03 0.05 ± 0.03 
C 20:5n-3 0.50 ± 0.14 0.46 ± 0.11 0.51 ± 0.10 0.48 ± 0.13 
C 22:5n-31,2 1.87 ± 0.29 1.78 ± 0.25 2.11 ± 0.22 1.96 ± 0.32 
C 22:6n-3 4.37 ± 1.00 4.23 ± 0.88 3.95 ± 0.98 3.76 ± 0.78 
N-31 6.92 ± 1.15 6.68 ± 0.96 6.77 ± 1.09 6.42 ± 1.00 
EPA+DHA 4.87 ± 1.04 4.70 ± 0.91 4.46 ± 1.03 4.25 ± 0.87 
Values are mean ± sd. Means with different letters are significantly different by Tukey’s post-hoc test, following a 
significant F-value for birth control status x time by the linear mixed models procedure. 
1 significant main effect of time 
2 significant main effect of birth control status  
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Table A2.1 Concentration of whole blood fatty acids in female rats over all four stages of the 
estrous cycle, and males. 
Whole Blood Fatty Acids 
µg fatty acid/100 µl whole blood 
Name Metestrus Diestrus Proestrus Estrus Males 
C 10:0 0.08  ±  0.08ab 0.13  ±  0.05ab 0.08  ±  0.06a 0.09  ±  0.08ab 0.18 ± 0.03b 
C 12:0 0.12  ±  0.04 0.14  ±  0.10 0.10  ±  0.06 0.11  ±  0.04 0.11 ± 0.04 
C 14:0 0.82  ±  0.37 0.78  ±  0.35 0.65  ±  0.20 0.69  ±  0.28 0.80 ± 0.26 
C 16:0 38.30  ±  3.26 35.44  ±  3.14 39.61  ±  5.41 35.36  ±  2.50 40.00 ± 6.24 
C 18:0 37.50  ±  2.66a 35.92  ±  3.29a 40.49  ±  5.12a 35.67  ±  1.45a 25.04 ± 4.74b 
C 20:0 0.43  ±  0.07ab 0.43  ±  0.07ab 0.53  ±  0.13a 0.41  ±  0.04ab 0.39 ± 0.06b 
C 22:0 0.87  ±  0.09 0.78  ±  0.21 1.01  ±  0.25 0.84  ±  0.13 0.76 ± 0.12 
C 23:0 0.39  ±  0.07 0.37  ±  0.13 0.41  ±  0.06 0.36  ±  0.11 0.32 ± 0.12 
C 24:0 2.27  ±  0.09 2.08  ±  0.30 2.43  ±  0.39 2.20  ±  0.24 2.13 ± 0.30 
SFAs 81.76  ±  5.75ab 76.92  ±  6.50ab 86.30  ±  11.09a 76.62  ±  4.08ab 70.56 ± 11.83b 
C 12:1 0.04  ±  0.02 0.03  ±  0.02 0.03  ±  0.01 0.02  ±  0.01 0.03 ± 0.01 
C 14:1 0.14  ±  0.15 0.17  ±  0.14 0.07  ±  0.08 0.08  ±  0.11 0.22 ± 0.11 
C 16:1n-7 0.59  ±  0.18a 0.40  ±  0.09b 0.54  ±  0.10ab 0.48  ±  0.11ab 0.49 ± 0.12ab 
C 18:1n-7 3.20  ±  0.23ab 2.98  ±  0.35a 3.29  ±  0.36ab 2.96  ±  0.27a 3.68 ± 0.57b 
C 18:1n-9 10.60  ±  2.04 9.24  ±  1.28 10.58  ±  1.27 9.85  ±  1.16 10.14 ± 1.70 
C 20:1n-9 0.12  ±  0.03a 0.17  ±  0.04a 0.16  ±  0.07a 0.17  ±  0.05a 0.28 ± 0.09b 
C 22:1n-9 0.13  ±  0.06 0.14  ±  0.06 0.16  ±  0.06 0.11  ±  0.06 0.15 ± 0.03 
C 24:1n-9 1.22  ±  0.13 1.12  ±  0.22 1.19  ±  0.36 1.16  ±  0.19 1.26 ± 0.22 
MUFAs 16.03  ±  2.34 14.25  ±  1.75 16.01  ±  1.99 14.83  ±  1.53 16.25 ± 2.65 
C 18:2n-6 21.79  ±  3.42ab 19.75  ±  2.34a 21.59  ±  2.99ab 20.50  ±  2.29ab 25.06 ± 4.91b 
C 18:3n-6 0.50  ±  0.18a 0.44  ±  0.08a 0.50  ±  0.09a 0.47  ±  0.11a 0.22 ± 0.05b 
C 20:2n-6 0.57  ±  0.07a 0.53  ±  0.07a 0.63  ±  0.09a 0.55  ±  0.05a 0.87 ± 0.13b 
C 20:3n-6 0.63  ±  0.09 0.60  ±  0.06 0.65  ±  0.07 0.56  ±  0.09 0.61 ± 0.09 
C 20:4n-6 51.75  ±  3.81a 50.10  ±  6.15a 53.73  ±  4.28a 50.74  ±  3.05a 42.31 ± 6.94b 
C 22:2n-6 0.09  ±  0.06a 0.12  ±  0.06a 0.10  ±  0.08a 0.08  ±  0.07a 0.25 ± 0.04b 
C 22:4n-6 2.21  ±  0.14 2.12  ±  0.31 2.14  ±  0.40 1.99  ±  0.26 2.18 ± 0.35 
C 22:5n-6 0.66  ±  0.22 0.62  ±  0.10 0.71  ±  0.26 0.57  ±  0.12 0.58 ± 0.15 
N-6 78.20  ±  7.46 74.27  ±  8.54 80.05  ±  7.59 75.47  ±  5.10 72.07 ± 12.18 
C 18:3n-3 0.36  ±  0.08ab 0.32  ±  0.08a 0.37  ±  0.13ab 0.30  ±  0.07a 0.49 ± 0.17b 
C 20:3n-3 0.03  ±  0.01 0.02  ±  0.02 0.05  ±  0.03 0.04  ±  0.04 0.02 ± 0.01 
C 20:5n-3 0.69  ±  0.19 0.66  ±  0.16 0.68  ±  0.27 0.59  ±  0.16 0.61 ± 0.16 
C 22:5n-3 1.90  ±  0.22ab 1.63  ±  0.14a 1.98  ±  0.52ab 1.63  ±  0.22a 2.18 ± 0.22b 
C 22:6n-3 4.94  ±  0.61ab 4.54  ±  0.63b 5.46  ±  0.49a 4.63  ±  0.35b 3.54 ± 0.61c 
N-3 7.92  ±  0.95ab 7.17  ±  0.78a 8.55  ±  0.96b 7.19  ±  0.58a 6.85 ± 1.06a 
C 20:3n-9 0.03  ±  0.03 0.03  ±  0.02 0.04  ±  0.01 0.03  ±  0.02 0.03 ± 0.02 
Total 183.95  ±  12.55 172.65  ±  16.37 190.95  ±  20.39 174.15  ±  9.96 165.76 ± 27.48 
Values are means ± SD. Means with different letters are significantly different by Tukey’s post-hoc test, 
following a significant F-value for one way ANOVA 
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Table A2.2 Concentration of plasma fatty acids in female rats over all four stages of the estrous 
cycle, and males. 
Plasma Fatty Acids 
µg fatty acid/100 µl plasma 
Name Metestrus Diestrus Proestrus Estrus Males 
C 10:0 0.00 ± 0.00 0.02 ± 0.03 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 12:0 0.28 ± 0.44 0.39 ± 0.68 0.75 ± 1.72 0.16 ± 0.10 0.36 ± 0.53 
C 14:0 1.03 ± 0.72 0.79 ± 0.50 1.23 ± 1.63 0.79 ± 0.32 0.83 ± 0.48 
C 16:0 26.75 ± 5.46 21.57 ± 2.90 26.07 ± 5.61 24.38 ± 4.41 26.02 ± 2.79 
C 18:0 32.92 ± 5.39a 28.61 ± 3.84a 32.31 ± 6.37a 31.68 ± 3.33a 18.20 ± 2.25b 
C 20:0 0.29 ± 0.07 0.25 ± 0.09 0.34 ± 0.17 0.31 ± 0.07 0.24 ± 0.06 
C 22:0 0.36 ± 0.09ab 0.28 ± 0.08ac 0.42 ± 0.11b 0.41 ± 0.08ab 0.21 ± 0.04c 
C 23:0 0.37 ± 0.14ab 0.25 ± 0.08ac 0.42 ± 0.14b 0.36 ± 0.14abc 0.19 ± 0.06c 
C 24:0 0.77 ± 0.20a 0.45 ± 0.17b 0.76 ± 0.19a 0.72 ± 0.20a 0.34 ± 0.05b 
SFAs 63.52 ± 10.43a 53.20 ± 6.63ab 62.99 ± 13.86a 59.50 ± 7.98ab 46.93 ± 4.98b 
C 12:1 0.02 ± 0.01 0.02 ± 0.01 0.01 ± 0.00 0.02 ± 0.01 0.01 ± 0.01 
C 14:1 0.03 ± 0.02 0.03 ± 0.01 0.03 ± 0.02 0.03 ± 0.01 0.02 ± 0.01 
C 16:1n-7 0.89 ± 0.28 0.62 ± 0.09 0.79 ± 0.29 0.84 ± 0.27 0.82 ± 0.17 
C 18:1n-7 2.21 ± 0.65ab 1.72 ± 0.21a 2.13 ± 0.48ab 2.01 ± 0.40a 2.60 ± 0.35b 
C 18:1n-9 12.77 ± 4.38 9.56 ± 1.53 10.89 ± 3.10 11.86 ± 2.98 13.00 ± 3.31 
C 20:1n-9 0.13 ± 0.03ab 0.09 ± 0.03a 0.13 ± 0.07ab 0.11 ± 0.04ab 0.18 ± 0.05b 
C 22:1n-9 0.25 ± 0.07 0.25 ± 0.09 0.34 ± 0.20 0.25 ± 0.04 0.21 ± 0.04 
C 24:1n-9 0.37 ± 0.13a 0.22 ± 0.23ab 0.37 ± 0.20a 0.44 ± 0.18a 0.09 ± 0.04b 
MUFAs 16.74 ± 5.43 12.52 ± 1.97 14.64 ± 3.72 15.55 ± 3.59 16.93 ± 3.70 
C 18:2n-6 29.72 ± 7.48ab 24.26 ± 3.50a 28.01 ± 5.75ab 27.28 ± 6.30ab 34.86 ± 5.10b 
C 18:3n-6 1.08 ± 0.38a 0.74 ± 0.19ab 0.95 ± 0.32a 0.89 ± 0.27a 0.37 ± 0.07b 
C 20:2n-6 0.18 ± 0.06a 0.16 ± 0.03a 0.19 ± 0.03a 0.18 ± 0.06a 0.39 ± 0.07b 
C 20:3n-6 0.53 ± 0.14a 0.35 ± 0.08b 0.43 ± 0.09ab 0.37 ± 0.10b 0.42 ± 0.06ab 
C 20:4n-6 59.35 ± 10.63a 50.97 ± 6.72ab 54.77 ± 8.92a 55.19 ± 8.95a 39.94 ± 5.92b 
C 22:2n-6 0.03 ± 0.01 0.04 ± 0.03 0.05 ± 0.04 0.04 ± 0.04 0.06 ± 0.03 
C 22:4n-6 0.48 ± 0.11 0.39 ± 0.08 0.49 ± 0.08 0.38 ± 0.08 0.40 ± 0.10 
C 22:5n-6 0.22 ± 0.06a 0.19 ± 0.13ab 0.28 ± 0.11a 0.20 ± 0.08ab 0.07 ± 0.03b 
N-6 91.58 ± 17.90 77.10 ± 9.49 85.19 ± 14.61 84.53 ± 15.03 76.51 ± 10.45 
C 18:3n-3 0.75 ± 0.28ab 0.57 ± 0.16a 0.67 ± 0.33ab 0.65 ± 0.21ab 1.00 ± 0.25b 
C 20:3n-3 0.03 ± 0.03 0.03 ± 0.02 0.04 ± 0.02 0.03 ± 0.02 0.03 ± 0.02 
C 20:5n-3 1.10 ± 0.33 0.85 ± 0.20 1.01 ± 0.35 0.89 ± 0.27 0.93 ± 0.19 
C 22:5n-3 0.86 ± 0.17a 0.54 ± 0.13c 0.76 ± 0.17abc 0.65 ± 0.14bc 0.79 ± 0.13ab 
C 22:6n-3 6.13 ± 1.22a 4.86 ± 0.88ab 5.98 ± 1.47a 5.22 ± 0.82a 3.38 ± 0.68b 
N-3 8.87 ± 1.91a 6.85 ± 1.18ab 8.47 ± 2.01a 7.44 ± 1.27ab 6.14 ± 1.13b 
C 20:3n-9 0.06 ± 0.04 0.06 ± 0.03 0.07 ± 0.04 0.08 ± 0.03 0.05 ± 0.02 
Total 183.28 ± 32.29 149.73 ± 16.96 176.54 ± 40.10 167.10 ± 26.20 146.56 ± 17.46 
Values are means ± SD. Means with different letters are significantly different by Tukey’s post-hoc test, 
following a significant F-value for one way ANOVA 
 178 
 
Table A2.3 Concentration of liver fatty acids in female rats over all four stages of the estrous 
cycle, and males. 
Liver Total Lipids 
µg fatty acids/mg liver 
Fatty Acid Metestrus Diestrus Proestrus Estrus Males 
C 10:0 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 12:0 0.02 ± 0.01 0.02 ± 0.01 0.01 ± 0.00 0.01 ± 0.01 0.01 ± 0.01 
C 14:0 0.08 ± 0.01 0.07 ± 0.01 0.08 ± 0.02 0.09 ± 0.02 0.08 ± 0.02 
C 16:0 5.43 ± 0.51 5.49 ± 0.52 5.76 ± 0.80 6.10 ± 1.16 6.76 ± 1.94 
C 18:0 8.32 ± 0.58ab 8.80 ± 0.91a 8.65 ± 0.78ab 8.83 ± 0.99a 7.05 ± 1.99b 
C 20:0 0.04 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0.05 ± 0.02 
C 22:0 0.06 ± 0.02 0.06 ± 0.01 0.05 ± 0.02 0.06 ± 0.01 0.06 ± 0.03 
C 23:0 0.07 ± 0.02 0.06 ± 0.02 0.06 ± 0.02 0.07 ± 0.02 0.06 ± 0.02 
C 24:0 0.14 ± 0.03 0.19 ± 0.03 0.14 ± 0.04 0.15 ± 0.02 0.16 ± 0.04 
SFAs 14.16 ± 1.05 14.72 ± 1.35 14.8 ± 1.20 15.34 ± 2.01 14.24 ± 3.97 
C 12:1 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 14:1 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 16:1n-7 0.15 ± 0.03ab 0.13 ± 0.02a 0.15 ± 0.04ab 0.18 ± 0.04b 0.14 ± 0.05ab 
C 18:1n-7 0.65 ± 0.09 0.62 ± 0.07 0.66 ± 0.07 0.69 ± 0.11 0.97 ± 0.29 
C 18:1n-9 2.14 ± 0.37 2.09 ± 0.34 2.26 ± 0.74 2.67 ± 0.79 2.24 ± 0.67 
C 20:1n-9 0.03 ± 0.01a 0.03 ± 0.01a 0.03 ± 0.01a 0.03 ± 0.01a 0.06 ± 0.02b 
C 22:1n-9 0.03 ± 0.02 0.02 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 
C 24:1n-9 0.05 ± 0.02 0.05 ± 0.01 0.04 ± 0.02 0.05 ± 0.01 0.06 ± 0.02 
MUFAs 3.06 ± 0.48 2.94 ± 0.38 3.17 ± 0.83 3.65 ± 0.95 3.50 ± 1.04 
C 18:2n-6 6.17 ± 0.56 6.67 ± 0.82 6.89 ± 2.14 7.76 ± 2.01 8.26 ± 2.41 
C 18:3n-6 0.15 ± 0.02ab 0.14 ± 0.03a 0.16 ± 0.04ab 0.19 ± 0.05b 0.08 ± 0.02c 
C 20:2n-6 0.10 ± 0.02a 0.10 ± 0.02a 0.10 ± 0.01a 0.11 ± 0.02a 0.24 ± 0.09b 
C 20:3n-6 0.16 ± 0.03 0.14 ± 0.01 0.14 ± 0.02 0.15 ± 0.03 0.17 ± 0.07 
C 20:4n-6 7.71 ± 0.51 8.08 ± 0.82 8.05 ± 0.59 8.29 ± 0.73 8.29 ± 2.27 
C 22:2n-6 0.02 ± 0.01 0.03 ± 0.02 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.02 
C 22:4n-6 0.17 ± 0.04 0.18 ± 0.03 0.18 ± 0.02 0.18 ± 0.04 0.16 ± 0.06 
C 22:5n-6 0.10 ± 0.01a 0.09 ± 0.04a 0.10 ± 0.02a 0.09 ± 0.03a 0.04 ± 0.01b 
N-6 4.57 ± 1.01 15.41 ± 1.3 15.64 ± 2.44 16.79 ± 2.77 17.25 ± 4.87 
C 18:3n-3 0.17 ± 0.03 0.20 ± 0.04 0.20 ± 0.12 0.25 ± 0.10 0.22 ± 0.08 
C 20:3n-3 0.02 ± 0.01ab 0.02 ± 0.01a 0.01 ± 0.01a 0.01 ± 0.01a 0.03 ± 0.01b 
C 20:5n-3 0.13 ± 0.02 0.14 ± 0.02 0.13 ± 0.04 0.15 ± 0.04 0.14 ± 0.06 
C 22:5n-3 0.29 ± 0.03ab 0.26 ± 0.03a 0.30 ± 0.05ab 0.27 ± 0.05ab 0.37 ± 0.12b 
C 22:6n-3 2.23 ± 0.24a 2.18 ± 0.33a 2.43 ± 0.15a 2.28 ± 0.27a 1.62 ± 0.51b 
N-3 2.84 ± 0.28ab 2.79 ± 0.33ab 3.08 ± 0.20a 2.97 ± 0.43ab 2.38 ± 0.77b 
C 20:3n-9 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
Total 34.65 ± 2.65 35.88 ± 2.97 36.72 ± 4.33 38.77 ± 5.91 37.39 ± 10.57 
Values are means ± SD. Means with different letters are significantly different by Tukey’s post-hoc test, 
following a significant F-value for one way ANOVA 
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Appendix 3 
Supplementary Data for Chapter 8 
Characterization of Fads2 Novel Transcript Variants 
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Table A3.1 Phospholipid fatty acid composition in HEK 293 cells electroporated with pCMV 
control, FADS2_v0/1or FADS2_v2. 
HEK 293 Phospholipids 
% weight total fatty acids 
 pCMV FADS2_v0/1 FADS2_v2 
C 10:0 0.14 ± 0.09 0.06 ± 0.04 0.05 ± 0.03 
C 16:0 26.21 ± 1.81 26.00 ± 1.80 24.19 ± 1.50 
C 18:0 22.29 ± 2.34a 25.34 ± 2.16a 18.30 ± 1.84b 
C 20:0 0.43 ± 0.08 0.41 ± 0.08 0.31 ± 0.17 
C 22:0 0.36 ± 0.10 0.35 ± 0.15 0.36 ± 0.07 
C 24:0 0.68 ± 0.21 0.46 ± 0.15 0.54 ± 0.10 
SFAs 50.21 ± 3.33a 52.72 ± 3.60a 43.87 ± 2.22b 
C 16:1n-7 3.17 ± 0.79a 2.71 ± 1.01a 5.90 ± 1.32b 
C 18:1n-7 4.62 ± 0.26a 4.51 ± 0.32a 5.21 ± 0.25b 
C 18:1n-9 22.70 ± 4.37a 20.22 ± 3.70a 28.87 ± 2.22b 
C 20:1n-9 0.34 ± 0.03 0.36 ± 0.06 0.41 ± 0.06 
C 22:1n-9 1.42 ± 0.76 1.67 ± 0.79 0.97 ± 0.37 
C 24:1n-9 0.53 ± 0.20 0.52 ± 0.15 0.38 ± 0.13 
MUFAs 32.95 ± 5.04a 30.11 ± 4.94a 41.94 ± 3.41b 
C 18:2n-6 1.91 ± 0.31 1.68 ± 0.15 1.60 ± 0.72 
C 18:3n-6 0.79 ± 0.72 1.06 ± 0.84 0.40 ± 0.58 
C 20:2n-6 0.31 ± 0.35 0.26 ± 0.26 1.16 ± 0.86 
C 20:3n-6 0.60 ± 0.16 0.63 ± 0.06 0.49 ± 0.07 
C 20:4n-6 5.54 ± 0.74a 6.47 ± 0.20b 5.06 ± 0.39a 
C 22:2n-6 0.27 ± 0.25 0.20 ± 0.14 0.20 ± 0.12 
C 22:4n-6 1.06 ± 0.13a 1.08 ± 0.10a 0.82 ± 0.11b 
N-6 10.47 ± 1.44 11.37 ± 0.72 9.72 ± 0.85 
C 18:3n-3 0.41 ± 0.25 0.39 ± 0.20 0.25 ± 0.24 
C 20:3n-3 0.42 ± 0.59 0.10 ± 0.09 0.28 ± 0.29 
C 20:5n-3 0.51 ± 0.27 0.64 ± 0.41 0.42 ± 0.46 
C 22:5n-3 0.91 ± 0.22 0.91 ± 0.18 0.79 ± 0.15 
C 22:6n-3 2.21 ± 0.56 2.30 ± 0.12 1.89 ± 0.49 
N-3 4.31 ± 1.36 4.33 ± 0.55 3.22 ± 1.14 
Values are means ± SD. Means with different letters are significantly different by Newman-Keul’s post-
hoc test, following a significant F-value for one way ANOVA 
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Table A3.2. Concentration of phospholipid fatty acids of HEK 293 cells electroporated with 
pCMV control, FADS2_v0/1or FADS2_v2. 
HEK 293 Phospholipids 
µg fatty acid/mg cellular protein 
 pCMV FADS2_v0/1 FADS2_v2 
C 12:0 0.01 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 
C 16:0 1.17 ± 0.27 1.39 ± 0.23 1.56 ± 0.29 
C 18:0 0.75 ± 0.26a 1.02 ± 0.32ab 1.36 ± 0.32b 
C 20:0 0.01 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
C 22:0 0.01 ± 0.01 0.02 ± 0.00 0.02 ± 0.02 
C 24:0 0.03 ± 0.01 0.03 ± 0.00 0.03 ± 0.01 
SFAs 1.98 ± 0.53a 2.49 ± 0.55ab 3.02 ± 0.60b 
C 12:1 0.00 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 
C 14:1 0.02 ± 0.01 0.02 ± 0.00 0.03 ± 0.01 
C 16:1n-7 0.29 ± 0.08 0.36 ± 0.04 0.30 ± 0.07 
C 18:1n-7 0.26 ± 0.06 0.29 ± 0.05 0.31 ± 0.05 
C 18:1n-9 1.46 ± 0.30 1.64 ± 0.24 1.74 ± 0.37 
C 20:1n-9 0.02 ± 0.01 0.02 ± 0.00 0.02 ± 0.01 
C 22:1n-9 0.03 ± 0.02 0.05 ± 0.03 0.07 ± 0.05 
C 24:1n-9 0.02 ± 0.01 0.02 ± 0.00 0.03 ± 0.01 
MUFAs 2.09 ± 0.46 2.40 ± 0.33 2.50 ± 0.47 
C 18:2n-6 0.04 ± 0.04a 0.06 ± 0.02ab 0.11 ± 0.03b 
C 18:3n-6 0.00 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 
C 20:2n-6 0.13 ± 0.12 0.06 ± 0.05 0.06 ± 0.05 
C 20:3n-6 0.02 ± 0.02 0.02 ± 0.01 0.04 ± 0.01 
C 20:4n-6 0.18 ± 0.11 0.25 ± 0.09 0.34 ± 0.10 
C 22:2n-6 0.04 ± 0.02 0.02 ± 0.01 0.02 ± 0.01 
C 22:4n-6 0.02 ± 0.02a 0.04 ± 0.02ab 0.06 ± 0.02b 
C 22:5n-6 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
N-6 0.43 ± 0.19 0.47 ± 0.17 0.62 ± 0.15 
C 18:3n-3 0.00 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 
C 20:3n-3 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
C 20:5n-3 0.02 ± 0.01 0.03 ± 0.04 0.03 ± 0.04 
C 22:5n-3 0.02 ± 0.01 0.03 ± 0.02 0.05 ± 0.02 
C 22:6n-3 0.06 ± 0.04a 0.09 ± 0.03ab 0.12 ± 0.04b 
N-3 0.11 ± 0.05 0.16 ± 0.08 0.21 ± 0.06 
PUFAs 0.54 ± 0.23 0.62 ± 0.24 0.83 ± 0.21 
HUFAs 0.32 ± 0.19 0.44 ± 0.19 0.63 ± 0.17 
Total 4.60 ± 1.15 5.51 ± 1.08 6.35 ± 1.25 
Values are means ± SD. Means with different letters are significantly different by Newman-Keul’s post-
hoc test, following a significant F-value for one way ANOVA  
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Table A3.3 Phospholipid fatty acid composition in HEK 293 cells electroporated with pCMV 
control or Fads2_v0/1 with increasing amounts of Fads2_v2. 
HEK 293 Phospholipids 
% weight total fatty acids 
 10 µg pCMV 5 µg FADS2_v0/1 
5 µg FADS2_v0/1 + 2.5 µg 
FADS2_v2 + 2.5 µg pCMV 
5 µg FADS2_v0/1 + 5 
µg FADS2_v2 
C 10:0 0.14 ± 0.09 0.06 ± 0.04 0.04 ± 0.04 0.06 ± 0.01 
C 16:0 26.76 ± 1.37 26.00 ± 1.80 26.14 ± 0.79 27.22 ± 0.82 
C 18:0 22.18 ± 2.59 25.34 ± 2.16 23.99 ± 4.86 23.07 ± 3.44 
C 20:0 0.42 ± 0.08 0.41 ± 0.08 0.47 ± 0.13 0.37 ± 0.14 
C 22:0 0.36 ± 0.11 0.35 ± 0.15 0.35 ± 0.00 0.38 ± 0.03 
C 24:0 0.71 ± 0.21 0.46 ± 0.15 0.59 ± 0.20 0.61 ± 0.17 
SFAs 50.72 ± 3.45 52.72 ± 3.60 51.59 ± 5.49 51.68 ± 4.06 
C 16:1n-7 3.30 ± 0.82 2.71 ± 1.01 2.66 ± 0.82 3.95 ± 1.97 
C 18:1n-7 4.54 ± 0.19 4.51 ± 0.32 4.75 ± 0.26 4.77 ± 0.38 
C 18:1n-9 23.31 ± 4.59 20.22 ± 3.70 21.52 ± 3.63 23.47 ± 3.43 
C 20:1n-9 0.34 ± 0.03 0.36 ± 0.06 0.29 ± 0.13 0.36 ± 0.08 
C 22:1n-9 1.23 ± 0.68 1.67 ± 0.79 0.89 ± 0.14 0.78 ± 0.11 
C 24:1n-9 0.55 ± 0.22 0.52 ± 0.15 0.72 ± 0.10 0.61 ± 0.08 
MUFAs 33.47 ± 5.45 30.11 ± 4.94 30.81 ± 4.42 33.94 ± 5.64 
C 18:2n-6 1.86 ± 0.33 1.68 ± 0.15 1.98 ± 0.41 1.34 ± 0.55 
C 18:3n-6 0.56 ± 0.48 1.06 ± 0.84 0.62 ± 0.59 0.42 ± 0.18 
C 20:2n-6 0.36 ± 0.36 0.26 ± 0.26 0.10 ± 0.12 0.07 ± 0.06 
C 20:3n-6 0.59 ± 0.17 0.63 ± 0.06 0.62 ± 0.13 0.63 ± 0.16 
C 20:4n-6 5.28 ± 0.43a 6.47 ± 0.20b 6.63 ± 0.26b 5.11 ± 1.09a 
C 22:2n-6 0.30 ± 0.26 0.20 ± 0.14 0.16 ± 0.13 0.05 ± 0.03 
C 22:4n-6 1.04 ± 0.14 1.08 ± 0.10 1.12 ± 0.13 0.89 ± 0.10 
N-6 9.99 ± 0.94 11.37 ± 0.72 11.24 ± 0.68 8.50 ± 1.86 
C 18:3n-3 0.31 ± 0.11 0.39 ± 0.20 0.30 ± 0.12 0.21 ± 0.10 
C 20:3n-3 0.42 ± 0.59 0.10 ± 0.09 0.07 ± 0.08 0.08 ± 0.06 
C 20:5n-3 0.47 ± 0.28 0.64 ± 0.41 0.60 ± 0.15 0.56 ± 0.13 
C 22:5n-3 0.84 ± 0.17 0.91 ± 0.18 0.96 ± 0.12 0.83 ± 0.19 
C 22:6n-3 2.12 ± 0.57 2.30 ± 0.12 2.46 ± 0.73 2.07 ± 0.23 
N-3 4.03 ± 1.31 4.33 ± 0.55 4.38 ± 0.87 3.75 ± 0.56 
Values are means ± SD. Means with different letters are significantly different by Newman-Keul’s post-
hoc test, following a significant F-value for one way ANOVA 
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Table A3.4. Concentration of fatty acids in phospholipids of HEK 293 cells electroporated with 
pCMV control or Fads2_v0/1 with increasing amounts of Fads2_v2. 
HEK 293 Phospholipids 
µg fatty acid/mg cellular protein 
 10 µg pCMV 
5 µg 
FADS2_v0/1 
5 µg FADS2_v0/1 + 
2.5 µg FADS2_v2 + 
2.5 µg pCMV 
5 µg FADS2_v0/1 + 
5 µg FADS2_v2 
C 10:0 0.01 ± 0.01 0.02 ± 0.02 0.01 ± 0.00 0.01 ± 0.00 
C 16:0 2.70 ± 0.63 4.08 ± 0.93 2.55 ± 0.90 3.95 ± 1.47 
C 18:0 2.19 ± 0.58 4.05 ± 0.88 2.10 ± 0.72 3.58 ± 1.00 
C 20:0 0.04 ± 0.01 0.08 ± 0.03 0.04 ± 0.03 0.06 ± 0.01 
C 22:0 0.04 ± 0.01 0.05 ± 0.02 0.04 ± 0.01 0.05 ± 0.01 
C 24:0 0.08 ± 0.01 0.09 ± 0.05 0.07 ± 0.01 0.07 ± 0.01 
SFAs 5.06 ± 1.22 8.39 ± 1.89 4.80 ± 1.67 7.72 ± 2.49 
C 16:1n-7 0.33 ± 0.10 0.31 ± 0.19 0.31 ± 0.16 0.45 ± 0.26 
C 18:1n-7 0.45 ± 0.11 0.65 ± 0.20 0.49 ± 0.17 0.68 ± 0.29 
C 18:1n-9 2.11 ± 0.45 2.65 ± 1.06 2.32 ± 0.70 3.09 ± 1.39 
C 20:1n-9 0.03 ± 0.00 0.06 ± 0.01 0.04 ± 0.03 0.05 ± 0.02 
C 22:1n-9 0.08 ± 0.01 0.18 ± 0.05 0.08 ± 0.04 0.10 ± 0.02 
C 24:1n-9 0.07 ± 0.02 0.08 ± 0.05 0.07 ± 0.03 0.09 ± 0.02 
MUFAs 3.07 ± 0.69 3.95 ± 1.46 3.30 ± 1.13 4.46 ± 2.00 
C 18:2n-6 0.18 ± 0.03 0.25 ± 0.07 0.20 ± 0.02 0.26 ± 0.09 
C 18:3n-6 0.08 ± 0.05 0.12 ± 0.07 0.03 ± 0.04 0.08 ± 0.02 
C 20:2n-6 0.01 ± 0.01 0.04 ± 0.02 0.00 ± 0.01 0.01 ± 0.00 
C 20:3n-6 0.06 ± 0.02 0.08 ± 0.03 0.07 ± 0.03 0.09 ± 0.03 
C 20:4n-6 0.52 ± 0.12 0.95 ± 0.24 0.65 ± 0.19 0.88 ± 0.33 
C 22:2n-6 0.04 ± 0.02 0.04 ± 0.05 0.02 ± 0.01 0.01 ± 0.01 
C 22:4n-6 0.10 ± 0.00 0.18 ± 0.05 0.11 ± 0.02 0.14 ± 0.05 
C 22:5n-6 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
N-6 0.98 ± 0.16 1.67 ± 0.32 1.08 ± 0.29 1.47 ± 0.53 
C 18:3n-3 0.03 ± 0.01 0.07 ± 0.03 0.02 ± 0.01 0.04 ± 0.01 
C 20:3n-3 0.04 ± 0.05 0.05 ± 0.07 0.01 ± 0.00 0.01 ± 0.01 
C 20:5n-3 0.06 ± 0.00 0.12 ± 0.01 0.06 ± 0.01 0.10 ± 0.04 
C 22:5n-3 0.08 ± 0.01 0.16 ± 0.07 0.09 ± 0.02 0.14 ± 0.08 
C 22:6n-3 0.24 ± 0.03 0.30 ± 0.14 0.29 ± 0.09 0.33 ± 0.14 
N-3 0.46 ± 0.01 0.70 ± 0.11 0.47 ± 0.13 0.62 ± 0.27 
PUFAs 1.44 ± 0.15 2.37 ± 0.44 1.55 ± 0.41 2.08 ± 0.80 
HUFAs 1.10 ± 0.11 1.85 ± 0.38 1.28 ± 0.35 1.68 ± 0.67 
Total 9.58 ± 2.01 14.71 ± 3.68 9.65 ± 3.21 14.26 ± 5.30 
Values are means ± SD. Means with different letters are significantly different by Newman-Keul’s post-
hoc test, following a significant F-value for one way ANOVA 
 
 
